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Abstract 
 Over the last six years, Canterbury residents have lived through two major earthquakes 
and thousands of aftershocks, with such events negatively impacting psychological health. 
Research shows rates of post-traumatic stress symptoms in children have doubled post-quake, 
and a classroom containing children who are experiencing chronically high physiological arousal 
has been shown to be a stressful environment for teachers. Such stress therefore negatively 
impacts teachers’ ability to sleep well, meaning many Christchurch teachers may suffer from 
insomnia, a debilitating condition leading to psychological distress and often comorbid with 
other mental health conditions. The present research sought to investigate the use of a broad-
spectrum micronutrient formula called EMPowerplus (EMP+) for chronic insomnia in teachers. 
This study examined the effect of EMP+ over an 8-10 week period using a multiple-baseline 
design with placebo. Seventeen teachers were randomized to one of three baseline sequences 
where they completed a one week baseline period, before receiving five, nine, or 14 days, of 
placebo as well as 8-10 weeks of the micronutrient formula. After completion of the trial, a 
three-month follow up was conducted. All participants completed the trial, and results showed a 
statistically reliable and clinically significant decrease in insomnia severity (Cohen’s dav = -
1.37), on at least one or more aspects of the sleep diary, and on emotional exhaustion (Cohen’s 
dav = -1.08). EMP+ also statistically significantly reduced insomnia severity compared to 
placebo (Cohen’s dav = -0.66). Statistically significant reduction was not seen in stress, anxiety 
and depression scores as compared to placebo, and these levels were not generally clinically 
raised to begin with. Sixteen out of 17 participants were compliant, and side effects were 
generally mild and transitory. The current study provides evidence for the beneficial effect of 
micronutrient supplementation on chronic insomnia in Christchurch teachers working in a 
stressful environment. Future research incorporating measurement of nutritional intake and pro-
inflammatory biomarkers, as well as conducting comparisons to other conventional treatments, is 
recommended.   
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 On September 4th 2010, at 4:35am local time, the region of Canterbury, New Zealand and 
its main city, Christchurch (population approximately 400,000), was struck by a 7.1 magnitude 
earthquake (Gledhill, Ristau, Reyners, Fry, & Holden, 2011). Despite widespread infrastructure 
and property damage throughout the region, miraculously there were no fatalities and few 
injuries. Five months later on February 22nd 2011, at 12:51pm local time, a second earthquake 
(an aftershock of the initial event) struck the region. This 6.3 magnitude earthquake resulted in 
185 fatalities and injured thousands both physically and psychologically. As well as this great 
loss Christchurch once again faced extensive and economically debilitating infrastructure 
damage, including building collapses throughout the city (Newell, Johnston, & Beaven, 2012). 
In the subsequent years the region has now experienced over 22,400 aftershocks 
(www.quake.crowe.co.nz). Both the immediate and persistent effects of these Christchurch 
earthquakes have exposed thousands of individuals to numerous psychological stressors over the 
years.  
1.1 Psychological outcomes of natural disasters  
  Earthquakes are natural disasters that are aversive, uncontrollable and unpredictable, 
thereby impacting psychological health and general wellbeing. Many studies have recorded the 
psychological impact that natural disasters can have on individuals, including fear, increased 
anxiety, post-traumatic stress (PTS), and depression (Bonanno, Brewin, Kaniasty, & Greca, 
2010; Fergusson, Horwood, Boden, & Mulder, 2014; V. A. Johnson & Ronan, 2014; Nolen-
Hoeksema & Morrow, 1991; Norris, Murphy, Baker, & Perilla, 2004; Rucklidge et al., 2012; 
Rucklidge, Blampied, Gorman, Gordon, & Sole, 2014). Moreover, higher rates of psychological 
distress in both adults and children following major earthquakes are evident around the world 
(Bödvarsdóttir & Elklit, 2004; Şalcıoğlu & Başoğlu, 2008; Yabe et al., 2014). Recent research 
found that after the Christchurch September earthquake, individuals were experiencing higher 
rates of stress, anxiety, and depression, as well as sleeplessness and cognitive dysfunction 
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(Dorahy & Kannis-Dymand, 2012; Kemp, Helton, Richardson, Blampied, & Grimshaw, 2011). 
Moreover, some studies posited that for individuals remaining in Christchurch after the February 
earthquake, feelings of tiredness, chronic stress, and uncertainty became the new norm (Gawith, 
2013; Rowney, Farvid, & Sibley, 2014).  
 These heightened stress levels have been maintained by many individuals six years on 
(Norriss, 2016). This is likely a result of ongoing-secondary stressors (i.e., situations that have 
persisted longer than the event of the earthquakes) (Bellamy, 2014; Lock et al., 2012) such as 
aftershocks (Radio New Zealand, 2016c), damage and loss resulting in loss of accommodation, 
employment, social support, and education networks, with property damage leading to thousands 
of insurance claims, many associated with difficult negotiations, as well as temporary or 
permanent residential relocation (CERA, 2014; Goodyear, 2014; Howden-Chapman et al., 2014; 
Wood, Noy, & Parker, 2016). Job loss and instability also resulted in which thus places financial 
pressure and strain on families (Garner, 2011; Gawith, 2013; Hartevelt & Small, 2011; Lock et 
al., 2012). These pressures are likely to disrupt normal daily family functioning and routine, 
therefore increasing the risk of deterioration in familial relationships (Lock et al., 2012). This has 
held true for Christchurch residents (Carville, 2013; Styliano & Carville, 2012; Towle, 2014). 
Additionally, high stress levels have further been maintained over the years as a result of 
continuing road works, worsened traffic, loss of community facilities, and decreased social 
connectedness (e.g., through relocating to another community or neighbours relocating or 
moving away from the city) (CERA, 2014).  
 These persistent on-going stressors have had a large impact on many Christchurch 
residents’ wellbeing and psychological health, with research showing a 39% increase in adult 
mental health service use since mid-2012 (Carville, 2016; CERA, 2014; Humphrey & Renison, 
2015; McCrone, 2015; Stewart, 2015). This is consistent with previous research showing the 
persistence of mental health disorders many years after the initial event of a disaster (Hussain, 
Weisaeth, & Heir, 2011; van der Velden, Wong, Boshuizen, & Grievink, 2013). This evidence 
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shows that Christchurch residents have lived in a stressful environment over the last six years; 
and although many residents may have recovered from their experiences, there is still a long road 
ahead for some.  
1.1.1 Impact of earthquakes on schools 
 The February 2011 earthquake had a tremendous impact on both primary (i.e., elementary 
school, New Entrants to year eight, with children aged from five years old to typically 13 years) 
and secondary schools (Years 9 to 13, with adolescents aged typically from 14 to 18) throughout 
the region. As a result, in order to resume schooling, some affected schools were co-located with 
schools residing in less damaged areas until decisions regarding repairs and rebuilding were 
made. The duration of these arrangements ranged from several weeks to years (Ham, Cathro, 
Winter, & Winter, 2012), with some continuing beyond 2017 (E. Murphy & Moir, 2016). Final 
decisions regarding the affected schools’ futures were made in November 2013, when it was 
announced that 11 schools were to be merged to establish five merged schools, 11 additional 
schools closed and two additional schools closed voluntarily due to roll decline since the 
earthquake (APNZ, 2014; CERA, 2014; Davis, 2016; Young, 2016). These decisions resulted in 
relocation of children to new or different schools and job losses for both teachers and support 
staff (Law, 2011a, 2011b; News, 2012; NZEI, 2013; Romanos, 2011). Moreover, the Canterbury 
Primary Principal’s Association state that long-lasting anxiety and trauma for schools and 
children has occurred as a result of this process (E. Murphy, 2016; Radio New Zealand, 2016b) 
(E. Murphy, 2016; Radio New Zealand, 2016b).   
 Notwithstanding the fact that challenging child behaviour is always a source of stress for 
teachers under normal circumstances, the combination of the general effect of the earthquakes on 
Christchurch residents and the specific stressors relating to school closures and relocations 
subsequently increased stress levels of affected children, school staff, their families and 
communities in a mutually reciprocal and interactive way. Consequently, these stressors 
compounded upon an already present problem, and children’s behaviour and emotions were 
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further negatively affected. This created a setting whereby the relationship of child behaviour to 
teacher stress needed consideration.  
1.1.2 Teaching: A stressful occupation  
 Johnson and colleagues (S.Johnson et al., 2005) found teachers provided the second 
worse average score in stress-related outcomes, and sixth lowest levels of job satisfaction when 
these were assessed across 26 occupations; with the main explanation for these outcomes being 
the emotional involvement of teachers with students (S.Johnson et al., 2005). The key sources of 
stress for teachers worldwide primarily include teaching students who display challenging 
behaviour and lack motivation, and maintaining discipline among students in their classes. 
Additional sources of stress include high workload, role ambiguity, and poor working conditions 
and relationships (Kyriacou, 2001).   
 Consistent with these findings, an exploratory survey conducted in 2016 by Save Our 
Schools NZ found over 80% of NZ teachers reported they feel stressed or anxious at work half 
of the time or more, with over 35% reporting they felt this way most of the time. Additionally, 
approximately 50% of respondents reported students’ needs and behaviour as a prevalent cause 
of stress and anxiety (Kahn & Edgington, 2016). Thus, that teaching is a stressful occupation is 
well-documented; therefore it is unsurprising that a natural disaster event would exacerbate any 
existing stress.   
1.1.3 Child distress and teacher stress  
 Psychological distress impacts individuals at any age. It has been found that children in 
particular have a higher risk of developing mental health issues following a disaster. Examples 
include childhood traumatic grief (a condition that may develop after the loss of a family 
member or close friend) and post-traumatic stress disorder (PTSD), whereby an individual may 
develop sustained changes in emotions, thoughts, and behaviour following exposure to traumatic 
events (Johnson & Ronan, 2014). A child’s reactions to a traumatic event and emotional tensions 
when they face stressful events following a disaster can be displayed in numerous ways 
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including re-experiencing of trauma, intrusive thoughts, and hyper-arousal; as well as 
behavioural issues such as delinquency, increased aggression, disruptive behaviours, withdrawal 
and avoidance, and decreased academic performance (Erkan, 2009; Fujiwara et al., 2014; V. A. 
Johnson & Ronan, 2014; Shaw, Espinel, & Shultz, 2007; Y. Wang et al., 2006). Moreover, 
previous research has found that after earthquake exposure children may experience 
posttraumatic symptoms such as anxiety, depression, hypervigilance, frequent crying and 
distractibility as well as psychological effects such as temper tantrums, irritability, sleep 
disturbances, enuresis and phobias (Jaycox, Morse, Tanielian, & Stein, 2006; Shaw et al., 2007). 
These effects can persist for many years post-disaster because of a child’s less developed 
capabilities to regulate emotion and cope with the trauma appropriately (Cénat & Derivois, 2015; 
Goenjian et al., 2011).  
 Recently in Christchurch, school principals and teachers have expressed concerns 
regarding the capacity of new entrants (i.e., children in their first year at primary school) to learn 
and settle in class, as well as delayed language and toileting, all of which can be related to PTS 
symptoms, a mental health condition associated with conduct and anxiety disorders in children 
(McCrone, 2014; S. Murphy, 2015; O’Callaghan, 2015; Price, 2014; Radio New Zealand, 2016a; 
S. Robinson, 2012; Stewart, 2015). Such concerns initiated a study by Liberty and colleagues 
(Liberty, Tarren-Sweeney, Macfarlane, Basu, & Reid, 2016) that studied 212 five year old 
children who experienced the Christchurch earthquakes when aged 12-48 months of age, through 
to the beginning years of primary school (age five to six) with an aim of determining whether the 
children displayed PTS symptoms as they began primary school. Study data were compared with 
data from a similar study conducted in 2009 but with children who had not been exposed to a 
natural disaster. Three years on, the findings were that, compared to the pre-earthquake group, 
the earthquake-exposed group exhibited clinical PTS symptoms twice as often (Mean = 2.91 vs. 
1.98) as well as greater number of high PTS scores (20.7% vs. 8.8%) (Liberty et al., 2016). 
These results are consistent with previous research looking at the rate of PTS symptoms in older 
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children and adolescents who have experienced earthquakes or other disasters (Chen & Wu, 
2006; Durkin, Khan, Davidson, Zaman, & Stein, 1993; Feo et al., 2014; Jia et al., 2013; Shaw, 
Applegate, & Schorr, 1996; Trickey, Siddaway, Meiser-Stedman, Serpell, & Field, 2012). As a 
result, contemporary Christchurch primary school classrooms include a number of children who 
present with persisting high stress symptoms, which in turn affects teachers’ abilities to teach 
and to cope with children’s problems (Liberty et al., 2016).   
 Such a classroom environment is stressful for teachers. Persistent and/or extensive 
expression of externalizing behaviour in class by children may lead to psychological distress on 
the part of teachers. For example, Ferguson, Frost, and Hall (2012) found that depression and 
anxiety in teachers was significantly influenced by both student behaviour and workload; and 
low job satisfaction resulted from stress and depression. Additionally, Friedman-Krauss, Raver, 
Morris, and Jones (2014) found child-teacher conflict and elevated stress levels in teachers 
increased when child behaviour problems were high and a more negative emotional climate was 
linked with high levels of job stress. Moreover, workload and psychological distress may derive 
from role overload and ambiguity (Mirowsky & Ross, 2003). This is something Christchurch 
teachers may be particularly familiar with as they work additional hours to put together 
supplemental support programmes for their students and experience increased pressure from 
Principals to support children’s learning; and deal with increased behaviour and learning needs 
in the classroom, (C. Harris, 2013; O’Callaghan, 2015).  
 Post earthquake, Christchurch teachers are not only teaching in a stressful environment, 
but are also on their own journey of recovery from the disaster. Many teachers working in 
earthquake-affected schools are not only dealing with the effects of stress on their students but 
are dealing with on-going earthquake stressors of their own, such as those mentioned earlier. 
Therefore, teachers’ wellbeing can be further negatively impacted as they juggle the demands of 
both work (school) and personal (home) lives. One potential negative effect of these demands, 
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acting as both a cause and effect of on-going stress, is sleep disruption. Thus the specific link of 
stress and insomnia is reviewed in the next section.  
1.2 Insomnia – a brief Review 
 A stressful environment such as is commonly experienced in a stressful occupation such 
as teaching can have numerous effects, one being insomnia, in which an individual experiences 
problems in the initiation of sleep, early morning awakening, and impaired sleep maintenance, 
despite adequate opportunity for sleep (American Psychiatric Association, 2013) (American 
Psychiatric Association, 2013). Moreover, insomnia is further associated with daytime 
functioning impairments and significant distress (American Psychiatric Association, 2013). 
Therefore, individuals with insomnia are unable experience sleep that is of an adequate duration 
or quality to yield refreshment the next morning (Attarian & Perlis, 2010). The threshold 
distinguishing normal and abnormal sleep is conventionally represented by whether it takes an 
individual more than 30 minutes to fall asleep and/or if they experience more than 30 minutes of 
wakefulness after sleep onset (Attarian & Perlis, 2010). Such sleep difficulty must occur at least 
three times per week, and this must have persisted for more than one month (Roth, 2007). 
Furthermore, insomnia may be acute, occurring in response to short-term stress and disturbance 
in life routines (e.g., worry about something; mild illness) or it can be chronic, with general 
population data showing severe insomnia can last on average four years (Chevalier et al., 1999), 
with 88.2% still reporting insomnia five years after onset (Mendelson, 1995).  
 Despite being the most commonly reported and highly prevalent sleep disorder (Ohayon, 
2002), insomnia often goes unrecognized and untreated (Morin, 2010). Literature has shown that 
30% of individuals report insomnia symptoms, and of these, 15-20% report associated daytime 
impairment (American Psychiatric Association, 2013). However, using standardised diagnostic 
criteria, 5-10% of adults meet the criteria for an insomnia diagnosis (American Psychiatric 
Association, 2013). New Zealand population prevalence estimates are consistent with this 
international literature. These estimates show 13.0% of New Zealanders between the ages of 20-
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59 years report at least one symptom of insomnia often or always, alongside daytime sleepiness 
(O'Keeffe, Gander, Scott, & Scott, 2012).  
1.2.1 Epidemiology and Risk Factors of Insomnia 
 Although data investigating predisposing factors for insomnia is limited, there are several 
hypothesized factors including a familial or personal history of insomnia, older age, female 
gender (Morin & Jarrin, 2013), and work stress (Jansson & Linton, 2006). Women tend to be at a 
higher risk of developing insomnia compared to men (Leger, Guilleminault, Dreyfus, Delahaye, 
& Paillard, 2000; Zhang & Wing, 2006). Hypotheses as to why women have higher risk ranges 
from reporting bias to hormonal changes during their fertile years and during menopause and to 
a higher prevalence of psychiatric disorders (e.g., depression) in women (M. J. Sateia, 2010). 
Furthermore, the risk of developing chronic insomnia increases with age (Ohayon, 2002; 
Pallesen, Sivertsen, Nordhus, & Bjorvatn, 2014), which is not surprising, as many factors covary 
with age, such as pain, medication use, medical illness, and prevalence of other sleep problems 
(M. J. Sateia, 2010). Work stress is also associated with the development and maintenance of 
insomnia, including specific perceived stressors such as work demands (Jansson & Linton, 
2006). Additionally, low socioeconomic status and unemployment have been found to be highly 
associated with insomnia (Léger & Bayon, 2010).  
  Previous research shows high levels of comorbidity of insomnia with multiple 
psychiatric disorders, particularly anxiety and depression (Goldman-Mellor et al., 2014; Staner, 
2010). Data from early studies (D. E. Ford & Kamerow, 1989; Ohayon, Caulet, & Guilleminault, 
1997) found, of those presenting with insomnia, over 40% of individuals reported comorbid 
psychiatric disorders, the majority being anxiety and major depression disorders (D. E. Ford & 
Kamerow, 1989; Ohayon et al., 1997). These results are similar to those found in more recent 
studies looking at the association between anxiety and depression and insomnia (Goldman-
Mellor et al., 2014; E. Johnson, Roth, & Breslau, 2006; Morphy, Dunn, Lewis, Boardman, & 
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Croft, 2007; Ohayon & Roth, 2003; Sivertsen et al., 2014; Sivertsen et al., 2012; Strine & 
Chapman, 2005).  
 For many years, it was understood that a crucial generating and maintaining factor in the 
association between psychiatric disorders and insomnia was psychopathology (M. J. Sateia, 
2010). Although such an interpretation remains today, several epidemiological studies (Breslau, 
Roth, Rosenthal, & Andreski, 1996; Riemann & Voderholzer, 2003; Taylor, Lichstein, & 
Durrence, 2003) suggest an alternate hypothesis, namely that chronic insomnia is a crucial 
generating and maintaining factor of psychiatric illness (i.e., the causal direction of the 
association is reversed). In a large population-based multinational study conducted in Europe, 
Ohayon and Roth (2003) found the first episode of depression was preceded by insomnia 41% of 
the time, and only 29% of the time did insomnia follow the onset of depression. Similar results 
were previously reported by Eaton, Badawi, and Melton (1995) and have been confirmed by 
longitudinal studies (Breslau et al., 1996; Chang, Ford, Mead, Cooper-Patrick, & Klag, 1997). 
Moreover, research has shown that greater levels of insomnia are associated with more severe 
depression (Manber & Chambers, 2009).  
 In terms of anxiety, some studies have found that insomnia precedes anxiety. A review of 
epidemiological studies by Taylor et al. (2003) found that individuals with insomnia were at 
greater risk of developing an anxiety disorder (Cohen’s d = .13-.43) compared to those without 
insomnia. These results have since been confirmed by later studies (Jansson-Fröjmark & 
Lindblom, 2008) and in a recent longitudinal study (Jackson, Sztendur, Diamond, Byles, & 
Bruck, 2014). However, results are mixed as other research has shown insomnia has not been 
significantly associated with the onset of anxiety disorders. For example, Ohayon and Roth 
(2003) found insomnia either emerged at the same time (>38%) or after (34%) an anxiety 
disorder. Similar results were also reported by Johnson, Roth and Breslau (2006).  
 Additionally, further research has shown that insomnia is associated with various other 
psychiatric disorders. Previous research shows that compared to controls, individuals with 
 10 
insomnia are at increased risk of developing panic disorder (Weissman, Greenwald, Niño-
Murcia, & Dement, 1997) substance abuse or dependence as a way to self-medicate for sleep 
(Brower, Aldrich, Robinson, Zucker, & Greden, 2001; Pigeon, 2010; Taylor et al., 2003; 
Weissman et al., 1997) and hallucinations (Sheaves et al., 2016).  
 As well as psychiatric illnesses, insomnia shows high comorbidity with many physical 
illnesses. Significant sleep disturbance is often reported in approximately 50% to 88% of 
individuals with musculoskeletal pain conditions such as osteoporosis, rheumatoid arthritis, and 
fibromyalgia (Mai & Buysse, 2008; Morphy et al., 2007; Pigeon, 2010; Sivertsen et al., 2014). 
Physical fatigue (Kyle, Espie, & Morgan, 2010), obesity (Altevogt & Colten, 2006; Hasler et al., 
2005; Sivertsen, Krokstad, Øverland, & Mykletun, 2009), and cardiovascular disease not 
associated with typical coronary risk factors (Sofi et al., 2014; Spiegelhalder, Scholtes, & 
Riemann, 2010; Taylor et al., 2007) also show high comorbidity with insomnia, with studies 
showing insomnia increases the risk of these diseases. Further research also shows associations 
between insomnia and type II diabetes (Vgontzas et al., 2009), asthma, migraine (Sivertsen et al., 
2009; Sivertsen et al., 2014) and increased gastrointestinal, urinary, neurologic and breathing 
issues (Taylor et al., 2007). It is clear from this research, that insomnia not only has negative 
impacts psychologically, but physically also.   
1.2.2 Consequences of Insomnia for daytime functioning 
  Numerous studies have shown insomnia negatively impacts individuals, including many 
areas of daytime functioning showing poorer outcomes on several quality of life measures such 
as daytime sleepiness, impaired memory and concentration, intrusive thoughts (Baker, Baldwin, 
& Garner, 2015), reduced ability to complete daily tasks, worsened social functioning, and less 
enjoyment of interpersonal relationships (Bolge, Doan, Kannan, & Baran, 2009; Orzeł-
Gryglewska, 2010; Paine, Gander, Harris, & Reid, 2005; Wilkerson, Boals, & Taylor, 2012). 
Such daytime consequences can worsen over time, as shown by Komada et al. (2012) in their 
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longitudinal study and more recently by Ford and colleagues (E. S. Ford, Cunningham, Giles, & 
Croft, 2015). 
Additionally, insomnia also affects individuals in the work place, and D. Henry, 
McClellen, Rosenthal, Dedrick, and Gosdin (2008) found it was viewed as a barrier to 
occupational success as it is linked to a higher risk of permanent work disability (e.g., baseline 
sleep duration and sick leave) (Sivertsen et al., 2009; Sivertsen et al., 2006), and decreased 
likelihood of future professional progression (e.g., salary increases and promotion) (Kucharczyk, 
Morgan, & Hall, 2012). Moreover, it has been reported that those with insomnia have a higher 
likelihood of changing occupations, lower job satisfaction and feelings of mastery and tend to 
utilize emotion-oriented rather than problem-solving oriented coping strategies (Morin, 
Rodrigue, & Ivers, 2003).  
There is a close association between insomnia and increased cognitive failures in day-to-
day activities (Fortier-Brochu, Beaulieu-Bonneau, Ivers, & Morin, 2012); ergo individuals with 
insomnia are at greater risk for occupational errors, mishaps, and work, home and car accidents 
compared with good sleepers (Daley, Morin, LeBlanc, Gregoire, et al., 2009; Leger, Massuel, 
Metlaine, & Group, 2006). For example, Leger et al. (2014) reported findings of increased rates 
of accidents not associated with hypnotic use side effects in those with insomnia compared to 
those without. Additionally, Kling, McLeod, and Koehoorn (2010) found that women in 
professional occupations such as teaching and nursing had increased risk of occupational injury 
due to lack of sleep compared to other occupations. Sleep difficulties and increased risk of work 
injury may be associated with these occupations as they are often characterized by long hours 
and high job demands. Extrapolating this to teachers in Christchurch in the post earthquake 
environment it is likely that there has been, increased risk of work injury is exacerbated due to 
the extra pressures in the job post-earthquake.  
In summary, insomnia is shown to have a wide range of adverse effects on sufferers. 
Insomnia may result in higher rates of medical consultations, increased use of medical services, 
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increased medication use, greater work absenteeism and decreased work productivity, and 
increased industrial and motor-vehicle accident risk (Araújo, Jarrin, Leanza, Vallières, & Morin, 
2017; Kyle et al., 2010; Léger, Guilleminault, Bader, Lévy, & Paillard, 2002). Therefore, the 
worldwide health and economic burden as a result of insomnia is substantial (Daley, Morin, 
LeBlanc, Grégoire, & Savard, 2009; Léger & Bayon, 2010). To understand insomnia and 
perchance treat it first requires us to understand normal sleep, the topic of the next section. 
1.2.3 The physiology of normal sleep 
 In contrast to those suffering from insomnia, in normal sleepers, the four sleep stages 
(Table 1) of the circadian rhythm (“an endogenous rhythm with a period of approximately 24 
hours that is entrainable, persists in the absence of external time cues, and is temperature 
compensated”, Potter et al. (2016), p585) occur overnight in succession in a ‘sleep cycle’, lasting 
for 90-120 minutes, before repeating approximately three to six times. Two types of sleep occur 
in this cyclic fashion; Non Rapid Eye Movement (NREM) sleep which represents a continuity of 
relative depth and accounts for 75-80% of normal sleep, and Rapid Eye Movement (REM) sleep 
which accounts for 20-25% of normal sleep (Carskadon & Dement, 2011; Stanley, 2005). In 
normal sleep, a brief awakening (i.e., “prolonged arousal with behavioural impact, including 
cardiovascular activation”) (Stanley, 2005, p3) is common amid or soon after REM sleep. In 
good sleep, awakenings are brief, hormones balanced and sleep is easily resumed; however, in 
disrupted sleep Slow Wave Sleep (SWS) is decreased and stage one sleep increased, meaning 












Table 1. Stages of the Sleep Cycle  
Stage Characteristics 
NREM Stage 1 (N1) 
 
Beginning of sleep onset; sleep is easily disrupted; muscle 
contractions. Lasts on average for 1-7 minutes and occurs as a 
transitional stage throughout the night. 
NREM Stage 2 (N2) Characterized by specific EEG complexes. At this stage of 
sleep it is harder to be awakened by external stimuli. Heart 
rate slows; body temperature drops. Lasts for approximately 
10 to 25 minutes.   
NREM Stages 3 and 4 (N3) Transition from light sleep to very deep sleep. Delta sleep 
(deep sleep), high-voltage slow-wave patterns are seen on 
EEG indicating restorative sleep. Hard to be awoken at this 
stage of sleep.  
Stage R (REM sleep) Characterized by episodic bursts of rapid eye-movements 
during sleep; muscle atonia; altered body temperature; heart 
rate and respirations increase; and EEG activation. Dreaming 
is associated with this sleep stage. Arousal threshold is 
variable during this stage. REM cycles become progressively 
longer throughout the night.  
• NREM = non-rapid eye movement, REM = rapid eye movement. EEG = 
electroencephalographic activity 
Note: Information in table obtained from Carskadon and Dement (2011) and Stanley (2005). 
 
1.2.4 Insomnia and the stress system 
 Previous research has found that the circadian rhythm, and consequently, sleep, is 
affected after stressful life events, therefore, stress is a risk period for prolonged cognitive and 
physiological hyperarousal, and thus insomnia (Vedaa et al., 2016). The cognitive hyperarousal 
model of insomnia (Espie, 2007; Harvey, 2002) posits that a stressed and anxious state evokes 
excessive negative cognitions about getting adequate sleep, and explains the consequence this 
has on daytime functioning and health. Autonomic arousal is elicited resulting from activation of 
the sympathetic nervous system (for instance, by a stressful event), and increased cortical arousal 
is commonly seen during the sleep onset period in those with insomnia (Levenson, Kay, & 
Buysse, 2015). Moreover, research shows reduced SWS and increased electroencephalographic 
(EEG) activity during NREM sleep in those with insomnia (Basta, Chrousos, Vela-Bueno, & 
Vgontzas, 2007; Cortoos, Verstraeten, & Cluydts, 2006; Hall et al., 2007), which is consistent 
with a state of hyperarousal. 
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In terms of physiological arousal, Palagini, Biber, and Riemann (2014) posited that 
neurobiologic systems that modulate stress-response and sleep-wake regulation are disrupted due 
to stress and insomnia exposure, therefore enhancing the risk of chronic insomnia. Several 
studies have provided evidence for physiological hyperarousal in those with insomnia (Bonnet & 
Arand, 2010; Hall et al., 2007; Riemann et al., 2010). Furthermore, elevated 
adrenocorticotrophic hormone and cortisol levels that occur during SWS, result in both 
wakefulness and spontaneous awakenings, both of which are symptoms associated with 
insomnia (Stanley, 2005). These findings indicate a significant correlation between 
psychological distress and physiological arousal during sleep.   
Additionally, times of high stress and anxiety are metabolically demanding on an 
individual and the ability of the gastric system to absorb nutrients is hindered. This imposes high 
nutritional needs that then impact other normal biological activity throughout times of prolonged 
stress (McCann & Ames, 2009). As a result, the circadian rhythm can be disrupted, thus 
negatively impacting sleep. 
It is clear that stress has a large capacity to disrupt the sleep cycle and promote chronic 
insomnia. This is of particular relevance to those in Canterbury who have experienced the 
earthquakes and numerous life stressors that have come with them.  As already shown, even 
under normal circumstances, teaching is a stressful occupation. In addition, previous research 
also shows that, in comparison to other occupations, teachers experience higher rates of 
emotional exhaustion, and in turn, increased stress levels (Kuntz, Näswall, & Bockett, 2013). As 
such, it is likely that teachers working in earthquake-affected schools in Christchurch, who are 
dealing with ongoing earthquake stressors and teach in classrooms that include a number of 
highly aroused and reactive children, are under significant daily stress and many may be 
experiencing the symptoms of insomnia.  
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1.3 Treatments for Insomnia 
Pharmacological Treatment 
It is important for individuals’ to seek treatment for insomnia, and to date the 
pharmacological approach is most widely used. Various pharmacological treatments target 
numerous aspects of the physiological processes mentioned above (For a review see Ioachimescu 
& El-Solh, 2012; Szabadi, 2014). Medications most commonly prescribed include hypnotics, 
benzodiazepines (BZD’s), nonbenzodiazepines (non-BZD’s), and melatonin receptor agonists 
(Lie, Tu, Shen, & Wong, 2015; Minkel & Krystal, 2013). BZD’s are known for their sedative-
hypnotic effects (Minkel & Krystal, 2013) and those approved to treat insomnia include 
temapzepam, triazolam, estazolam, quazepam, and flurazepam; however, off-label BZD’s may 
also be used (e.g., diazepam and lorazepam) (Lie et al., 2015). BZD use increases gamma-
aminobutyric acid (GABA) neurotransmitter inhibitory effects in the central nervous system, 
thereby decreasing sleep onset latency and increasing sleep duration (Cape, 2008); they also 
suppress slow-wave and REM sleep and prolong stage two sleep (Ebert, Wafford, & Deacon, 
2006). Non-BZD’s were created in order to decrease adverse effects associated with BZD’s; 
those used for hypnotic use include zolpidem, zalepon, and zopiclone (Lie et al., 2015), of which 
zopiclone is commonly used in New Zealand to treat insomnia (Kershaw, Vella-Brincat, & 
McKean, 2011). Non-BZD’s elicit decreased slow-wave activity and increased beta and spindle 
activity in sleep as shown by EEG, thereby increasing the amount of restorative sleep (Ebert et 
al., 2006).  
However, although commonly prescribed, both BZD’s and non-BZD’s often produce 
numerous adverse side effects and daytime sedation. Such effects include drowsiness, light 
headedness, anxiety, anterograde amnesia, impaired memory and balance, cognitive impairment, 
psychomotor impairment, paradoxical inhibition, increased likelihood of falls, and complex 
sleep behaviours including sleep-related driving, eating, and sleep walking (Buysse, 2013; Cape, 
2008; Krystal, 2010; Lie et al., 2015). 
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In terms of melatonin (an endogenous hormone involved in circadian rhythms which is 
produced by the pineal gland), its agonist ramelteon is commonly used to treat insomnia. It is 
posited that due to its high-affinity for the MT1 receptor, ramelteon regulates drowsiness through 
weakening wake-promoting signals from the suprachiasmatic nucleus (where sleep-wake 
rhythms are thought to be controlled) (Minkel & Krystal, 2013; Pigeon, Bishop, & Marcus, 
2013; Roehrs & Roth, 2012). Furthermore, melatonin administered externally is posited to 
accelerate adaptation to sleep phase shifts as well as decrease sleep latency (Deacon & Arendt, 
1995). However, ramelteon does not come without side effects; those most commonly reported 
include headaches, dizziness, nausea and somnolence (Minkel & Krystal, 2013; Lie et al., 2015).  
Pharmacological Treatment Efficacy 
Regarding efficacy of pharmacological treatment for chronic insomnia, although short-
term efficacy has been established (Buscemi et al., 2007; Smith et al., 2002), long-term efficacy 
has not (Krystal, 2010; Krystal, Rogers, & Fitzgerald, 2006). Long-term use may be associated 
with dependence, tolerance, drug-drug interactions, decreased daytime functioning and symptom 
rebound upon discontinuation, which may be more severe than the original insomnia disorder  
(Krystal, 2010; Morin & Benca, 2012; M. J. Sateia & Nowell, 2004; Smith et al., 2002). 
Moreover, studies have not found sustained improvement when pharmacological treatments are 
discontinued (Schutte-Rodin, Broch, Buysse, Dorsey, & Sateia, 2008). Studies on the efficacy 
and effectiveness of melatonin as a hypnotic are inconclusive, showing a small reduction in sleep 
latency of 7.2 minutes, and no increase in total sleep time (Buscemi et al., 2007; Schutte-Rodin 
et al., 2008). Such adverse and/or minimal outcomes of pharmacological treatment have 
prompted a search for alternative treatments that are beneficial in the long-term.   
Cognitive Behavioural Treatment for Insomnia 
One such alternative is cognitive behavioural treatment for insomnia (CBT-I), which uses 
a multicomponent approach in order to decrease the perpetuating aspects that define insomnia, 
including irregular sleep-wake schedules, daily napping, excessive time spent in bed, exorbitant 
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worry and rumination about sleep loss and daytime consequences, and performance anxiety 
(Morin, 2004; Siebern, Suh, & Nowakowski, 2012). CBT-I is a short-term treatment consisting 
of approximately four to eight sessions, that encompasses multiple behavioural components 
(sleep restriction therapy, relaxation training, stimulus control), a cognitive component 
(restructuring of maladaptive thoughts, beliefs, and attitudes interfering with sleep or that hinder 
behavioural treatment components), and guidelines that incorporate both cognitive and 
behavioural components (sleep and sleep hygiene education) (Manber et al., 2011). CBT-I aims 
to alter cognitions and learned behaviours that perpetuate insomnia, as well as help individuals 
understand and remove factors contributing to the condition.  
CBT-I Treatment Efficacy 
CBT-I has proven effectiveness (i.e., produces a positive effect under ordinary day-to-day 
conditions and aims to enhance external validity while maintaining internal validity) and efficacy 
(i.e., produces a positive effect under ideal circumstances and aims to enhance internal validity) 
(Irwin, Cole, & Nicassio, 2006b; Mitchell, Gehrman, Perlis, & Umscheid, 2012; Okajima, 
Komada, & Inoue, 2011; M. Y. Wang, Wang, & Tsai, 2005), with research showing that it is 
effective at reducing sleep onset latency (d = -0.52) and wake after sleep onset (d = -0.64), and 
increasing sleep efficiency (d = -0.99) and quality (d = 0.90) (Irwin, Cole, & Nicassio, 2006a). 
These benefits have been shown to sustain over time compared to the effects of pharmacological 
treatment, which are often brief (Edinger & Means, 2005; Mitchell et al., 2012; M. Y. Wang et 
al., 2005). However, despite this, individuals need access to a good therapist and often those 
diagnosed with insomnia only have limited access to one. This holds true in a post-disaster 
environment, as there are likely to be few trained mental health professionals available (Suzuki 
& Kim, 2012), which then creates long waitlists for treatment, something that has been seen in 
Christchurch post-earthquake (McLennan, 2016). Individuals also need to be willing to put in the 
time and effort required for sleep practices to change in order for the treatment to be effective 
(Morin, 2006).  
 18 
1.4 Why Micronutrients Should be Considered for Treating Insomnia 
Recent research into the treatment of mental health disorders has looked at the use of 
both single-micronutrient and broad-spectrum micronutrients. Micronutrients include all 
vitamins and minerals required in trace amounts in order to maintain health (Popper, 2014). They 
are essential for all metabolic processes, and consequently, are essential for physical and mental 
wellbeing (Kaplan, Rucklidge, Romijn, & McLeod, 2015). In order to maintain physical and 
mental health and biologic functionality, micronutrient intake must meet nutritionally adequate 
levels; otherwise deficiencies emerge which can have large impact on both brain development 
and physical growth (Popper, 2014). Epidemiological research has shown that over the last 
century, dietary changes in the Western world (Cordain et al., 2005; Crawford et al., 1999), 
mean that many people are consuming diets significantly lower in micronutrients in comparison 
to the diets of earlier times (Cordain et al., 2005). With the rise in prevalence of mental health 
disorders, it is not surprising that a link has been proposed between nutritional intake and mental 
health.  
In order to understand how micronutrients play a role in mental health, it is first 
important to understand their role in biological functions. Vitamins and minerals play a crucial 
part in all physiologic, biologic, and chemical processes in the human body (Popper, 2014). 
Many enzymes require cofactors (coenzymes) so that enzymatic functions within the body can 
be carried out effectively (Kaplan, Rucklidge, Romijn, & McLeod, 2015; Popper, 2014). 
Vitamins play a large role in the make-up of cofactors, either being a cofactor (e.g., biotin) or a 
component of a cofactor (e.g., folate in tetrahydrofolate); whilst minerals can be a structural 
component of enzymes, operate as cofactors, or switch on enzymes or other proteins (Popper, 
2014).  As a result, vitamins and minerals are essential for the synthesis and metabolism of many 
neurotransmitters, which are important chemicals that communicate information throughout the 
brain and body. For example, pyridoxal 5 phosphate (Vitamin B6) is a cofactor in the synthesis 
of GABA, serotonin, and epinephrine and norepinephrine, helping to decrease stress-induced 
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cortisol response; niacinamide (Vitamin B3) helps convert tryptophan to serotonin; 
methylcobalamin (Vitamin B12) and ascorbic acid (Vitamin C) assist in the synthesis of 
monoamine neurotransmitters; iron plays a role in the enzyme system that assists in serotonin, 
dopamine, norepinephrine and epinephrine production and it is also a cofactor assisting synthesis 
of tyrosine to dopamine; zinc plays a role in almost all areas of metabolism, acting as a cofactor 
for over 200 enzymes; magnesium is a cofactor that converts carbohydrates and fats to create 
adenosine triphosphate (ATP), as well as assisting in synthesis of nucleic acids and proteins 
(Head, Kelly, & 2009; Kaplan, Crawford, Field, & Simpson, 2007; O’Kennedy, 2016).  
Furthermore, vitamins and minerals can strengthen and weaken neurotransmitter receptor 
binding. For example, iron enhances serotonin and dopamine binding to serotonin proteins in the 
frontal cortex. Moreover, calcium and magnesium play an important role in chemical signalling 
between cells, whilst cobalamin (Vitamin B12) has an important function in sustaining myelin 
sheaths, which in turn assists in messages being transmitted between cells (Kaplan et al., 2007). 
In short, vitamins and minerals play a vital role in normal biological and brain function, meaning 
they are an avenue worth exploring in the area of mental health and wellbeing generally and in 
sleep difficulties specifically.  
1.5 Metabolic Mechanisms, Mental Health, and Sleep 
How then might micronutrients play a role in sleep? Previously it was believed that 
neurotransmitter imbalances were the primary cause of abnormal mood states, a notion referred 
to as the catecholamine or biogenic amine hypothesis (Kaplan, Rucklidge, Romijn, & McLeod, 
2015). However, more recently it has emerged that this is not the primary cause. In turn, the 
emerging mental health field of nutritional psychology/psychiatry posits a new model of the 
biological basis of psychiatric illness which investigates how metabolic mechanisms may play a 
role in the development of psychiatric problems (Kaplan, Rucklidge, Romijn, & McLeod, 2015).  
In particular, the role of gastrointestinal inflammation, microbiome alterations and oxidative 
stress and mitochondrial dysfunction are being investigated (Kaplan, Rucklidge, Romijn, & 
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McLeod, 2015). Kaplan and colleagues (Kaplan et al., 2007; Kaplan, Rucklidge, Romijn, & 
McLeod, 2015) have found increasing evidence suggesting these metabolic mechanisms are 
linked to deficiencies and/or malabsorption of vitamins and trace elements in the expression of 
some psychiatric symptoms.  
1.5.1 Inflammation  
Numerous biological mechanisms associate mental health and diet together, and among 
these, inflammatory processes are hypothesized to play a vital role. Inflammation refers to a non-
specific immune response to injury, homeostatic imbalance or infection (N. Simpson & Dinges, 
2007). The association between sleep and inflammation is posited to be bi-directional, in that 
decreased sleep and insomnia can be elicited via stress hormone increases (Krueger, Obál, Fang, 
Kubota, & Taishi, 2001) and elevated inflammation markers including interleukin 1 (IL-1), 
interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-a) can be increased due to insomnia 
(Motivala, 2011; N. Simpson & Dinges, 2007). These proinflammatory cytokines (“cell-
signalling molecules involved in intracellular communication” Kaplan, Rucklidge, Romijn and 
McLeod, 2015, p2) both elicit inflammatory responses and are involved in sleep regulation 
(Motivala, 2011). Cellular and natural immune functioning are altered as a result of both acute 
and chronic sleep deprivation; however it is not clear what mechanism relates sleep and 
inflammation (Berk et al., 2013). One suggestion is that lifestyle factors impacting sleep may 
moderate inflammatory biomarkers through an existing bidirectional relationship that balances 
host-defence and sleep mechanisms (Berk et al., 2013). Research looking at those with insomnia 
has found elevated levels of TFN-a, IL-6 and C-reactive protein (CRP) proportional to the 
duration and quality of sleep (Burgos et al., 2006; Motivala, 2011; Patel et al., 2009; N. Simpson 
& Dinges, 2007; Vgontzas et al., 2003), and such activation may be a consequence of night-time 
sympathetic arousal as well as lowered natural immune functioning (Berk et al., 2013).  
These IL-6 and CRP elevations are similar to those found in individuals with major 
depression as compared to non-depressed individuals (Haapakoski, Mathieu, Ebmeier, Alenius, 
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& Kivimäki, 2015), providing a mechanism by which insomnia may contribute to the etiology of 
depression. Furthermore, evidence suggests inflammatory system activation occurs in other 
psychiatric disorders such as schizophrenia (Borovcanin et al., 2012) and bipolar disorder 
(Hamdani, Tamouza, & Leboyer, 2011). Therefore, if chronic inflammation plays such an 
important role in the development of mental illness it is important to know its causes, and 
emerging research points to the role of the gastrointestinal (GI) system.  
1.5.2 The Microbiome 
Over 90% of our body’s cells are microbial cells comprising the human microbiome. The 
bulk of these microorganisms reside in the gut (microbiota), where they carry out various 
functions pivotal to health and survival. Microbial cells help to protect the intestinal defence 
barrier system, digest our food, extract nutrients and help with nutrient synthesis in some cases 
(Kaplan, Rucklidge, Romijn, & McLeod, 2015; Moos et al., 2016). These microbiota play a 
pivotal role in the “gut-brain axis”, whereby bidirectional communication between the gut and 
the brain occurs. This communication is reliant on the health of the microorganisms, and 
imbalance of the gut bacteria, known as dysbiosis, can lead to inflammatory responses thereby 
contributing to a range of problems in the host including that of mood and behaviour problems 
via hormone signalling (Berk et al., 2013; Hawrelak & Myers, 2004; Nicholson et al., 2012).  
Gut dysbiosis can be a result of numerous causes such as an environment that is too 
clean, broad-spectrum antibiotic use, poor nutrition, psychological stress (Kaplan, Rucklidge, 
Romijn, & McLeod, 2015) and sleep difficulties (Reynolds et al., 2016). For example, 
composition and diversity of gut microbiota can be altered due to psychological stress as shown 
by animal models in the prenatal period (Golubeva et al., 2015), in early life (Bailey & Coe, 
1999; O'Mahony et al., 2009) and in adulthood, where it was found that altered microbiota 
increased circulating levels of pro-inflammatory cytokines (Bailey et al., 2011), thus increasing 
the risk of psychiatric problems. 
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The influence microbiota can have on the host’s immune system is substantial, and 
dysbiosis can produce an inflammatory reaction to toxic material produced by gram-negative 
bacteria, including Lypopolysaccharide (LPS) (Kaplan, Rucklidge, Romijn, & McLeod, 2015). 
This inflammatory reaction is evident through increased plasma levels of immunoglobulin (Ig) A 
and/or M in response to gram-negative bacteria, as seen in those with clinical depression 
(Kaplan, Rucklidge, Romijn, & McLeod, 2015; Maes, Kubera, Leunis, & Berk, 2012). Such a 
response suggests that bacterial translocation (whereby bacteria transfers from the inside of the 
intestinal tract to the outside) plays a part in the development of inflammatory responses in 
mental illness such as depression (Berk et al., 2013). Bacterial translocation occurs when the 
mucosal barrier across the gut wall becomes permeable as a result of loosening of the tight 
junction barrier. This allows gram-negative bacteria to pass outside of the intestinal tract, thus 
triggering inflammatory pathway activation via cells in the immune system that are not readily 
prepared against the LPS encased within gram-negative bacteria (Berk et al., 2013; Kaplan, 
Rucklidge, Romijn, & McLeod, 2015); consequently, brain function can be affected. Evidently, 
there is a strong relationship between dysbiosis and inflammation; however, there are other 
factors that may cause inflammation, such as oxidative stress.   
1.5.3 Oxidative Stress  
Oxidative stress (OS) is an important mechanism to consider when investigating potential 
causes of inflammation. Oxygen is an essential factor of life, and it is important to note that pro-
inflammatory cells exist in normal metabolic function and help fight off infection. Normal 
metabolic functioning creates molecules with unpaired electrons containing oxygen, known as 
reactive oxygen species (ROS)  (Kaplan, Rucklidge, Romijn, & McLeod, 2015). These free 
radicals are essential for cellular signalling, mitosis and physiological immunological responses; 
however, due to differing oxidative strengths, damage to DNA, RNA, cellular proteins, 
carbohydrates, lipids and nucleic acids is possible (Ng, Berk, Dean, & Bush, 2008). In normal 
conditions, these negative effects are controlled via certain intrinsic biological processes (e.g., 
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antioxidant production) (Kaplan, Rucklidge, Romijn, & McLeod, 2015; Ng et al., 2008). 
Increased OS occurs when ROS levels are elevated and antioxidant production is decreased, 
which in turn, can contribute to the pathogenesis of mental health issues (Kaplan, Rucklidge, 
Romijn, & McLeod, 2015).   
 Biomarkers including superoxide dismutase (SOD – an antioxidant enzyme that 
decreases cell damage via ROS detoxification), nitric oxide activity and thiobarbituric acid 
reactive substances (TBARS – a byproduct of lipid peroxidation) are often employed to detect 
OS (Kaplan, Rucklidge, Romijn, & McLeod, 2015). Altered levels of these biomarkers have 
been found in those with depression (Maes, Galecki, Chang, & Berk, 2011), bipolar disorder 
(Brown, Andreazza, & Young, 2014), Attention-Deficit/Hyperactivity Disorder (ADHD) 
(Ceylan, Sener, Bayraktar, & Kavutcu, 2012), and schizophrenia (Ciobica, Padurariu, Dobrin, 
Stefanescu, & Dobrin, 2011). Lack of adequate sleep is known to have a worsening effect on 
these conditions. Previous research has found significantly increased malondialdehyde (MDA – 
end product of lipid peroxidation) and decreased glutathione peroxidase (GSH-Px – antioxidant 
enzyme containing selenium) levels in insomnia patients relative to healthy controls, indicating 
that sleep deprivation can result in greater OS (Hamdani et al., 2011) and decreased antioxidant 
factors (GSH-Px), therefore suggesting that sleep plays an important role in OS reduction (Gulec 
et al., 2012; Tsaluchidu, Cocchi, Tonello, & Puri, 2008). Therefore if OS is a causal factor of 
inflammation and plays an important role in the pathogenesis of mental disorders, it is important 
to determine what influences oxidative stress in the first place, and recent research is finding 
growing evidence that mitochondrial dysfunction may play a vital role. 
1.5.4 Mitochondrial Impairment 
Through evolution humans have developed cellular organelles called mitochondria that 
aid in managing inflammation and OS. Mitochondria are energy producing intracellular 
organelles present in large numbers in virtually all human cells. The energy supplied comes in 
the form of adenosine triphosphate (ATP). ATP production starts with carbohydrates, fats and 
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proteins being broken down (a process that begins in the gut under the influence of the 
microbiome) resulting in the production of acetyl coenzyme-A, which is then oxidised (electrons 
are removed) in the Kreb’s cycle. These electrons are then donated to the electron transport chain 
(ETC), where they then transfer through a sequence of chemical reactions which supply a stable 
environment for ATP production. In order for the Kreb’s cycle and ETC to function optimally 
many coenzymes are needed, many synthesized from dietary nutrients (Kaplan, Rucklidge, 
Romijn, & McLeod, 2015).   
Apart from the nucleus, mitochondria are the only cell organelle containing DNA 
(mtDNA), and are thereby vulnerable to ROS induced damage due to their close proximity to the 
ETC. Mitochondrial dysfunction resulting from mtDNA mutation and OS negatively impacts 
brain function through reduction of ATP. The brain requires ATP produced by mitochondria to 
function optimally, and uses approximately 20% of all energy produced by mitochondria. Most 
of this energy facilitates excitatory neurotransmission in the cortex, where the amino acid 
glutamate as well as other antioxidants, play an important role to help protect the brain from 
oxidative damage. Therefore, reduction in ATP availability negatively impacts brain function, 
and research posits that this may be a causal factor of some mental illness, a further idea worth 
considering (Kaplan, Rucklidge, Romijn, & McLeod, 2015).   
In terms of sleep disorders, it is reasonable to assume that mitochondrial dysfunction may 
occur as a result of sleep deprivation due to the crucial role sleep plays in OS (Gulec et al., 
2012). Sleep may act as a protection against oxidative damage, and it is posited that ROS levels 
increase during wakefulness and are removed during sleep. Sleep deprivation decreases the 
chance of free radical removal, meaning there is increased risk of ROS-induced damage in the 
ETC of mitochondria which may lead to mitochondrial disease. For example, Frau‐Méndez et al. 
(2017) found that complex I, II, III, IV and V levels (i.e., ETC complexes that aid in ATP 
production) were decreased in a human sample of individuals with fatal familial insomnia, with 
the authors concluding that severe mitochondrial impairment contributes to the course of FFI as 
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a result of sleep deprivation, which in turn leads to increased ROS production, thereby resulting 
in oxidative damage to DNA, proteins and lipids. Moreover, further research in humans has 
found reduced sleep efficiency and duration is associated with lowered mtDNA copies within 30 
monozygotic twin pairs (Wrede et al., 2015), suggesting mitochondrial energy production is 
impaired, and factors such as OS are likely to contribute to this dysfunction.  
Together, these findings suggest that mitochondrial dysfunction may play a role, 
potentially and important one, in the development of sleep disorders; however, causation cannot 
be determined. Mitochondrial dysfunction can be significantly influenced by nutrition; however, 
it is difficult to determine specific nutrients that optimize mitochondrial functioning (Kaplan et 
al., 2015b). When the mitochondrial functioning process are looked at as a whole, most vitamins, 
minerals, amino acids, and essential fatty acids play a role (Kaplan, Rucklidge, Romijn, & 
McLeod, 2015); and as inflammation, gut dysbiosis, oxidative stress and mitochondrial 
functioning are all interrelated, it is plausible that use of multiple nutrients may play a role in the 
restoration of the impaired metabolic mechanisms seen in those with sleep disturbances and 
psychiatric illness. 
1.6 Association between micronutrient deficiencies and sleep 
Given the evidence reviewed above there has recently been a growing interest in the 
association between sleep and nutrition, albeit often speculative; however, the impact that 
micronutrients in particular may have on sleep has received little attention. Previous 
experimental studies have posited that sleep regulation neurotransmitters and nerve-signaling 
chemicals such as N-methyl-D-aspartate (NMDA) (Sowa-Kućma et al., 2008), serotonin (Ursin, 
2002), and melatonin secretion (Honma, Kohsaka, Fukuda, Morita, & Honma, 1992) may be 
impacted by micronutrients, which has further lead researchers to investigate the relationship 
between sleep and micronutrients in both observational and clinical studies.  
Although research on the relationship between micronutrient intake and insomnia 
specifically is scarce, several observational studies have identified an association between 
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micronutrient deficiencies and sleep patterns. In terms of B vitamins, previous research has 
found that lower vitamin B12 and B6 status in young women was associated with a later 
midpoint of sleep (Sato-Mito, Shibata, Sasaki, & Sato, 2011), and Zadeh and Begum (2011) 
found that in a study of 87 adults, those with insomnia displayed deficiencies in thiamine 
(Cohen’s d = -0.74), vitamin B12 (d = -0.74) and B9 (folic acid) (d = -0.73) in comparison to 
normal sleepers, a significant result. Further significant associations were found between lower 
levels of vitamins B2 (d = -0.75) and B3 (d = -0.72) and insomnia compared to those without 
(Zadeh & Begum, 2011). When looking at sleep quality and duration in a cross-sectional sample 
of 2,459 adults, Beydoun et al. (2014) found that, those with lower intakes of vitamin B12 and 
folic acid reported shorter sleep duration compared to normal sleepers. Reports of both vitamin 
B12 and vitamin B9 deficiencies is not surprising as a secondary deficiency in folic acid can 
occur as a result of vitamin B12 deficiency. This is because both these vitamins are involved in 
monoamine neurotransmitter synthesis, and vitamin B12 plays a role in the metabolism of folate 
(Kaplan et al.,2007).  
Several studies have also reported on the association between vitamin D (25(OH)D) 
deficiencies and sleep. For example, treatment seekers at a sleep medicine clinic displayed 
significantly greater levels of vitamin D deficiency compared to clinically normal sleepers (54% 
vs 29.5%) (McCarty et al., 2013). Several cross-sectional studies consistently found that short 
sleep duration and lower sleep efficiency were significantly associated with lower levels of 
serum 25(OH)D in older adults compared to normal sleepers (Bertisch, Sillau, De Boer, Szklo, & 
Redline, 2015; Kim, Chang, Kim, & Kang, 2014; Massa et al., 2015). Furthermore, in a cross-
sectional sample of 6139 adults aged over 20 years who were on average vitamin D deficient, 
lower 25(OH)D serum levels were statistically significantly associated with greater sleep latency 
(Shiue, 2013).  
In terms of mineral deficiencies and sleep, a nationally representative sample of 5587 
adults disclosed that very short sleep (<5 hours) was statistically significantly associated with 
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lower intake of magnesium, phosphorous, iron, zinc and selenium in comparison to normal 
sleepers (Grandner, Jackson, Gerstner, & Knutson, 2013). Lower intake of iron has also been 
found to be significantly associated with insomnia (d =-0.72) (Zadeh and Begum, 2011). 
Moreover, Sato-Mito et al. (2011) found that later sleep midpoint (the halfway time point 
between sleep onset and offset) was significantly associated with lower potassium (d = 4.17), 
magnesium (d = 5.00), calcium (d = 6.00) and zinc (d = 4.00) intake in female students aged 18-
20 years. Additionally, in relation to sleep efficiency and duration, a cross-sectional sample of 
126 women aged 21 – 72 years showed that lower sleep efficiency and short sleep duration was 
associated with lower zinc:copper ratio serum levels  (d = -3.67) and lower zinc levels  (d = -
1.29) (Song, Kim, & Jung, 2012).  
1.7 Effect of single micronutrient interventions on sleep patterns 
In past research the focus has been on investigating the effect of one vitamin and mineral 
at a time on the treatment of psychiatric illness (Kaplan et al., 2007), and given the association 
between deficient micronutrient status and poor sleep, a small number of experimental trials 
have investigated the effect of single nutrient supplementation on sleep. Randomized controlled 
trials (RCT) investigating the effect of vitamin B12 supplementation on poor sleep have found 
mixed results. An experimental trial of 9 healthy males between 20-28 years of age found no 
significant differences in both the duration and timing of sleep after four weeks supplementation 
of vitamin B12 (methylcobalamin - 3mg/d) compared to placebo (Honma et al., 1992). Okawa et 
al. (1997) found similar results in an RCT whereby no significant differences were found in 
sleep duration and daytime sleepiness in a sample of 50 individuals aged 13-55 years with 
delayed sleep phase syndrome after administration of methylcobalamin (3mg/day) for four 
weeks compared to placebo. An RCT investigating the dose effect of 8-week methylcobalamin 
supplementation in 48 individuals with sleep-wake rhythm disorders found a statistically 
significant improvement in delayed sleep phase and longer sleep-wake cycles after four weeks 
between the high dose group (6mg/d) and low dose control group (0.03mg/d); however, after 8 
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weeks of supplementation this difference was no longer significant (Takahashi et al., 1999). In 
contrast, Mayer and colleagues (1996) (Mayer, Kroger, & Meier-Ewert, 1996) found that 10 
healthy adults receiving methylcobalamin (3mg/d) supplementation for 14 days showed 
significant improvements in night sleep and daytime alertness and concentration in comparison 
to adults receiving cyanocobalamin (3mg/d).       
Previous RCTs have, however, found evidence to suggest vitamin B1 supplementation 
positively impacts sleep. For example, Smidt, Cremin, Grivetti, and Clifford (1991) reported 
improvement in sleep patterns and significant decrease in daytime fatigue  (d = 5.15) in a sample 
of 80 elderly women after vitamin B1 supplementation (10mg/d) for six weeks compared to 
placebo. Furthermore, Wilkinson, Hanger, Elmslie, George, and Sainsbury (1997) found vitamin 
B1 supplementation (10mg/d) for three months elicited a positive effect on sleep and energy in 
76 deficient elderly individuals compared to control; however, these results did not reach 
statistical significance. In terms of vitamin B3, statistically significant increases in REM sleep 
and increased sleep efficiency were found in a small study of both normal sleepers and those 
with insomnia after vitamin B3 supplementation (500-3000mg/d) for three weeks (C. Robinson, 
Pegram, Hyde, Beaton, & Smythies, 1977). When looking at vitamin D in an uncontrolled trial, 
Huang, Shah, Long, Crankshaw, and Tangpricha (2013) reported significantly improved sleep 
duration (d = -0.42) and latency (d = 0.19) after vitamin D supplementation in 28 veterans with 
vitamin D deficiency or insufficiency. Moreover, another uncontrolled trial of 1500 individuals 
with diverse sleep disorders also showed reduced sleeping difficulties after vitamin D 
supplementation (Gominak & Stumpf, 2012). However, these findings are to be considered with 
caution as the methods and analyses for this trial are not yet published.  
Previous research has also looked into the effect of mineral supplementation on poor 
sleep status. An RCT by Abbasi et al. (2012) demonstrated statistically significant improvements 
in sleep time (d = 0.42), sleep efficiency (d = 0.81), sleep onset latency (d = -0.95),  and early 
morning awakening (d = -0.53), in 43 older adults compared to controls after 8-week magnesium 
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supplementation (500mg/d). In contrast, Nielsen, Johnson, and Zeng (2010) found that despite 
96 adults with poor sleep quality showing decreased Pittsburgh Sleep Quality Index (PSQI) 
scores, no statistically significant difference was found between the 7-week magnesium 
supplementation group and placebo group. When investigating the effects of potassium 
supplementation on sleep quality in a crossover RCT of young men, Drennan, Kripke, Klemfuss, 
and Moore (1991) found that sleep efficiency was statistically significantly improved (d = -0.53) 
and sleep latency and sleep interval (time in bed) were statistically significantly reduced in both 
sleep log and actigraph measures in those receiving potassium supplementation (96meq/day) 
compared to controls.  
 When looking at these findings as a whole, it is important to consider that the treatment 
durations varied greatly, from as little as one week to 12 weeks. Additionally, doses used were 
also low which may have further impacted study outcomes. Therefore, while some of these 
studies provide some evidence of efficacy in treating sleeping difficulties with single nutrients, 
the findings are not consistent and are largely modest, suggesting that single nutrient 
interventions are not reliable treatments for insomnia. Given that micronutrients work best when 
they are properly balanced together and that they play a coordinated role in optimal brain 
functioning, studying a broad range of multiple nutrients simultaneously for the treatment of 
mental health disorders has become more accepted (Kaplan, Rucklidge, Romijn, & McLeod, 
2015).   
1.8 The effect of multinutrient interventions on mental health 
 A growing body of research is demonstrating the effectiveness of multinutrient treatment 
for a variety of mental health conditions including mood, anxiety, stress and sleep. This 
approach is proving to have greater beneficial effects compared to one nutrient alone.  
1.8.1 Mood  
 Several RCTs have shown positive effects of multiple micronutrients on mood in adults. 
E. Harris et al. (2011) conducted an 8-week double-blind RCT on 50 healthy older men (50-69 
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years), and found those receiving a multivitamin (Swisse Men's Ultivite) experienced improved 
mood compared to placebo (d = 0.39 - 0.53). Sarris et al. (2012) sought to extend these particular 
findings in a 16-week double-blind RCT of 114 healthy adults, and found those taking a 
multivitamin showed statistically significant improvements in both mood and energy levels 
compared to placebo. Additionally, Lewis et al. (2012) conducted a double-blind RCT involving 
60 adults diagnosed with depression and found those receiving a vitamin B complex formula 
(i.e., with a range of B vitamins) compared to placebo displayed statistically significanty more 
improvement as measured by the Beck Depression Inventory (BDI).  
1.8.2 Anxiety 
 Numerous studies have looked at the effect of micronutrients on stress and anxiety, 
showing positive results. Five RCT’s have examined the effects high dose B vitamins have on 
both stressed and healthy adults (Rucklidge & Kaplan, 2013), with all showing positive effects. 
Four of these were double-blind RCTs with similar treatment lengths of 28 days (Carroll, Ring, 
Suter, & Willemsen, 2000), 30 days (Schlebusch et al., 2000), 33 days (Kennedy et al., 2010), 
and 90 days (Stough et al., 2011). These studies showed that 80 healthy male volunteers (18-42 
years) (Carroll et al., 2000), 300 highly stressed adults (18-65 years) (Schlebusch et al., 2000), 
215 males (30-55 years) (Kennedy et al., 2010) and 60 adults (Stough et al., 2011) taking an 
over-the-counter B vitamin complex were less anxious, stressed, and depressed on average than 
those on placebo. Berocca (a dissolvable tablet containing vitamins B and C) was used in three 
of these trials (Carroll et al., 2000; Kennedy et al., 2010; Schlebusch et al., 2000), and another 
high dose vitamin B formula (Blackmores executive B Active) was used in the fourth (Stough et 
al., 2011). The fifth unblinded RCT (Rucklidge et al., 2012) will be discussed below.  
1.8.3 Insomnia 
 As previously stated, little attention has been paid to the impact micronutrients have on 
sleep. However, Rondanelli and colleagues (Rondanelli et al., 2011) in a double-blind RCT 
investigated the effect of 8-week nightly administration of magnesium (225mg/d), zinc 
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(11.25mg) and melatonin (5mg) on insomnia in 43 older adults (≥70 years). It was found that 
supplementation compared to placebo significantly improved sleep quality as measured by the 
PSQI (Cohen’s d = -1.92), and statically significant improvements were also seen in sleep onset 
latency, hangover on awakening from sleep, and alertness the next morning (Rondanelli et al., 
2011).  
1.9 Literature on EMPowerplus  
 These micronutrient studies demonstrate the effectiveness of using a wider range of 
micronutrients in the treatment of some mental health conditions. The most studied broad-
spectrum micronutrient formula studied to date is called EMPowerplus (EMP+; there are similar 
formulations with other names), consisting of 36 various vitamins, minerals, amino acids, and 
antioxidants (see Appendix A). EMP+ has been shown to be effective in a wide range of 
psychiatric conditions including mood, Attention-Deficit/Hyperactivity Disorder (ADHD), 
anxiety and stress, and obsessive compulsive disorder (OCD) in both adults and children 
(Rucklidge & Kaplan, 2013).  
1.9.1 Mood  
 All four publications of open-label trials (Frazier, Fristad, & Arnold, 2012; Kaplan et al., 
2001; Popper, 2001; Simmons, 2003) using EMP+ have shown significant reduction in bipolar 
symptoms in adults and children with bipolar disorder. Kaplan and colleagues (2001) 
demonstrated a significant reduction in bipolar symptoms as measured by the Hamilton Rating 
Scale for Depression, Brief Psychiatric Rating Scale and Young Mania Rating Scale measures 
(Cohen’s d > .80) in 11 adults (19-46 years) after six months of supplementation. Popper (2001) 
found that, of 22 patients (10 adults, nine adolescents, three children), 19 individuals displayed 
clinician evaluated improvements in bipolar symptoms (10 clinical, seven mild, two moderate). 
In a similar naturalistic trial Simmons (2003) reported that of 19 patients (18-68 years), 16 
individuals displayed clinician-evaluated improvements in bipolar symptoms (12 clinical, three 
mild, one moderate). In all cases, clinically significant symptom improvement was retained over 
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at least a 6-month period, and less medication was required to maintain symptom control (d > 
.80). An ABAB reversal design case study on a female adult (21 years) diagnosed with bipolar 
disorder II and ADHD (Rucklidge & Harrison, 2010) reported significant clinical improvement 
in mood and ADHD symptoms after 8-week supplementation of EMP+, and at 1-year follow-up 
was reported to be in remission of all psychiatric symptoms. Furthermore, a database analyses on 
adults (N = 358) (Gately & Kaplan, 2009) with bipolar disorder found that taking EMP+ 
improved bipolar symptoms significantly, with an effect size of Cohen’s d = 0.76. These 
improvements were sustained over six months, and were related to increased micronutrient 
dosage and medication reduction (Gately & Kaplan, 2009; Kaplan, Rucklidge, Romijn, & 
McLeod, 2015).  
1.9.2 Attention-Deficit/Hyperactivity Disorder  
 In terms of ADHD, broad-spectrum micronutrient supplementation has been found to be 
effective in adults. An open label 8-week trial of EMP+ with a 2-month natural extension found 
significant improvement (Cohen’s d = 0.66 – 2.55) in all outcome measures 
(hyperactivity/impulsivity, inattention, quality of life, mood, anxiety and stress) in 14 
medication-free adults (nine men, five women; 18-55 years) diagnosed with ADHD and severe 
mood dysregulation (Rucklidge, Taylor, & Whitehead, 2011). These improvements were 
maintained at follow-up in those continuing to take EMP+. Additionally, a recent placebo-
controlled 8-week RCT (Rucklidge, Frampton, Gorman, & Boggis, 2014a) demonstrated 
significant improvements in ADHD symptoms and general functioning after EMP+ 
supplementation compared to placebo in 80 adults (d = 0.46 – 0.67).  Moreover, these changes 
were sustained at 1-year follow up compared to baseline in adults (d = 0.39 – 0.62) (Rucklidge, 
Frampton, Gorman, & Boggis, 2014b). Cohen’s d effect sizes for these studies fell in the 
moderate to large range (0.46 to > 0.80), therefore increasing confidence in the positive effect 
micronutrients have on ADHD symptom improvement.  
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1.9.3 Obsessive Compulsive Disorder 
 Rucklidge (2009) demonstrated in an ABAB design the effectiveness of EMP+ on OCD 
in a case study of an 18-year old male, who previously underwent unsuccessful psychological 
treatment. The subject underwent EMP+ supplementation for 8 weeks, which yielded significant 
improvement in anxiety; however, symptoms of depression were still relatively high. After an 8-
week withdrawal from treatment, anxiety, obsession and depression scores increased 
significantly. EMP+ supplementation was reintroduced yielding improvements after just 12 days, 
and by four weeks OCD symptoms were in remission. These improvements were maintained six 
months later, with further reduction in depression symptoms (Rucklidge, 2009).  
1.9.4 Anxiety in a Post-disaster Context 
 The Christchurch earthquakes have provided researchers the opportunity to demonstrate 
the impact micronutrients can have on anxiety, stress and resilience in a post-disaster context. 
The fifth unblinded RCT (Rucklidge et al., 2012) mentioned above investigated the effect of  
micronutrient formulas, CNE (an equivalent of EMP+) high dose (8 capsules) and CNE low dose 
(4 capsules) and Berocca (one tablet per day), on stress, anxiety, and PTSD symptoms in 84 
adults (>18 years) following the Christchurch 6.3 earthquake after shock in February, 2011. 
Results found that all groups yielded statistically significant improvement in all symptoms; 
however, those on the high dose CNE with a broader spectrum of minerals improved the most. 
This result was sustained at the one year naturalistic follow-up (Cohen’s d = 0.69-1.31) 
(Rucklidge et al., 2014). Kaplan, Rucklidge, Romijn, and Dolph (2015) replicated this research 
in an RCT of 56 Canadian adults (23-66 years) following a severe flood in the city of Calgary 
and environs. After six-week supplementation by either EMP+ (N=18), a B-complex formula 
(N=17) or Vitamin D (N=21), significant improvement was found in stress and anxiety in those 
receiving the B-complex or EMP+ formulas compared to those receiving vitamin D alone as 
measured by the Depression, Anxiety, and Stress Scale (DASS-42)  (d = 0.76 – 1.08).  
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 Additionally, Rucklidge and Blampied (2011) found that 17 adults taking EMP+ with 
pre-existing vulnerabilities (ADHD) and facing the stress accompanying the initial Christchurch 
earthquake displayed greater resilience and therefore significantly less anxiety and stress as 
measured by the DASS compared to 16 controls (d = 0.69). Therefore, these findings provide 
evidence that vitamins and minerals may be strongly involved in regulation of the stress 
response, specifically in a post-disaster context.  
 1.9.5 Insomnia  
 In terms of insomnia, recent research has emerged showing the significant positive effects 
of micronutrients on insomnia in adults (Lothian, Blampied, & Rucklidge, 2016). Lothian et al. 
(2016) have shown that use of a broad-spectrum micronutrient, Daily Self Defense (DSD) 
(www.hardynutritionals.com) (a revision of EMP+ developed for general population use), over 
an 8-week period in an open-label multiple baseline design yielded improvements in insomnia 
symptoms (d = 3.45), stress (d = 2.53), anxiety (d = 1.36) and mood (d = 1.33), with all adult 
participants displaying reliable positive change. Such results show that alleviation of insomnia 
symptoms with micronutrients restores sleep after stressful life events through adequate 
nutrition. Considering the DASS measure, micronutrients had the greatest effect on stress, 
however, despite the association between stress and sleep, insomnia symptoms improved before 
stress during the intervention. This meant that insomnia symptom improvements were not in 
response to stress reduction and therefore stress did not directly mediate sleep improvement. 
 In summary, EMP+ (and related formulations) has been investigated for numerous mental 
health conditions in adults, including those associated with stress, and shows promising 
outcomes in the treatment of these conditions. In particular, given the evidence that nutritional 
supplementation has beneficial effects on stress and sleep, a trial of micronutrients with teachers 
experiencing stress and insomnia in the post-earthquake environment in Christchurch seems 
warranted. 
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1.10 Aims and Hypotheses 
 The aim of the current study is to investigate the effect of a broad-spectrum micronutrient 
formula, EMP+, on chronic insomnia in teachers. As Lothian et al. (2016) found positive results 
using a broad-spectrum micronutrient formula to treat insomnia in adults, the following research 
endeavours to determine whether this positive effect can be replicated in teachers working in 
schools that have been impacted by the Christchurch earthquakes, whilst improving on the 
methodology of Lothian et al. (2016) through use of a placebo. Such research is important 
because it is essential that teachers are able to function optimally both cognitively and 
emotionally in order to not only improve their own mental and physical wellbeing, but also to 
optimize the children’s learning, and teacher’s ability to cope with and help highly aroused and 
chronically distressed children.  
 It is hypothesised that this study will find the following: 
1. The micronutrient formula will be associated with improvements in insomnia 
symptoms relative to placebo. 
2. The micronutrient formula will also be associated with improvements in stress and in 
anxiety and mood if relevant, relative to placebo. 
3. The micronutrient formula will also be associated with improvement in emotional 
exhaustion and depersonalisation if relevant. 
4. The micronutrient intervention will have greater effect than placebo on primary 
measures of insomnia and wellbeing. 
5. Improvements will be maintained over the follow-up period if participants remain on 
the micronutrient formula, and improvements will be maintained at a lower level for 
those who discontinue. 
6. The micronutrient formula will not be associated with significant side effects and if 





 Between September and early October 2016 teachers from selected schools in 
Christchurch, New Zealand, were, with their Principal’s permission, approached via email to 
participate in the study, with the email including Information and FAQ sheets (see Appendix B). 
Those approached were teachers from primary and secondary schools substantively affected by 
the 2010 and 2011 earthquakes, including those from the east and coastal areas of the city. This 
particular sample was selected because many teachers in these schools were likely to have 
experienced increased stress (including symptoms of insomnia), with stress arising in particular 
from the presence in their classes of numbers of children with emotion regulation difficulties and 
high levels of chronic arousal.  
 The Information Sheet contained comprehensive information about the study as well as 
contact details of the researchers. Potential participants were directed to a website 
(www.bit.ly/insomniaandnutrition), with a link to an online screening questionnaire developed 
using Qualtrics software (www.qualtrics.com), which contained demographic information 
questions and screening questions about sleep and associated psychological measures (e.g., 
depression, anxiety and stress) (see Appendix C). At the end of the questionnaire, teachers were 
thanked for completing the screening and were informed that the researcher would be in contact 
about their eligibility as soon as possible. Potential participants not meeting inclusion criteria 
cut-off scores, or selecting an answer set as part of exclusion criteria (see below), were provided 
with information on the study product and how to obtain it themselves, and directed to local 
services available for both sleep and mental health care.  
2.1.1 Inclusion and exclusion criteria 
 In order to be considered eligible for the study, teachers were required to meet the criteria 
for insomnia as measured by the Pittsburgh Insomnia Symptom Questionnaire (PISQ, for 
explanation see below in Measures). Therefore they must have trouble falling asleep or 
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maintaining sleep at least three or four times a week, and this must have occurred for at least 4 
weeks. They also must rate their lack of sleep as affecting their daily functioning at least “quite a 
bit”. In order to determine the severity of insomnia, the Pittsburgh Insomnia Rating Scale- 20 
(PIRS-20, for explanation see below in Measures) was employed, and participants were included 
if their score was above the clinical cut-off of 20, identifying people with at least mild to 
moderate insomnia. Teachers had to be Registered and have at least two years experience 
working full time, live in Canterbury, be at least 18 years of age, have access to a computer and 
home internet connection, and have been psychiatric and/or sleep medication-free for at least 4 
weeks prior to commencing the study. 
 Exclusion factors assessed by self-report included (a) any neurological disorder involving 
CNS function or the brain (e.g., narcolepsy, epilepsy, Multiple Sclerosis); (b) sleep apnoea; (c) 
any serious medical disorder requiring treatment during the trial; (d) any known abnormality of 
mineral metabolism (e) pregnant/breastfeeding, or intending to have children in the near future; 
(f) parent of a young child under two; and (g) have consumed an oral antibiotic in previous six 
weeks. 
 The study protocol was approved by the University of Canterbury Human Ethics 
Committee, and the trial was registered prospectively with the Australian New Zealand Clinical 
Trials Registry (ACTRN12616001026415).  
2.1.2 Final Sample 
 Of 42 teachers who completed the online screening questionnaire, 25 either did not meet 
the PISQ and PIRS cut-off scores for insomnia or were identified to currently be taking 
psychiatric/sleep medication. This left 17 teachers who were experiencing the symptoms of 
insomnia and were not taking any psychiatric/sleep medication. Of the 17 teachers, 11 taught at 
primary schools and 6 taught at secondary schools. One participant indicated they had a past 
anxiety disorder that was no longer current and no participants disclosed that they had a current 
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psychiatric disorder. All 17 eligible participants entered and completed the trial (Figure 1 
demonstrates participant flow throughout the study).  
 
Figure 1. CONSORT flow diagram 
2.2 Measures  
 Four of the measures listed below were completed online by the participants using 
Qualtrics both at baseline, throughout the intervention and at follow-up. The fifth measure (the 
Consensus Sleep Diary-Morning) was completed in hard copy format at baseline, throughout the 
intervention and at follow-up. 
2.2.1 Demographic Information 
  At screening, participants indicated their date of birth, ethnicity, highest educational 
qualification (measured on a five-point scale from 1 “university bursary or scholarship” to 4 
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“university degree” and an option for “other”), and household income (measured on a five-point 
scale from 1 “less than $20,000” to 5 more than $80,000”).  
2.2.2 Primary outcome measures 
The Pittsburgh Insomnia Symptom Questionnaire (PISQ)  
 The PISQ was completed once at initial screening and aims to identify insomnia through 
a 13-item self-report questionnaire that incorporates both the DSM-IV criteria for insomnia as 
well as those of the International Classification of Sleep Disorders (Okun et al., 2009). The first 
five questions of the PISQ aim to determine the frequency of individual’s complaints regarding 
difficulty in ability to initiate or maintain sleep, or not feeling refreshed or restored after sleep 
due to poor sleep quality, as well as symptom duration, and the remaining eight questions assess 
the severity of daytime correlates of sleep complaints (Okun et al., 2009). In order to evaluate 
the presence, frequency, and/or severity of a complaint in questions 1-5, the items are presented 
as multiple-choice questions on an ordinal scale of 0 = never to 5 = always. This is followed by 
open-ended questions that allow individuals to indicate whether the duration of the problem has 
persisted for weeks, months, or years. Questions 6-13 are scored similarly on an ordinal scale 
from 0-4 where 0 = not at all to 4 = extremely (Okun et al., 2009). 
Pittsburgh Insomnia Rating Scale - 20 (PIRS-20) 
 The PIRS-20 is a shorter version of the 65-item PIRS, that focuses on sleep and wake 
symptoms as they occurred in the week prior to completion of the instrument. The 20 items were 
chosen from the original study of insomnia patients and control subjects, and item selection was 
based upon their classical and item response characteristics, to include daytime and night-time 
items, excluding influence of depressive and anxiety symptomatology (Michael J. Sateia & 
Buysse, 2010). The PIRS-20 includes 12 items examining the intensity of distress related to 
night-time and daytime symptoms of insomnia on a scale from 0-3 where 0 = not at all bothered 
and 3 = severely bothered; four items also scored on a 0-3 scale assessing quantitative sleep 
parameters (e.g., sleep latency and sleep durations); and four items assessing regularity, quality, 
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and depth of sleep on a 0-3 scale were 0 = excellent and 3 = poor. Insomnia severity is indicated 
by the sum of the item scores. Scores range from 0-60 whereby 20 is a useful cut-off for clinical 
insomnia, and the RCI value was calculated as 6 (based on information in Sateia & Buysse, 
2010). The PIRS-20 is found to respond greatly to clinical change and has a test-retest reliability 
of 0.92 and Cronbach’s alpha of 0.95 (Satiea & Buysse, 2010).  
The Expanded Consensus Sleep Diary for Morning (CSD-M)  
 Sleep diaries are the gold-standard for assessment of sleep continuity variables in both 
research and clinical practice. The CSD-M (Carney et al., 2012) is a self-report measure 
developed by a group of experts in order to obtain a standardized measure of sleep. It is an 
expanded version of the Consensus Sleep Diary including 10 items that report on the previous 
night’s sleep (e.g., time in bed, sleep duration, sleep awakenings, and quality of sleep), items 
reporting on alcohol, caffeine and sleep medication intake, and space for additional comments 
(Carney et al., 2012). This sleep diary is to be completed daily, preferably one hour after 
wakening, and has a third-grade reading level (Carney et al., 2012). In terms of validity, there is 
very limited research comparing the validation of the CSD-M with objective sleep measures, 
however Levinson and colleagues (Levenson et al., 2015) found that compared with actigraphy 
(an objective sleep measure), a sleep diary was more accurate at identifying older adults with 
insomnia.  
2.2.3 Secondary outcome measures 
Depression, Anxiety, and Stress Scale (DASS-21)  
 The DASS-21 is a shorter version of the DASS-42 which measures the negative 
emotional states of depression, anxiety, and stress through a 42 item self-report questionnaire 
(Lovibond & Lovibond, 1995). Each of the three DASS-21 scales contains 7 items. These items 
are rated on a 4-point Likert scale that assesses the severity/frequency to which individuals have 
experienced each symptom over the last week ranging from did not apply to me at all (0) to 
applied to me very much, or most of the time (3). The RCI values were calculated as 3.7 for 
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depression, 3.5 for anxiety, and 3.4 for stress, with clinical cut-off scores of 7, 6, and 9 
respectively (based on data in Henry & Crawford, 2005).  Internal consistency demonstrated by 
the DASS-21 is high with Cronbach’s alpha’s of 0.88-0.94 for depression, 0.82-0.87 for anxiety, 
and 0.90-0.91 for stress (Antony, Bieling, Cox, Enns, & Swinson, 1998). Strong reliability and 
consistency of the DASS-21 has been shown in both clinical and non-clinical samples (Antony et 
al., 1998; J. D. Henry & Crawford, 2005). Moreover, correlations are high between the three 
scales, typically being greater than .60 (Lovibond & Lovibond, 1995), as well as high 
correlations with other validation measures including the Beck Depression Inventory –II (.76), 
Beck Anxiety Inventory (.74), and Positive and Negative Affect Schedule-NA (.74) (Gloster et 
al., 2008).  
The Maslach Burnout Inventory Educators Survey (MBI-ES)  
 The MBI-ES (Maslach, Jackson, & Leiter, 1996) is an adaptation of the MBI whereby the 
word recipient is replaced by student. This was completed at the beginning of baseline and end 
of intervention to measure the two core burnout dimensions of emotional exhaustion and 
depersonalization (cynicism). The emotional exhaustion subscale consists of nine items (e.g., “I 
feel emotionally drained from my work”) and the cynicism subscale consists of five items (e.g., 
“I feel I treat some students as if they were impersonal objects”). Items are rated on a scale of 1 
to 7, where individuals rate how often they experience feelings associated with each item where 
1 = never and 7 = daily.  The RCI values were calculated as 9 for emotional exhaustion and 7 for 
depersonalization, with clinical cut-off scores of 26 and 13 respectively. Internal consistency of 
the emotional exhaustion subscale has been shown to range from a = 0.88-.90 and internal 
consistency of the depersonalization subscale ranges from a = .74-.86 (Whitehead, Ryba, & 
O'Driscoll, 2000).  
2.3 Design and Procedure 
 To carry out this research, a multiple-baseline design across participants with placebo 
control was used (Kazdin, 2010). This design allowed us to obtain baseline assessment of sleep 
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and wellbeing over a one-week period, as well as assessment of sleep and wellbeing over a 5 to 
14 day placebo period and a staggered entry into the active intervention phase. By repeating the 
measures twice in baseline the baseline phase allowed for assessment of the baseline stability of 
the measures. This phase also allowed us to establish the existing pattern of sleep and wellbeing 
in participants. Placebo phases allowed for the determination of any expectancy effects as a 
result of taking pills, as well as blinding of both participants and the researcher. This then 
reduces bias arising from knowledge of treatment assignments. Staggered entry into the active 
intervention phase allowed for any replication of changes from baseline to be identified when 
treatment began, demonstrating experimental control (Kazdin, 2010).  
 Teachers meeting the study criteria were invited by email to make an appointment at the 
University of Canterbury or a place of convenience for them such as their school or home to 
discuss the study and participation. During the initial appointment, the teacher was provided with 
a detailed information sheet and consent form (see Appendix D), and information about the 
study including its aims, the requirements of participants, and any known risks, and were advised 
that participants agreeing to take part in the study would receive a placebo pill for a short length 
of time which would be unknown to both the participant and researcher. All teachers were 
provided with adequate opportunity to ask any questions, and were also informed that they could 
withdraw from the study without penalty at any time. All teachers who attended an initial 
appointment agreed to continue, and written informed consent was obtained from each. 
 As mentioned above, the study followed a multiple-baseline-across-participants design 
with placebo and was split into four phases: a baseline phase, a placebo phase, the micronutrient 
phase and a follow-up phase. Once eligibility and informed consent was established, all 
participants were randomized into one of three sequences determining baseline, placebo and the 
micronutrient formula treatment phases. Randomisation was completed by a research student not 
involved in the study whereby 17 numbers were generated (a mix of ones, twos and threes 
representing each baseline) using http://www.randomization.com, a website which uses a 
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random number generator to randomise participants into blocks of 3. One generated list was 
blindly selected and pills were packed according to the randomisation code by a pharmacist. 
Thus both participants and researcher were blind as to what sequence participants were allocated 
until after the study’s completion. Participants were then followed up three months after 
completion of the study. The baseline, placebo and micronutrient intervention phases are 
described below. 
2.3.1 Baseline phase 
  Once eligibility and informed consent were established, the researcher met participants 
prior to the start of baseline to go over the questionnaires and answer any questions. Participants 
were assigned an identification number, given in order from 1 through 17, representing which 
(blinded) sequence they had been assigned to. At this appointment participants received the 
CSD-M sleep diary which was used daily throughout baseline to record their sleep. Sufficient 
pills for 4 weeks (combining placebo and micronutrients in numbers determined by the allocated 
sequence),were provided in sachet format and, given to participants with instructions as to what 
date to start taking them, and to make sure they take the pills with plenty of food and water.  
 All participants started the one-week baseline phase on the same day, and completed the 
PIRS-20, DASS-21 and MBI-ES measures online using Qualtrics. Sleep was recorded daily 
using the CSD-M. Participants were contacted via phone at the end of the one-week baseline to 
see how the first week was going and to answer any questions. At the end of the baseline phase, 
participants again completed the PIRS-20 and DASS-21 online.  
2.3.2 Intervention phase      
Intervention, titration and dosage 
 The micronutrient formula used was EMPowerplus Advanced (EMP+) developed by 
Truehope (www.truehope.com) and is a broad-spectrum micronutrient formula containing 14 
vitamins, 16 trace minerals, 3 amino acids and 3 antioxidants (see Appendix A). Micronutrient 
pill dose was titrated up over four days to eight capsules per day, in two doses of four capsules 
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morning and night, taken with plenty of food and water. Participants were provided with EMP+ 
at no cost for the duration of the study. The placebo product, also provided by Truehope, 
contained fiber acacia gum, maltodextrin, cocoa powder and riboflavin powder and was visually 
identical to the active product. It was emphasized to participants the importance of taking the 
pills with plenty of food and water to minimize the likelihood of any side effects.  
  Participants transitioned from the baseline phase into the intervention phase at the 
beginning of term 4 of the school year, where they received both placebo and micronutrients. 
These sequences varied, with each group receiving a placebo for differing phase lengths, as 
follows (also see Figure 2 below): 
1. Five days placebo phase then switch to a ten-week active intervention phase.  
2. Nine days placebo phase then switch to an eight week and 5 days active intervention phase.  
3. Fourteen days placebo phase then switch to an eight-week active intervention phase.
  
Figure 2. Gives an example of the multiple-baseline design with the baseline, placebo and 
micronutrient phases. As shown, placebo lengths differ for each of the three baselines (e.g., 5,9, 





1	 3	 5	 7	 9	 11	 13	 15	 17	 19	 21	 23	 25	 27	 29	 31	 33	 35	 37	 39	










1	 3	 5	 7	 9	 11	 13	 15	 17	 19	 21	 23	 25	 27	 29	 31	 33	 35	 37	 39	
 45 
 In these phases, participants transitioned from placebo to micronutrients without their 
knowledge (or the knowledge of the researcher). As described above, the pharmacist constructed 
the required sequences of pills according to the randomization schedule, as this ensured both the 
researcher and participants would be blinded. Participants received the first four weeks of pills in 
a sachet format (see Figure 3 below) meaning each four pill dose sets were placed in separate 
envelopes to give 28 days supply in all. These sachets were dispensed in a continuous roll and 
were labelled with the participant identification number, labelled morning or tea dose, and what 
day to be taken. This allowed participants to tear off each envelope when needed and allowed for 
each participant to transition from the placebo to micronutrients at the correct time without their 
knowledge. Participants were advised that the pills would be in sachet format for the first four 
weeks in order for participants to get used to taking the pills daily. For the remainder of the 
intervention the pills came in bottle format (see Figure 4 below), whereby participants took 4 
pills out of the bottle themselves twice a day. Therefore, the placebo phase for each group varied 
and all participants received micronutrients for a minimum of 8 weeks and maximum of 10 
weeks. Participants were instructed to contact the researcher if they experienced any adverse 
effects from taking the pills. 
 During the intervention phase, participants completed the PIRS-20 and DASS-21 online 
at days five, nine and 14 and then the end of at weeks 4 and 10. Participants also completed the 
MBI-ES online at the end of week 10. A side effect questionnaire was also completed at these 
time points (see Appendix E), which asked about side effects including stomach aches, nausea 
and headaches. Any issues while taking the pills were addressed and side effects monitored and 
remedied via lowering the dosage. Participants met with the researcher monthly in order to check 
how they felt the study was going and if there were any changes they had noticed. These 
appointments were also important to check for side effects, compliance and any problems with 
participation. Participants were provided with more pills as needed at these appointments and 
any unused pills were returned. All participants received a $25 supermarket voucher at 
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completion of the study as a koha (gift) and thank-you for taking part. Participants were also 
provided with contact details of the EMP+ supplier so that they could purchase the 






Figure 3. Shows the sachet packaging used to supply the pills. 
 
Figure 4. Shows the bottle format used to supply the pills. 
 
2.3.3 Three month follow-up 
 All participants were contacted and asked to complete an online follow-up questionnaire 
three months after the end of their treatment phase. This questionnaire contained the PIRS-20 
and DASS-21 measures referring to the previous week, questions regarding whether or not 
participants decided to continue taking the micronutrients, as well as a 5-point Likert scale 
asking participants to rate their experience in the study, using ratings from poor (0) to     
excellent (5).  
2.4 Data Analyses  
 The primary outcome measures of this research included the CSD-M daily diary data and 
PIRS-20. Regarding the CSD-M, standard multiple-baseline time series graphs were used to 
detect individual changes across CSD-M variables of sleep onset latency, number of night 
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wakings, sleep efficiency, total time asleep, and subjective sleep quality from baseline to 
intervention. The Percentage Exceeding the Median (PEM) (Ma, 2006) was used as the single-
case effect size for this research. The PEM is the “percentage of Phase B data points exceeding 
the median of the baseline phase” (Ma, 2006; in the current study "exceeding" should be taken as 
in the clinical direction, which is reduction for variables such as frequency of night wakings and 
increase for variables such as sleep efficiency). To calculate PEM a horizontal line is drawn from 
the baseline phase through the treatment phase indicating the baseline median and the number of 
data points falling above or below the median in the direction of clinical change is counted in the 
treatment phase and expressed as a percent of the total data points in that phase (Ma, 2009). 
PEM interpretation is given by the criterion of Scruggs and colleagues (Scruggs, Mastropieri, 
Cook, & Escobar, 1986) whereby 70%<PEM<90% = a moderate ES and PEM > 90% = a large 
ES (after Lothian et al., 2016).  
 Individual changes in the PIRS-20 primary outcome measure and DASS-21 and MBI-ES 
secondary outcome measures over baseline and intervention phases were analysed using 
modified Brinley plots (Blampied, 2017; Jacobson & Truax, 1991). Modified Brinley plots 
provide a visual analysis of individual change over time so that intervention effects can be 
recognised, whilst also placing each individual participant's scores in the context of those of all 
other participants. Each individual’s data at time 1 - baseline (x-axis) and time 2 – posttreatment 
(Y axis) are displayed on a scatter plot as a coordinate pair. Intervention effects are evident when 
scores/data points deviate from the diagonal line of no change. If data points do not deviate from 
the line of no change, the baseline score = intervention score meaning no treatment effect has 
occurred. When clinical change is indicated by a reduction in scores, data points situated above 
the diagonal line signify greater impairment and data points situated below the diagonal line 
signify less impairment (or improvement), and when a high score indicates better functioning, 
the opposite holds true. Additional lines may be supplied to signify clinical cut-off scores, which 
enables clinical significance of outcomes to be easily seen. Clinical cut-offs can be employed for 
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any dependant variable and can assist in interpretation of therapeutic change through classifying 
individuals in terms of clinical status and symptoms levels (Blampied, 2017). Arrows are 
displayed on the graph in order to aid interpretation through displaying the direction of desired 
change. Therefore, if reduction of initial score at baseline indicates clinical improvement the 
arrow will point downwards, and if increase of the initial score at baseline indicates clinical 
improvement the arrow will point upwards. In terms of this research, scores falling below the 
horizontal clinical cut-off line indicate a non-clinical score at time-point two. When looking at 
the graph it is important to note the transition of individuals from the clinical to the nonclinical 
section of the graph (Gordon, Rucklidge, Blampied, & Johnstone, 2015). Therefore, in terms of 
this research a treatment effect will be evident if scores deviate below the line of no change for 
the PIRS-20, DASS-21 and MBI-ES. Textual information on the graph can also provide Effect 
Size information, such as Cohen's d (Blampied, 2017).  
 Change from baseline to intervention can be classified using the Reliable Change Index 
(Jacobson & Truax, 1991). The SEM for each measure is used to calculate the RCI, which 
signifies the amount of change needed for a score to lie outside the expected range due to 
measurement error alone (Jacobson & Truax, 1991). Thus, the RCI indicates how much change 
has occurred over treatment, and someone who has crossed the cut-off point will have changed 
considerably. The RCI was set at a value such that individuals whose change scores exceed this 
value can be noted as displaying reliable change (p < .05). The Effect Size (ES) for PIRS-20, 
DASS-21 and MBI-ES outcomes was calculated two ways, first, using the Common Language 
Effect Size (CLES;Lakens, 2013), which gives the likelihood (expressed as a percentage) that 
after controlling for individual differences any participant will have an improved score at the 
second measurement, and, second, the standardized mean difference effect size, Cohen’s dav, 
calculated using software provided by Cumming (2012), where dav is the ES for the within-
subjects design. The ES confidence interval, also calculated using software provided by 
Cumming (2012), was set at 95% and signifies that if the trial was repeated numerous times, we 
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can expect the true value of the ES to fall in this range 95% of the time. Therefore, if the CI does 
not cross zero we can conclude that there has been a reliable treatment effect, as the ES is 
reliably not zero, and that the mean at time two is statistically significantly different to the mean 




 The following sections present the results of the intervention as assessed by the primary 
and secondary outcome measures. Individual changes across CSD-M variables over 
experimental phases were analysed using conventional time series graphs and visual analysis and 
are presented first. Individual changes in the PIRS-20 primary measure and DASS-21 and MBI-
ES secondary measures over experimental phases were analysed using modified Brinley plots 
(Blampied, 2017; Jacobson & Truax, 1991) and are presented second. Demographic 
characteristics of the final sample are presented in Table 2 below. 
 Figure 1 shows the flow of participants through the trial. Of the 17 participating teachers, 
11 taught at primary schools and 6 taught at secondary schools. One participant indicated they 
had a past anxiety disorder that was no longer current and no participants disclosed that they had 
a current psychiatric disorder. 
 
Table 2: Demographic Characteristics of Final Sample 
 
  
 In terms of gender distribution, the participants were a fair representation of the New 
Zealand teaching population as a whole, as the latest teaching census reports 73% of NZ teachers 
are female and 27% male (Ministry of Education, 2005), but the sample had an 
overrepresentation of NZ European/Pakeha in comparison to the census which reports 79% of 
NZ teachers nationwide identify as European/Pakeha, 10% identify as Maori, 2% as Pasifika and 
2% as Asian (Ministry of Education, 2004).  
Characteristic Final Sample
Sex, n (%)
    Male 5 (30)
    Female 12 (70)
Age in years, mean (SD) 48.1 (10.1)
    Household Income, n (%)
    From $40,000 to $60,000 1 (6)
    From $60,000 to $80,000 5 (29)
    More than $80,000 11 (65)
Education, n (%)
    Post-secondary (e.g., diploma) 1 (6)
    University Degree 11 (65)
    Other 5 (29)
Ethnic origin, n (%)
    New Zealand European/Pakeha 17 (100)
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3.1 Safety, Adherence and Participant Experience 
  Reported side effects experienced by participants were of mild to moderate intensity (see 
Tables 3 and 4; one participant experienced moderate intensity headaches, as indicated in Table 
4). Side effects were remedied through instructions to take the pills with more food and water 
(see Table 3). During the placebo phase, headaches were reported by four participants and 
gastrointestinal disturbances by two participants. These side effects were reported to only last 2-
3 days during this time. In the micronutrient phase, headaches were reported in nine (53%) 
participants as an adverse event; however, for the majority of participants these were mild and 
transitory, with one participant experiencing moderate intensity headaches. Gastrointestinal 
disturbance was reported by three participants; however, these were reported by each of these 
participants at one visit and were gone by the next. Agitation and dry mouth were reported by 
eight and six participants respectively; however, they were unclear as to whether this was due to 
the micronutrients. All side effects were predominantly reported at the beginning of the 
micronutrient phase and lessened over the course of the intervention. Additionally, one 
participant experienced gastrointestinal symptoms and fatigue toward the end of the intervention. 
To remedy this, the dosage was lowered to four pills per day with the participant reporting that 
the symptoms had then decreased; however, at the end of the intervention the researcher was  
notified that these symptoms were not a result of the intervention but of an undiagnosed infection.  
Table 3. Treatment-emergent side effects reported by participants during the trial. 
  Definitely Related Possibly Related 
Adverse Event n % n % 
Micronutrient Phase         
Headache 1 6 8 47 
Gastrointestinal Disturbance   3 18 
Nausea     5 29 
Dry Mouth     8 47 
Agitation     6 35 
Constipation     4 24 
Abdominal Pain     4 24 
Placebo Phase 		 		 		 		
Headache 		 		 4 24 
Gastrointestinal Disturbance 		 2 12 
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Table 4. Treatment-emergent side effects reported by each individual participant during 
the trial. 
 
 Overall, adherence to the intervention protocol was good and 16 out of 17 participants 
(94%) achieved compliance of greater than 80% and therefore did not miss a significant number 
of doses. Of the compliant participants, one participant took the micronutrients at a lower dose of 
four pills per day for the last three weeks of the intervention as a response to perceived side 
effects (see above). For the one non-compliant participant (P13 - who achieved a compliance 
rate of 77%) non-compliance was largely due to forgetting to take the scheduled doses.  
3.2 Sleep Diary Data: Time Series Data Analyses  
At the end of the intervention phase, all 17 participants had supplied complete data sets 
for the CSD-M. The diary data for each participant for each night are presented visually below in 
the form of separate multiple-baseline time series graphs for each CSD-M variable. Transitions 
between trial phases are indicated by vertical lines and phase labels. Percentage Exceeding the 
Median (PEM) was used as a summary of the effects experienced by each participant and were 
averaged across participants for each DV to assess the overall outcomes of the intervention 
(Tables 5 and 6). As previously stated in the Methods section, in the current study "exceeding" 
should be taken as in the clinical direction (i.e., the number of data points falling above or below 
Table # Treatment-emergent side effects reported by each individual participant during the trial .
Micronutrient Phase Placebo Phase
Participant Headaches Gastrointestinal Nausea Dry Agitation Constipation Abdominal Headaches Gastrointestinal 
Disturbance Mouth Pain Disturbance
1
2
3       
4   
5
6     
7  
8  
9  (Moderate)    
10
11     
12    
13   




Note:  indicates participants experiencing mild and transitory side effects unless otherwise stated.
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the median in the direction of clinical change is counted in the treatment phase and expressed as 
a percent). Based on the PEM, of the 17 participants, sleep diary data show that 14 (82%) 
reported one or more beneficial effects of the micronutrient intervention with moderate to large 
effect sizes (as shown by the PEM, defined in the Method section above). Of these 14 
participants, all demonstrated moderate to large effects for sleep efficiency, 10 for Total Sleep 
Time (TST), 8 for reduced night wakings, 3 for subjective sleep quality and two for sleep onset 
latency (SOL). Further, of these 14 participants, 12 (85.7%) indicated multiple improvements. At 
follow up, these 14 participants rated their experience participating in the study as a mean of 
4.21 (SD = 1.12) on a 5-point Likert scale ranging from poor (0) to excellent (5). The remaining 
three participants, P13, P14, P15, reported no moderate or large effects. Of these three, 
participant P13 was the one non-compliant participant, and participant P14 reported multiple 
side effects (however, these were only “possibly related” to intervention). These participants 
rated their experience in the study as 3, 4 and 4 respectively. Only the mean PEM for sleep 
efficiency demonstrated a moderately large treatment effect overall, with TST approaching 
moderate effect overall (Table 5). In contrast, during the placebo phase mean no PEM for any of 
the sleep variables achieved even a moderate overall effect size, with sleep efficiency reaching 











Table 5. Percentage Exceeding the Median in the Micronutrient Phase for each 
Participant and each Dependant Variable from the Consensus Sleep Diary-Morning. 
  Sleep  Night wake Sleep  Total sleep Subjective Mean 95% 
Participant latency frequency efficiency time quality PEM CI (±) 
1* N/A 52 90 77 45 66.00 10.02 
2* N/A 52 70 78 46 61.50 7.13 
3 N/A 34 91 55 23 50.75 14.23 
4* 6 61 75 86 9 57.75 17.83 
5* 93 99 93 91 0 75.20 20.03 
6* N/A 49 81 71 12 53.25 14.53 
7* 63 79 92 85 65 76.80 5.98 
8* 98 77 93 97 81 89.20 4.56 
9* N/A 100 75 45 58 69.50 11.29 
10* N/A 91 92 51 100 83.50 10.48 
11* 38 75 86 56 8 56.25 14.71 
12* N/A 69 90 77 54 72.50 7.16 
13 N/A 20 63 32 6 30.25 11.54 
14 N/A 53 57 46 32 47.00 5.22 
15 N/A 17 17 37 17 22.00 4.75 
16* N/A 87 87 85 98 89.25 2.81 
17* N/A 71 80 82 33 66.50 10.86 
Mean 59.60 63.88 78.35 67.71 40.41     
95% CI (±) 18.32 11.92 9.15 9.66 15.17     
Note: Bold numbers indicate a moderate to large effect size (>70%). Mean = mean percentage; 
CI = Confidence Interval; N/A = not applicable; * = participants experiencing more than one  
positive effect. 
 		 		 		 		 		 		
Table 6. Percentage Exceeding the Median in the Placebo Phase for each Participant 
and each Dependant Variable from the Consensus Sleep Diary-Morning. 
  Sleep  Night wake Sleep  Total sleep Subjective  Mean 95% 
Participant latency frequency efficiency time quality PEM CI (±) 
1 N/A 22 43 57 44 41.50 6.88 
2 N/A 40 20 60 20 35.00 9.10 
3 N/A 0 71 64 33 42.00 15.45 
4 0 20 60 60 0 35.00 14.26 
5 86 71 57 50 0 52.80 14.70 
6 N/A 33 100 56 22 52.75 16.42 
7 40 20 80 80 20 50.00 16.47 
8 86 57 86 86 86 80.20 6.89 
9 N/A 67 89 44 56 64.00 9.09 
10 N/A 100 100 60 100 90.00 9.51 
11 0 89 34 33 0 31.20 17.53 
12 N/A 57 64 86 29 59.00 11.18 
13 N/A 0 20 0 0 5.00 4.75 
14 N/A 100 67 44 56 66.75 11.44 
15 N/A 20 20 20 0 15.00 4.75 
16 N/A 71 71 78 93 78.25 4.93 
17 N/A 93 57 14 14 44.50 18.14 
Mean 42.40 50.59 61.12 52.47 33.71     
95% CI (±) 20.45 16.17 12.57 11.77 16.10     
Note: Bold numbers indicate a moderate to large effect size (>70%). Mean = mean percentage; 
 CI = Confidence Interval; N/A = not applicable         
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3.2.1 Sleep onset latency 
 Sleep onset latency (SOL) refers to how long it takes an individual to transition from full 
wakefulness to sleep. SOL may be problematic for individuals when it is consistently longer than 
desired and/or when it is highly variable, so that on a substantial number of (unpredictable) 
nights the individual has difficulty falling asleep. Both aspects of SOL are examined below. By 
convention, if it takes an individual longer than 30 minutes to make this transition, then they are 
classified as having an excessive SOL and only 6/17 participants experienced consistent 
problems with SOL in baseline. Time-series data for all participants on this measure are 
presented below in Figure 5. Participants P5 and P8 both showed large improvements in SOL 
throughout the micronutrient phase in comparison to baseline and placebo phases, as can be seen 
by decreases in latency values and the variability of data. Although SOL reduction can be seen in 
the placebo phase, participant P7 displays further SOL reduction as the micronutrient phase 
continues, with only slight variability in weeks five and six. Participants P11 and P14 both show 
increased variability in SOL throughout baseline and placebo phases, but both SOL and 
variability reduce during the micronutrient phase for P11; and P14 shows an immediate positive 
effect at the beginning of the micronutrient phase, which continues throughout, except for some 
nights with higher variability during week three. Although participant P6 does not display a SOL 
problem during baseline, SOL was problematic in the placebo phase, and a positive effect is seen 
in the micronutrient phase through the reduction in outliers and variability. The remaining 11 
participants did not show any treatment effect on this measure, as they did not have a problem 






























































































































































































Figure 5. Times series graphs of sleep diary self-reported nightly sleep onset latency (SOL; in 
minutes) for each participant. The first vertical line shows the transition from baseline to placebo 
phase at one week and the second vertical line shows the transition from placebo to 
micronutrient intervention condition at 5, 9, or 14 days. The horizontal line shows the baseline 
median and the percentage reports the percentage exceeding the median (PEM) single-case effect 
size for each participant if applicable. As explained in the Methods section, PEM goes in the 
clinical direction. Numbers on the graphs indicate the value of data points that are off-scale. 
 
3.2.2 Night wake frequency 
 Frequency of night waking refers to how many times participants awoke during each 
night over the course of the trial, with frequent night waking on at least three out of seven nights 
being part of the definition of insomnia. As for SOL, variability of night-waking from night to 
night may be problematic for individuals even if on occasion they have nights with few or no 
wakings. Time-series data for all participants on this measure are presented below in Figure 6. 
The solid horizontal line represents the median. All participants reported awaking during the 
night at least once during the baseline phase. Participants P7, P10, P9, P11, P5, P8, P16 and P17 

















































participants, P10, P9, P11, P8, P16 and P17 show a decrease in night waking during the placebo 
phase, with P8 and P17 displaying high variability. Participants P7, P10 and P17 show an 
immediate decrease in wakings in the first four days of the micronutrient phase, variability and 
wakings then increase, before both gradually decrease as the intervention continues. P16 displays 
decreased wakings with some variability in the first and last week of the micronutrient phase. 
Participants P9, P11, P5 and P8 also display a gradual positive effect in the level and trend of 
data via a gradual decrease in number of wakings and variability throughout the intervention 
phase. It is important to note that participants P10, P11 and P17 experienced a greater reduction 
in wakings in the placebo phase compared to the micronutrient phase; however, the remaining 
five participants experienced a greater reduction in wakings during the micronutrient phase as 
shown by the PEM.  
Of those who did not show a moderate to large effect on this measure, small treatment 
effects are displayed by participants P2, P4, P13, P14, and P12. Participant P2 displays high 
variability throughout the trial; however, this reduces toward the end of intervention and a 
positive effect in the level and trend of data is seen (increase at end reportedly due to a storm 
with strong winds and shared accommodation). Participant P4 began to show a decrease in night 
wakings from day five of the micronutrient phase and by week seven variability and wakings 
decreased substantially. Participant P14 displays an initial placebo response during the placebo 
phase. Wakings then increase and become variable throughout the first five weeks of the 
intervention, with both then reducing in the last three weeks of the intervention. Although 
variability in wakings remained throughout the trial for participants P12 and P13, a positive 
trend throughout the micronutrient phase is still shown. Participant P14 experienced greater 
reduction in wakings in the placebo phase; however, the remaining four participants experienced 
a greater reduction in wakings during the micronutrient phase. Of the remaining participants, 





















































































































































































































Figure 6. Times series graphs of sleep diary self-reported nightly waking frequency. Numbers on 
the graphs indicate the value of data points that are off-scale. Phase and median lines and 
percentages are as for Figure 5. 
 
3.2.3 Sleep efficiency 
 Sleep efficiency is a measure that combines multiple elements of sleep latency and total 
time asleep and expresses the sum as a proportion of total time spent in bed. Time-series data for 
all participants displaying low SE% in baseline are presented below in Figure 7. Individuals who 
obtain a SE% of less than 85% are considered to be poor sleepers (Spielman, Saskin, & Thorpy, 
1987). This threshold is represented in Figure 7 as a dashed horizontal line. The solid horizontal 
line represents the median (from which the PEM is calculated). At baseline, two participants 
(P13 and P15) were at or above the SE% threshold; and levels of SE% were maintained during 
intervention for participants P15 and increased slightly for P13. 
Of 17 participants, 14 showed moderate to large improvements in SE%. Of these, 























































the micronutrient phase, despite high variability throughout. Participants P1 and P5 also show 
gradual improvement at the beginning of the micronutrient phase, SE% then increases and unlike 
the participants above, P1 and P5’s SE% variability reduces (P5’s variability increases at the end 
due to being out of routine with social events). In contrast, participants P10 and P11 show a 
more immediate positive effect on SE% at the beginning of the micronutrient phase, which 
persists throughout the remainder of the trial for both participants despite some variability. For 
participants P8 and P16 a slight positive trend can be seen during the placebo phase as compared 
to the baseline phase, and a gradual increased positive effect is seen in the micronutrient phase. 
In terms of variability of SE%, participant P8’s SE% remains relatively stable, with the odd 
night of low SE%. On the other hand participant P16 continues to display high variability despite 
overall improved SE%. Participants P6 and P9 also display low SE% in baseline and an increase 
in placebo. As both participants enter the micronutrient phase, variability remains high 
throughout the trial, however an increase in SE% compared to baseline can still be seen as the 
trial continues. For participant P12, a delayed positive effect is displayed from week three of the 
micronutrient phase and remains throughout. Participant P17 also displays a positive effect in the 
micronutrient phase in comparison to baseline and placebo; however, variability continues to 
remain high. Of the 14 participants showing moderate to large effect sizes, participant P3 was 
the only individual to display relatively high SE% during baseline. SE% increased and remained 
high for the remainder of the intervention. Participants P2, P6 and P9 experienced greater SE% 
in the placebo phase; however, the remaining 11 participants experienced a greater SE% during 
the micronutrient phase. 
 Of the three participants (P13, P14 and P15) who did not display a large to moderate 
effect size on SE%, participant P14 displayed greater SE% in the placebo phase in comparison to 
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Figure 7. Times series graphs of sleep diary self-reported sleep efficiency percentage (Total time 
asleep/Total time in bed x 100) for each participant. Numbers on the graphs indicate the value of 
data points that are off-scale. Phase lines and percentages are as for Figure 5. The dashed 
horizontal line represents the 85% sleep efficiency criterion, and the solid horizontal line 
represents the baseline median.  
 
3.2.4 Total sleep time 
 Total sleep time (TST) is defined as the duration of time participants spent asleep during 
each night, and is calculated as a percentage of eight hours (taken as a conventional length of 
good sleep for adults). Time-series data for all participants displaying problems in TST in 
baseline are presented below in Figure 8. Eight hours of sleep is represented as a dashed 
horizontal line in Figure 8, and the median is represented as a solid horizontal line.  
 Of the participants who displayed a moderate to large improvement in TST, all displayed 
a gradual improvement as the micronutrient phase continues (i.e., there is no immediate change 



















































TST over the micronutrient phase in comparison to baseline and placebo phases, and display 
steady positive trends. Additionally, participant P4 shows a positive delayed effect in TST from 
week six of the micronutrient phase. A similar trend is seen in participant P6 where improvement 
in TST is consistently shown from week five in the micronutrient phase, with the exception of 
three nights of lower TST. Participant P2 displays gradual improvement in TST in the 
micronutrient phase as compared to the baseline and placebo phases, with variability stabilizing 
in the last three weeks of the intervention. These participants display further improvement in the 
micronutrient phase compared to placebo. Participants P7, P1, P12 and P17 display moderate to 
large improvements in TST over the micronutrient phase. However, in comparison to the 
placebo phase this improvement is small for P7, and P12 shows greater improvement in the 
placebo phase.  
 Of those participants who did not show a substantial improvement in TST (P10, P13, P9, 
P11 and P14), participants P10, P13 and P11 maintained a stable TST percentage throughout the 
intervention, with slight improvements seen in the micronutrient phase in participants P13 and 
P11 relative to baseline and placebo. Participant P10 displayed greater increase in the placebo 
phase in comparison to the micronutrient phase. Participants P9, P14, and P3 displayed no 




























































































































































































Figure 8. Times series graphs of sleep diary self-reported total nightly sleep duration expressed 
as a percentage of 8 hours (100% indicated by dashed horizontal line) for each participant. 
Numbers on the graphs indicate the value of data points that are off-scale. Phase and median 
lines and percentages are as for Figure 5.  
 
3.2.5 Subjective sleep quality 
 Subjective sleep quality refers to how participants rated the quality of their sleep 
throughout the trial on a scale of “very poor” to “very good”. Time-series data for participants 
displaying change on this measure are presented below in Figure 9. Only three participants (P8, 
P10 and P16) displayed moderate to large effect sizes in subjective ratings of their sleep quality. 
These three participants rated the quality of their sleep as “very poor” to “fair” during the 
baseline phase. In the placebo phase, ratings increase, however high variability is seen in 
participants P8 and P16. As participants enter the micronutrient phase, participant P10’s scores 
initially decrease after the placebo phase; however, subjective sleep quality is then generally 





















































four as a result of an earthquake (large enough to produce sustained shaking over the city but 
without reported damage) and subsequent tsunami warnings during the night involving loud 
sirens. Furthermore, although participant P10 displays a placebo effect, a further increase in 
sleep quality ratings in the micronutrient phase is evident. Participant P8 displays a positive 
trend in comparison to baseline that steadily increases over the micronutrient phase with the 
average sleep quality rating noted as “very good”, and variability reduces at the end of the trial. 
Although participant P8 shows slightly higher ratings in the placebo phase, these ratings are 
maintained during the micronutrient phase. For participant P16, rated sleep quality initially 
decreases at the start of the micronutrient phase; however, a steady increase in sleep quality is 
seen over the remainder of the trial with average sleep quality rated as either “good” or “very 
good” (some variability is due to being woken up during the night by a young child). It is 
important to note however, that the increase from placebo to the micronutrient phase for P16 is 
small.  
 Of the participants who did not show substantive improvement, participants P7 and P12 
showed a small treatment effect. For both participants, sleep quality ratings show no change 
throughout baseline and placebo phases. Participant P7’s ratings then increase during the 
micronutrient phase, and although sleep is variable, the majority of sleep quality ratings are 
either “good” or “very good” for remainder of the intervention. Participant P12 continues to 
display no change in sleep quality ratings until week three of the micronutrient phase, where 
sleep quality ratings increase, variability decreases and sleep quality ratings become more stable. 
Additionally, although effects are small, participants P2 and P17 show increased ratings during 
the micronutrient phase in comparison to baseline and placebo. Of the remaining participants, 
P4, P13, P15, P1, P6, P9, P11, P14, P3, and P5 showed no beneficial effect of micronutrients on 
subjective sleep quality from baseline to the end of intervention. This is largely due to the fact 
that all of these participants, except participant P9, were rating their sleep quality as either “fair” 


























































































































































































Figure 9. Times series graphs of sleep diary self-reported sleep quality ratings for each 
participant. Phase and median lines and percentages are as for Figure 5.  
 
3.3 Modified Brinley Plot Analyses 
 Data for the PIRS-20, DASS-21 and MBI-ES are presented visually below as modified 
Brinley plots (see Figure 10 for the interpretation of these plots). For each measure, data are 
presented on these plots as the score for any individual at one time-point against the score of the 
same individual at a later time-point. As described earlier, scores that deviate from the diagonal 
line of no effect indicate a change from one time point to another, and thus any effect of an 
intervention if one has occurred during the time interval, with the extent of change being further 
quantified by reference to the Reliable Change Index (Weissman et al., 1997) and clinical cutoffs 
(based on prior research). For the PIRS-20, DASS-21 and MBI-ES, scores that deviate below the 
line of no change indicate a treatment effect, and therefore improvement. Refer to Figure 10 
below for an interpretation of modified Brinley plots. Unless otherwise indicated, scores are 



























































Additionally, to further aid in interpretation each figure below is accompanied with a Table 
displaying Cohen’s dav, the CLES, and the 95% confidence interval (CI) on d for each phase 
comparison. In the analysis of the data for the thesis, the modified Brinley plots were used to 
address three questions: (1) How stable was the measure during baseline? (2) What was the 








Figure 10. Modified Brinley plot interpretation of graph zones (after Blampied, 2017) when 
reduction in score indicates clinical improvement.  
 
3.3.1 Primary measure 
 The following figures show the effect of the placebo and micronutrient intervention on 
insomnia as measured by the PIRS-20. Figure 11 (see below) assesses baseline stability of 
insomnia symptoms and tracks the placebo response for each of the three phase-length groups. 
For the relevant ES of Cohen’s dav, and CLES and the 95% CI on d, see Table 7 below. The 
initial plot presents baseline stability for phase-length group one (five days placebo), and shows 
three participants’ scores exceed the lower RCI boundary, with two below the clinical cut-off. 
The CLES shows that the probability of participant’s PIRS-20 scores being reduced at baseline 
two compared to initial baseline is 89%, and as the 95% CI on d does not cross zero, the mean 
level of change in scores is reliable after the one week baseline (i.e., the mean change in scores is 
significantly different from zero). Over the course of the next five days in the placebo phase, one 
 76 
of these participants continued to reduce their PIRS-20 score relative to initial baseline, whilst 
the score for the other sits just below the clinical cut-off line. The remaining four participants 
display little mean change in PIRS-20 scores at placebo day five compared to initial baseline. 
The CLES shows that the probability of these participant’s PIRS-20 scores being reduced (to any 
degree) in placebo compared to initial baseline is 95%. However, as the 95% CI on d crosses 
zero, the mean level of change in scores is not reliably different from zero.  
 The three plots in the middle of Figure 11 display change for phase-length group two 
(nine days placebo) across baseline and placebo phases. The initial plot presents baseline 
stability for group two, and shows that relative to their first baseline PIRS-20 score, participants 
demonstrate little mean level of change after the one-week baseline. Compared to their initial 
baseline score, three participants demonstrate a slight deterioration in PIRS-20 scores after one-
week baseline, and are on the verge of demonstrating reliable deterioration as they sit on the 
upper RCI line. Over the course of the next two plots, participants show little mean level of 
change at placebo day five relative to initial baseline score, and by placebo day nine two 
participants reduced their scores below the clinical cut-off and demonstrate reliable positive 
change. The CLES shows that the probability of participant’s PIRS-20 scores being reduced by 
placebo day nine compared to initial baseline is 90%. However, as 95% CI’s on d for group two 
were not computable (because the data violated the requirements for iterative computation built 
into the software) it cannot be determined whether overall change is reliably different from zero.  
The last four plots at the bottom of Figure 11 display change for phase duration group 
three. The initial plot presents baseline stability for group three (14 days placebo), and shows 
that relative to their first baseline PIRS-20 score, three participants show slight deterioration in 
scores after the one-week baseline, with one participant demonstrating reliable deterioration. 
However, d is not reliably different from zero. The remaining three participants display little 
change. The next plot demonstrates that group three displays an initial placebo effect, but over 
the course of the next two plots this effect stays fairly stable, indicating that over the whole 
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placebo phase there was no incremental increase in the placebo effect. By placebo day nine The 
CLES shows that the probability of participant’s PIRS-20 scores being reduced in the placebo 
phase compared to initial baseline is 89%; d was not reliably different from zero. 








Group Timepoint Baseline 1 Later Score Mean 95% CIa CLESb Cohen'sc
Mean Mean Difference LL UL d av
Group 1 Baseline 1 vs Baseline 2 30 23.67 6.33 -1.72 -0.08 89% -0.92
Baseline 1 vs Placebo 1 30 21.33 8.67 -2.51 0.19 95% -1.2
Group 2 Baseline 1 vs Baseline 2 30.2 34 -3.8 x x 68% 0.35
Baseline 1 vs Placebo 1 30.2 31 -0.8 x x 54% 0.07
Baseline 1 vs Placebo 2 30.2 20.4 9.8 x x 90% -1.06
Group 3 Baseline 1 vs Baseline 2 27.67 32.5 -4.83 -0.11 1.04 73% 0.48
Baseline 1 vs Placebo 1 27.67 21 6.67 -1.78 0.39 79% -0.72
Baseline 1 vs Placebo 2 27.67 16.83 10.84 -2.64 0.23 89% -1.25
Baseline 1 vs Placebo 3 x x x x x x x
Note: x = non-computable 
          a. 95% CI on d  = 95% Confidence Interval on d  (LL = Lower Limit; UL = Upper Limit)
Note: b. CLES = Common Language Effect Size
Note: c. Cohen's d av  = the effect size for within subject design
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Figure 11. Modified Brinley plots showing baseline stability of insomnia symptoms and the 
placebo response for each of the three groups as measured by the PIRS-20. The top panel 
represents phase-length group 1 (5 days placebo); the middle panel represents phase-length 
group 2 (9 days placebo); and the bottom panel represents phase-length group 3 (14 days 
placebo). 
 
 Figure 12 (see below) shows the micronutrient treatment response relative to baseline one 
for each group. For Cohen’s dav, 95% CI’s on d and CLES see Table 8 below. Because different 
participants have different durations of exposure to the placebo, the mean placebo response was 
computed for each participant and used to represent the overall placebo response for that 
individual. The top five plots represent the treatment response for phase-length group one. The 
initial plot presenting baseline one vs mean placebo shows the majority of participants show 
little mean level of change in their initial and mean placebo PIRS-20 scores, with only two 
reducing their scores below the clinical cut-off line. The CLES shows that the probability of 
participant’s PIRS-20 scores being reduced at mean placebo compared to initial baseline is 95%; 
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in PIRS-20 scores is seen, and by the end of treatment all participants’ scores are reduced to 
below the clinical cut-off and display reliable positive change. The CLES shows 100% 
reduction; and the dav ES is large and reliable (effect size magnitudes are interpreted using 
Cohen’s (Cohen, 1992) criteria whereby 0.2 indicates a small effect, 0.5 a medium effect and 0.8 
a large effect).  
The middle four plots represent the treatment response for phase-length group 2. The 
initial plot presenting baseline 1 vs mean placebo shows that participants display little mean 
change in PIRS-20 scores with four out of five participants above the clinical cut-off. Over the 
next three plots, PIRS-20 scores scatter around the line of no change, and by the end of treatment 
one participant reduced their PIRS-20 score to below the clinical cut-off, and demonstrates 
reliable positive change. The CLES shows 75% reduction; however, as 95% CI’s on d for this 
group were non-computable, it cannot be determined whether the mean change was reliable.  
 The bottom three plots represent the treatment response for phase-length group three. The 
initial plot presenting baseline 1 vs mean placebo shows the placebo response demonstrated by 
this group. Additionally, the CLES shows 86% reduction, but d is not reliably different from 
zero. The next plot demonstrates that participant’s scores continue to decrease by week four with 
all scores below the clinical cut-off line. The CLES shows 98% reduction; and the dav ES is large 
and reliable. By the end of treatment, one participant’s score deviated above the clinical cut-off 
line demonstrating reliable deterioration, and four participants’ scores remained in the non-
clinical range. The CLES shows 96% reduction; however d is not reliably different from zero.  
Notably, this overall effect is due to the deterioration in score of the one participant, who was 








Table 8. Means and Effect Sizes for Baseline 1 vs later score comparisons for each group treat-
ment response on the PIRS-20 Stability and Baseline vs Placebo comparisons for the PIRS-20. 
 
 
Figure 12. Modified Brinley plots showing the effect of the micronutrient intervention on 
insomnia as measured by the PIRS-20 for each of the three groups.  
 
Figure 13 (see below) shows the effect of the micronutrient treatment on all participants 
over the treatment phase, relative to scores at initial baseline (the top panel), and relative to mean 
Group Timepoint Baseline 1 Later Score Mean 95% CIa CLESb Cohen'sc
Mean Mean Difference LL UL d av
Group 1 Baseline 1 vs Mean Placebo 30 21.33 8.67 -2.51 0.19 95% -1.2
Baseline 1 vs Treatment Day 9 30 22.67 7.33 -2.24 -0.05 93% -1.18
Baseline 1 vs Treatment Day 14 x x x x x x x
Baseline 1 vs Treatment Week 4 30 17.5 12.5 -2.76 0.18 95% -1.33
Baseline 1 vs Treatment End 30 10.67 19.33 -5.32 -0.67 100% -3.04
Group 2 Baseline 1 vs Mean Placebo 30.2 25.7 4.3 x x 71% -0.53
Baseline 1 vs Treatment Day 14 30.2 21.8 4.5 x x 84% -0.75
Baseline 1 vs Treatment Week 4 30.2 19.8 10.4 x x 91% -0.99
Baseline 1 vs Treatment End 30.2 24.4 5.8 x x 75% -0.51
Group 3 Baseline 1 vs Mean Placebo 27.67 17.59 10.8 -2.49 0.22 86% -1.17
Baseline 1 vs Treatment Week 4 27.67 10 17.67 -3.76 -0.07 98% -1.97
Baseline 1 vs Treatment End 27.67 13.5 14.7 -3.01 0.39 96% -1.39
Note: x = non-computable 
          a. 95% CI on d  = 95% Confidence Interval on d  (LL = Lower Limit; UL = Upper Limit)
Note: b. CLES = Common Language Effect Size
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placebo (middle panel) in order to detect any treatment effect of micronutrients over and above 
the effect of placebo. The bottom panel shows the follow-up data relative to scores at the end of 
treatment to examine the durability of any effect. For Cohen’s dav, 95% CI’s on d and CLES see 
Table 9 below. The initial four plots present PIRS-20 scores vs mean placebo, treatment week 4, 
end of treatment and follow-up relative to initial baseline 1 scores. Of these, the first plot 
presenting PIRS-20 scores at baseline 1 vs mean placebo shows that there was a strong placebo 
effect as six participants reduced their scores to either at or below the clinical cut-off line and 
displayed reliable positive change. The CLES shows 89% reduction; and the dav ES is large and 
reliable. By week four it becomes clear that the treatment effect is greater than the placebo effect 
as participants’ PIRS-20 scores reduce further, with nine participants both below the clinical cut-
off line and demonstrating reliable positive change. By the end of treatment it further becomes 
clear that participants have formed two groups - there is a group of responders and a group of 
non-responders. Twelve participants scores fall below the clinical cut-off line, and 11 of these 
demonstrate reliable positive change. Moreover, the CLES shows 97% reduction at treatment 
end; and the dav ES’s are both large and reliable at week four and end of treatment. At follow-up 
the two groups of responders and non-responders is still evident, and although overall 
participants scores have attenuated, reduction in PIRS-20 scores remains at follow-up as eight 
participants fall below the clinical cut-off line and also demonstrate reliable positive change. 
Furthermore, the CLES shows 89% reduction; and the dav ES is large and reliable.  
 The middle panel of four plots present PIRS-20 scores vs mean baseline, treatment week 
4, end of treatment and follow-up relative to mean placebo scores. The initial plot presenting 
PIRS-20 scores at mean placebo vs mean baseline show all participants but one have PIRS-20 
scores in the clinical range. Over the course of the next two plots a reduction in PIRS-20 scores 
is shown, and by the end of treatment, 12 participants have reduced their PIRS-20 scores below 
the clinical cut-off line compared to their mean placebo score, with eight of these demonstrating 
reliable positive change. The CLES shows that the probability of participant’s PIRS-20 scores 
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being reduced at week four and at end of treatment compared to mean placebo is 81% and 78% 
respectively; the respective dav ES’s are medium-large and medium and were both reliable. By 
follow-up PIRS-20 scores have attenuated; however, 14 participants scores are either at or below 
the clinical cut-off line, with five participants demonstrating reliable positive change. The CLES 
shows 61% reduction; but d is not reliably different from zero. Additionally, a group of 
responders and non-responders is evident at the end of treatment and follow-up relative to mean 
placebo, as was the case when change was viewed relative to initial baseline scores. 
 The bottom panel plot shows change in PIRS-20 scores at follow-up relative to those at 
the end of treatment. Overall, participants’ PIRS-20 scores attenuated at follow-up in comparison 
to end of treatment, with five participants scores sitting at the clinical cut-off line and two 
participants PIRS-20 scores falling well above the clinical cut-off and demonstrating reliable 
deterioration. Four participants maintained PIRS-20 scores in the non-clinical range and 
demonstrated reliable positive change. The CLES shows 65% reduction; but d is not reliably 
different from zero.  
Overall, Figure 13 shows that although a placebo effect was seen, there was an additional 
effect of treatment by micronutrients. 
Table 9. Means and Effect Sizes for Timepoint 1 vs later score comparisons for all groups 
combined on the PIRS-20 
 
Group Timepoint Timepoint 1 Later Score Mean 95% CIa CLESb Cohen'sc
Mean Mean Difference LL UL d av
Combined Baseline 1 vs Mean Placebo 29.24 21.29 7.95 -1.68 -0.28 89% -0.99
Group Baseline 1 vs Treatment Week 4 29.24 15.53 13.71 -2.3 -0.53 97% -1.44
Baseline 1 vs Treatment End 29.24 15.71 13.53 -2.26 -0.45 97% -1.37
Baseline 1 vs Follow-up 29.24 18.88 10.36 -1.71 -0.18 89% -0.96
Combined Mean Placebo vs Mean Baseline 21.29 29.53 -8.26 0.38 1.81 92% 1.11
Group Mean Placebo vs Treatment Week 4 21.29 15.53 5.76 -1.29 -0.14 81% -0.72
Mean Placebo vs Treatment End 21.29 15.71 5.58 -1.25 -0.06 78% -0.66
Mean Placebo vs Follow-up 21.29 18.88 2.41 -0.88 0.38 61% -0.25
Combined 
Group 
Note: a. 95% CI on d  = 95% Confidence Interval on d  (LL = Lower Limit; UL = Upper Limit)
Note: b. CLES = Common Language Effect Size
Note: c. Cohen's d av  = the effect size for within subject design
1 65% 0.29Treatment End vs Follow-up 15.71 18.88 -3.17 -0.44
 83 






































0 10 20 30 40 50 60
0 10 20 30 40 50 60 0 10 20 30 40 50 60
PIRS-20 @ Baseline - 1
@ Treatment 
  Week 4
0 10 20 30 40 50 600 10 20 30 40 50 60
0 10 20 30 40 50 60
PIRS-20 @ Mean Placebo
@ Treatment






 @ Week 4 @ Treatment









Figure 13. Modified Brinley plots showing the effect of the micronutrient intervention on 
insomnia in all three groups combined as measured by the PIRS-20. 
 
Table 10 below presents CLES, Cohen’s dav, 95% CI’s on d and mean change over the 
course of the intervention for the four participants who continued to take the micronutrients after 
the intervention concluded. The CLES show that by follow-up, the probability of participant’s 
PIRS-20 scores being reduced at follow-up compared to initial baseline and mean placebo are 
88% and 69% respectively. Although the 95% CI’s on d could not be computed and thus 
reliability of mean level of change cannot be determined, the dav ES’s are generally moderate to 
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large throughout the micronutrient phase and at follow-up. In terms of follow-up relative to 
treatment end, the CLES shows that the probability of participant’s PIRS-20 scores being 
reduced at follow up compared to treatment end is 54%; however, the 95% CI’s on d could not 
be computed and thus reliability of mean level of change cannot be determined.  
 
Table 10. Means and Effect Sizes for Timepoint 1 vs later score comparisons on the PIRS-20 for 
participants who continued micronutrients after the intervention concluded.  
 
 
3.3.2 Secondary measures  
 The following figures show the effect of the intervention on depression, anxiety and stress 
symptoms as measured by the DASS-21 over the course of the intervention relative to baseline 1. 
Table 11 presents Cohen’s dav, 95% CI’s on d and CLES for DASS-21 scores over the 
intervention relative to baseline 1. When interpreting the results, it is important to remember that 
for all three subscales (depression, anxiety and stress), the majority of participants were below 
the clinical cutoffs at initial baseline, thus indicating that the current sample was essentially non-






Group Timepoint Timepoint 1 Later Score Mean 95% CIa CLESb Cohen'sc
Mean Mean Difference LL UL d av
Continued Baseline 1 vs Mean Placebo 35.75 28.88 6.87 x x 72% -0.71
Micronutrients Baseline 1 vs Treatment Week 4 35.75 11.5 24.25 x x 99% -2.2
Baseline 1 vs End of Treatment 35.75 18.5 17.25 x x 95% -1.2
Baseline 1 vs Follow-up 35.75 19.75 16 x x 88% -0.9
Continued
Micronutrients
Mean Placebo vs Follow-up 28.88 19.75 9.13 x x 69% -0.64
Continued
Micronutrients Treatment End vs Follow-up 18.5 19.75 -1.25 x x 54% 0.02
Note: x = non-computable 
          a. 95% CI on d  = 95% Confidence Interval on d  (LL = Lower Limit; UL = Upper Limit)
Note: b. CLES = Common Language Effect Size
Note: c. Cohen's d av  = the effect size for within subject design
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Table 11. Means and Effect Sizes for Baseline 1 vs later score comparisons for the DASS-21.  
 
Figure 14 assess baseline stability of DASS-21 measures and shows the analysis of 
change in these symptoms over the one week baseline period (baseline 1 vs baseline 2). For 
Cohen’s dav, 95% CI’s on d and CLES see Table 11. The top two plots show that depression and 
anxiety were relatively stable and show little change, with just one participant above the clinical 
cut-off for anxiety and demonstrating reliable deterioration. In terms of stress, scores are widely 
scattered around the line of no change with the thirteen deviating below this line and nine 
exceeding the lower RCI boundary. Overall however, the fourth plot indicates that total DASS-
21 scores did not significantly improve over the one-week baseline, which is confirmed as all 
95% CI’s on d cross zero.  
 
Timepoint Subscale Baseline 1 Later Score Mean 95% CIa CLESb Cohen'sc
Mean Mean Difference LL UL d av
Baseline 1 vs Baseline 2 Depression 2.29 2.76 -0.47 -0.28 0.68 61% 0.2
Anxiety 2.71 3.12 -0.41 -0.18 0.52 59% 0.18
Stress 6.47 6.94 -0.47 -0.35 0.6 57% 0.13
Total 11.47 12.82 -1.35 -0.23 0.64 61% 0.2
Baseline 1 vs Mean Placebo Depression 2.29 1.82 0.47 -0.7 0.3 61% -0.21
Anxiety 2.71 1.99 0.72 -0.7 -0.01 68% -0.36
Stress 6.47 5.56 0.91 -0.82 0.29 64% -0.27
Total 11.47 10.41 1.06 -0.57 0.22 59% -0.18
Basline 1 vs Treatment Week 4 Depression 2.29 1.06 1.23 -1.3 0.09 76% -0.61
Anxiety 2.71 1.71 1 -0.96 0.04 72% -0.47
Stress 6.47 4.65 1.82 -1.18 0.22 74% -0.49
Total 11.47 7.41 4.06 -1.33 0.05 81% -0.65
Baseline 1 vs Treatment End Depression 2.29 1.88 0.41 -0.8 0.46 59% -0.17
Anxiety 2.71 1.41 1.3 -1.3 -0.13 82% -0.73
Stress 6.47 3.94 2.53 -1.47 0.09 83% -0.7
Total 11.47 7.24 4.23 -1.4 0.06 82% -0.68
Baseline 1 vs Follow-up Depression 2.29 2.06 0.23 -0.8 0.64 54% -0.08
Anxiety 2.71 1.71 1 -1.08 0.17 73% -0.46
Stress 6.47 5.71 0.76 -0.82 0.42 61% -0.21
Total 11.47 9.47 2 -0.92 0.33 65% -0.3
Note: a. 95% CI on d  = 95% Confidence Interval on d  (LL = Lower Limit; UL = Upper Limit)
Note: b. CLES = Common Language Effect Size
Note: c. Cohen's d av  = the effect size for within subject design
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Figure 14. Modified Brinley plots showing baseline stability of depression, anxiety and stress 
symptoms as measured by the DASS-21.  
  
Figure 15 shows whether participants displayed a change in depression, anxiety and 
stress symptoms over the placebo phase period as compared to baseline 1. For Cohen’s dav, 95% 
CI’s on d and CLES see Table 11. The initial plot displaying change in depression scores 
indicates that little mean change was seen, with only one participant reducing their depression 
score and demonstrating reliable positive change over the placebo period, and one participant 
increasing their depression score and demonstrating reliable deterioration. The second plot 
displaying anxiety scores does not indicate much change; however, the CLES shows that the 
probability of participant’s anxiety scores being reduced at mean placebo compared to initial 
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baseline is 68%; and the dav ES is small and statistically reliable. The third plot displaying 
change in stress symptoms indicates that a small placebo effect was seen for stress, as shown by 
three participants reducing their scores over the placebo period and demonstrating reliable 
positive change. The CLES shows 64% reduction, but d is not reliably different from zero. The 
fourth plot presenting total DASS-21 scores at initial baseline relative to mean placebo scores 
indicates that overall there was a very slight placebo effect with nine participants scores 
deviating below the line of no change, and only two demonstrating reliable positive change. The 
CLES shows 59% reduction, but d is not reliably different from zero. 
 
 
Figure 15. Modified Brinley plots showing the change in depression, anxiety and stress at mean 
placebo relative to baseline 1 score as measured by the DASS-21.  
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 Figure 16 shows the effect of the intervention on depression, anxiety and stress symptoms 
at week 4 relative to baseline 1. For Cohen’s dav, 95% CI’s on d and CLES see Table 11. The 
plot presenting depression scores at week 4 relative to baseline 1 indicates that by this stage of 
the intervention, all participants are below the clinical cut-off score, with two participants 
reducing their scores to demonstrate reliable positive change. It is important to remember, 
however, that the majority of participants’ scores were below the clinical cut-off at baseline. The 
plot presenting change in anxiety scores shows all but two participants’ scores are below the 
clinical cut-off line, with two participants reducing their scores to demonstrate reliable positive 
change. In terms of stress, although scores are scattered above and below the line of no change, 
the majority of scores deviate below it with four participants demonstrating reliable positive 
change. The final plot presenting the effect of the intervention on total DASS-21 scores at week 
4 relative to baseline 1 displays a range of scatter above and below the line of no change. Seven 
participants reduced their scores below the line of no change, with four participants 
demonstrating reliable positive change. The CLES shows that the probability of participant’s 
depression, anxiety, stress and total DASS-21 scores being reduced at treatment week 4 
compared to initial baseline is 76%, 72%, 74% and 81% respectively; the respective d’s 
however, were not reliably different from zero.  
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Figure 16. Modified Brinley plots showing the effect of the micronutrient intervention on 
depression, anxiety and stress at week 4 relative to baseline 1 score as measured by the DASS-
21.  
 
Figure 17 shows the effect of the intervention on depression, anxiety and stress 
symptoms at the end of the intervention relative to baseline 1. For Cohen’s dav, 95% CI’s on d 
and CLES see Table 11. The initial plot presenting baseline 1 vs treatment end for depression, 
shows slight attenuation in scores in comparison to treatment at week 4, with two participants 
sitting on the clinical cut-off line. However four participants reduced their scores to below the 
line of no change, with two demonstrating reliable positive change. The CLES shows that the 
probability of participant’s depression scores being reduced at end of treatment compared to 
initial baseline was 59%; but d was not reliably different from zero. In terms of anxiety, this plot 
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shows a trend toward a decrease in anxiety symptoms with all participants in the non-clinical 
range. The CLES shows 82% reduction; and the dav ES is medium-large and statistically reliable. 
The third plot presenting change in stress scores at baseline 1 relative to treatment end shows a 
decrease in stress as 10 participants fall below the line of no change, with six of these 
demonstrating reliable positive change. The CLES shows 83% reduction, but d is not reliably 
different from zero. Both the plot presenting change in stress scores and the final plot presenting 
change in total DASS-21 scores show that at the end of the intervention there were a group of 
responders and a group on non-responders, as demonstrated by the clusters of data points above 
and below the line of no change. The final plot shows that 10 participants reduced their scores 
below the line of no change with four demonstrating reliable positive change. The CLES shows 





Figure 17. Modified Brinley plots showing the effect of the micronutrient intervention on 
depression, anxiety and stress at end of treatment relative to baseline 1 score as measured by the 
DASS-21.  
 
 Figure 18 presents depression, anxiety and stress scores for baseline 1 relative to follow-
up. For Cohen’s dav, 95% CI’s on d and CLES see Table 11. The initial plot presenting 
depression scores for baseline 1 relative to follow-up shows that some participants continued to 
reduce their scores, as five participants scores deviated below the line of no change; and two 
deteriorated into the clinical range. In terms of anxiety, the second plot shows five participants’ 
scores deviated above the line of no change, with one participant’s score increasing above the 
clinical cut-off at follow-up. Of five participants who reduced their scores below the line of no 
change, three demonstrated reliable positive change. The third plot demonstrates that at follow-
up stress scores changed for the worse, with three participants entering the clinical range. The 
Stress - Baseline 1


















DASS-21 Total - Baseline 1






















Depression - Baseline 1





















Anxiety - Baseline 1


















DASS-21 Baseline 1 vs Treatment End
 92 
increase in scores is most evident in the final plot presenting change in total DASS-21 scores, 
with just six participants deviating below the line of no change and three demonstrating reliable 
positive change. The CLES shows that the probability of participant’s depression, anxiety, stress 
and total DASS-21 scores being reduced at follow-up compared to initial baseline was 54%, 
73%, 61% and 65% respectively; the respective d’s however, are not reliably different from zero. 
 
 
Figure 18. Modified Brinley plots showing the effect of the micronutrient intervention on 
depression, anxiety and stress at follow-up to baseline 1 score as measured by the DASS-21.  
 
The following figures show the effect of the intervention on depression, anxiety and 
stress symptoms as measured by the DASS-21 over the course of the intervention relative to the 
mean placebo effect. Table 12 presents Cohen’s dav, 95% CI’s on d and CLES for DASS-21 
scores over the intervention relative to mean placebo. 
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Table 12. Means and Effect Sizes for Mean Placebo vs later score comparisons for the DASS-21.  
 
 
Figure 19 presents depression, anxiety and stress scores at week 4 relative to mean 
placebo scores. For Cohen’s dav, 95% CI’s on d and CLES see Table 12. The initial plot 
presenting mean placebo vs treatment at week 4 for depression scores shows that all participants 
were below the clinical cut-off line and two demonstrated reliable positive change in depressive 
symptoms. The second plot presenting mean placebo vs treatment at week 4 for anxiety scores 
shows that the majority of participants’ scores fall below the clinical cut-off and lie closely 
around the line of no change. Two participants scores increased at week 4 and sit at the clinical 
cut-off line; and another two participants show a reduction in scores compared to their mean 
placebo score, with one demonstrating reliable positive change and one sitting on the RCI line. 
The CLES shows that the probability of participant’s depression and anxiety scores being 
reduced at treatment week 4 compared to mean placebo was 70% and 57% respectively; the 
respective d’s however, were not reliably different from zero. 
The third plot presenting mean placebo vs treatment at week 4 for stress scores shows 
that 14 participants scores are below the clinical cut off, with seven participants scores deviating 
below the line of no change and two demonstrating reliable positive change. Of the two 
participants above the clinical cut-off for stress, one participant shows reliable deterioration and 
Timepoint Subscale Mean Placebo Later Score Mean 95% CIa CLESb Cohen'sc
Mean Mean Difference LL UL d av
Mean Placebo vs Treatment Week 4 Depression 1.82 1.06 0.76 -0.97 0.16 70% -0.41
Anxiety 1.99 1.71 0.28 -0.55 0.28 57% -0.14
Stress 5.56 4.65 0.91 -0.71 0.18 64% -0.27
Total 9.72 7.41 2.31 -0.88 0.12 69% -0.38
Mean Placebo vs Treatment End Depression 1.82 1.88 -0.06 -0.6 0.66 51% 0.03
Anxiety 1.99 1.41 0.58 -0.82 0.14 67% -0.34
Stress 5.56 3.94 1.62 -1.13 0.14 75% -0.5
Total 9.72 6.59 3.13 -1.01 0.19 71% -0.41
Mean Placebo vs Follow-up Depression 1.82 2.06 -0.24 -0.46 0.64 54% 0.09
Anxiety 1.99 1.71 0.28 -0.8 0.53 57% -0.14
Stress 5.56 5.71 -0.15 -0.58 0.67 52% 0.04
Total 9.72 8.88 0.84 -0.68 0.43 56% -0.13
Note: a. 95% CI on d  = 95% Confidence Interval on d  (LL = Lower Limit; UL = Upper Limit)
Note: b. CLES = Common Language Effect Size
Note: c. Cohen's d av  = the effect size for within subject design
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the other deviates just about the line of no change. The CLES shows 64% reduction, but d is not 
reliably different from zero. The fourth plot presents overall DASS-21 scores and shows that 
total scores scatter widely around the line of no change. Some participants display deterioration 
in scores at week 4 whereas five participants demonstrate reliable positive change in total score. 
The CLES shows 69% reduction, but d is not reliably different from zero.  
 
 
Figure 19. Modified Brinley plots showing the effect of the micronutrient intervention on 
depression, anxiety and stress at week 4 relative to mean placebo score as measured by the 
DASS-21.  
 
Figure 20 presents depression, anxiety and stress scores at end of treatment relative to 
mean placebo scores. For Cohen’s dav, 95% CI’s on d and CLES see Table 12. The initial plot 
presenting mean placebo vs treatment end for depression scores shows little mean change at the 
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end of treatment relative to initial mean placebo depression scores was seen compared to initial 
mean placebo scores. Eleven participants scores fall below the clinical cut-off, with five 
reducing their scores below the line of no change, and one demonstrating reliable positive 
change. The CLES shows that the probability of participant’s depression scores being reduced at 
end of treatment compared to mean placebo was 51% (i.e., at chance level) and d is not 
significantly different from zero. The second plot presenting anxiety scores shows little mean 
change at end of treatment relative to mean placebo, as twelve participants scores fall inside the 
RCI boundaries. Despite this, all scores are below the clinical cut-off, although the CLES = 67% 
and d was not significantly different from zero. The third plot presents stress scores at treatment 
end relative to mean placebo, and it can be seen that there is a group of responders and non-
responders. Fifteen participants scores are below the clinical cut-off, and 8 participants deviate 
below the line of no change with five of these demonstrating reliable positive change. The CLES 
shows that the probability of participant’s stress scores being reduced was 75% but d is not 
reliably different from zero. The final plot presents DASS-21 total scores, which shows there is 
again a group of responders and a group of non-responders. Overall, the plot shows a decrease in 
total scores at treatment end relative to placebo, with 11 participant’s scores deviating below the 
line of no change, and six either at or below the lower boundary of the RCI. The CLES was 




Figure 20. Modified Brinley plots showing the effect of the micronutrient intervention on 
depression, anxiety and stress at end of treatment relative to mean placebo score as measured by 
the DASS-21.  
 
Figure 21 presents depression, anxiety and stress scores at follow-up relative to mean 
placebo scores. For Cohen’s dav, 95% CI’s on d and CLES see Table 12. The initial plot 
presenting depression scores at mean placebo vs follow-up shows little mean change; however, 
11 participant’s scores fall below the clinical cut-off line, and four participant’s reduced their 
scores below the line of no change, with one demonstrating reliable positive change. The second 
plot presenting anxiety scores shows a small amount of mean change, with scores deviating both 
above and below the line of no change. One participant’s score increases above the clinical cut-
off in comparison to their mean placebo score. The remaining 14 participant’s scores fall below 
the clinical cut-off with four of these either at or below the lower RCI boundary. The third plot 
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demonstrates an overall increase in stress scores at follow-up compared to mean plot, with three 
participants’ stress scores increasing to clinical levels. The CLES shows that the probability of 
participant’s depression, anxiety and stress scores reduced at follow-up compared to mean 
placebo was 54%, 57% and 52% respectively; the respective d’s however, were not reliably 
different from zero. The final plot demonstrates that overall DASS-21 scores increased, with a 
wide scatter around the line of no change. The CLES shows that the probability of participants’ 
total DASS-21 scores being reduced at follow-up compared to mean placebo was 56%; d was 
not reliable.  
 
Figure 21. Modified Brinley plots showing the effect of the micronutrient intervention on 
depression, anxiety and stress at follow-up relative to mean placebo score as measured by the 
DASS-21.  
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The following figure shows the effect of the intervention on emotional exhaustion (EE) 
and depersonalisation (DP) as measured by the MBI-ES. Table 13 presents Cohen’s dav, 95% 
CI’s on d and CLES for MBI-ES scores at the end of treatment relative to initial baseline 1 score. 
 
Table 13. Means and Effect Sizes for Baseline 1 vs Treatment End for the MBI-ES 
 
 
Figure 22 presents EE and DP scores at the end of treatment relative to baseline 1. As this 
measure was only completed at the beginning of baseline and end of intervention, only three 
Brinley plot comparisons are presented. The initial plot presenting the effect of the intervention 
on EE scores shows 10 participants’ reduced their scores below the clinical cut-off, and six of 
these demonstrate reliable positive change. The CLES = 93% reduction; and dav ES is large and 
statistically reliable. In terms of depersonalization, the second plot indicates no strong effect of 
the intervention was seen at end of treatment relative to baseline 1, with data points widely 
scattered around the line of no change. However, eight participants reduced their scores below 
the line of no change and three demonstrate reliable positive change. Additionally, the CLES 
shows 75% reduction, but d is not reliably different from zero. The final plot presenting MBI-ES 
total scores at the end of intervention relative to baseline 1 indicates that overall there was 
significant improvement in mean change of MBI-ES scores; the CLES 91% reduction; dav ES is 
large and reliable, and 13/17 participants fall below the line of no change.  
 
Timepoint Subscale Baseline 1 Treatment End Mean 95% CIa CLESb Cohen'sc
Mean Mean Difference LL UL d av
Baseline 1 vs Treatment End Emotional Exhaustion 31.59 22.18 9.41 -1.69 -0.46 93% -1.08
Depersonalization 5.29 3.18 2.11 -1.19 0.12 75% -0.54
Total 36.88 25.35 11.53 -1.61 -0.38 91% -1.01
Note: a. 95% CI on d  = 95% Confidence Interval on d  (LL = Lower Limit; UL = Upper Limit)
Note: b. CLES = Common Language Effect Size
Note: c. Cohen's d av  = the effect size for within subject design
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Figure 22. Modified Brinley plots showing the effect of the micronutrient intervention on 
emotional exhaustion and depersonalization at end of treatment relative to baseline 1 score as 
measured by the MBI-ES.   
  
 
In summary, the results show that the majority of participants demonstrated a reliable and 
clinically significant decrease in insomnia severity, as well as demonstrating improvements on at 
least two aspects of sleep as measured by the CSD-M. Although a placebo effect was evident, 
there was an additional effect of the micronutrients overall. By the end of treatment, it becomes 
evident that the participants have split into two groups: five who did not respond and 12 who did. 
By follow-up, overall, no additional improvement is seen from the end of treatment to follow-up. 
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However, improvements obtained during the intervention still remain, as only a slight 
deterioration in scores is seen. Those that continued with the micronutrients after the intervention 
also show a slight deterioration in scores at follow-up compared to end of treatment.  
In terms of anxiety, stress and depression scores, the majority of participants were in the 
non-clinical range on these scales at baseline; and no statistically significant reduction was seen 
in anxiety, stress and depression scores at end of treatment. At follow-up, overall no further 
improvement was seen, with the majority of participants’ scores deteriorating back toward initial 
baseline. Additionally, a statistically significant reduction was seen in emotional exhaustion 
scores as measured by the MBI-ES, however, statistically significant change was not seen for 




4.1 Discussion of Findings 
 The current sample reflected a group of Christchurch teachers working in earthquake-
affected schools, who were experiencing clinically significant levels of chronic insomnia. A 
discussion of the findings relating to the innovative micronutrient intervention is presented 
below.  
Insomnia.  Overall, the results show that the micronutrient intervention was associated 
with improvements in insomnia symptoms relative to placebo. This primary hypothesis was 
supported in that the group mean insomnia severity rating (as measured by the PIRS-20) dropped 
from 29.4 at baseline to 15.71 at treatment end, with a large and statistically reliable effect size 
(Cohen’s dav = -1.37, CLES = 97%). The reliability of this result was further supported as 11 out 
of 17 participants experienced a clinically significant decrease in insomnia severity on the PIRS-
20 (i.e., their scores dropped below the clinical cut-off).  
 Improvement in insomnia symptoms of participants was also shown by daily sleep 
diaries, with eight out of 17 (47%) showing a moderate or large treatment effect on frequency of 
night waking, 14 out of 17 (82%) showing a moderate or large treatment effect on sleep 
efficiency, and 10 out of 17 (59%) showing a moderate or large treatment effect on total sleep 
time. Interestingly, in terms of subjective sleep quality, just three out of 17 (18%) participants 
showed a moderate to large treatment effect. Additionally, just two out of 17 (12%) participants 
showed a moderate to large treatment effect for sleep onset latency, however only five 
participants presented with a problem in sleep onset latency to begin with. Therefore, greatest 
improvements were observed for the sleep efficiency and total sleep time variable measures, 
which is consistent with the findings of Lothian and colleagues (Lothian et al., 2016).  
Additionally, a significant placebo effect was seen; however, greater reduction of 
severity of insomnia symptoms and greater improvement in sleep aspects measured by the CSD-
M were observed during the micronutrient phase, thus supporting the hypothesis that the 
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micronutrient intervention had an effect additional to any placebo on primary measures of 
insomnia. This is evidenced as the overall group mean insomnia severity rating dropped from 
21.29 at mean placebo to 15.71 at the end of treatment with a statistically reliable medium effect 
size (Cohen’s dav = -0.66, CLES = 78%), with 12 out of 17 participants experiencing a clinically 
significant reduction at end of treatment compared to placebo as shown by the modified Brinley 
plots. Additionally, the positive effect was also shown by the CSD-M sleep diary data, as the 
mean PEM for none of the sleep variables reached even a moderate effect size during placebo; 
and all mean PEM scores were higher in the micronutrient phase compared to placebo (see 
Tables 5 and 6). Thus, there was clearly an additional positive effect of the micronutrients. 
However, due to the short lengths of placebo phases, it is possible that the placebo did not have a 
sufficient amount of time to produce a maximum effect. 
Short sleep duration is known to elevate levels of pro-inflammatory biomarkers (e.g., 
TNF-a, IL-1, IL-6) (Motivala, 2011; Vgontzas et al., 2003), and as aforementioned, previous 
research has found individuals with insomnia exhibit elevated levels of these biomarkers 
(Motivala, 2011; Vgontzas et al., 2003). The current study showed the greatest increase in total 
sleep time and sleep efficiency after micronutrient supplementation. It is plausible that the 
micronutrients reduced the levels of these pro-inflammatory biomarkers thus increasing total 
sleep time and sleep efficiency. However, as these biomarkers were not measured in the present 
research, this theory cannot be confirmed and thus needs further exploration.  
The overall finding that the majority of participants reported significant reduction in 
insomnia on two or more aspects of sleep measured by the CSD-M, and reliable and clinically 
significant decrease in insomnia severity supports the findings of Lothian and colleagues 
(Lothian et al., 2016). This finding is strengthened in the current study as the results show the 
micronutrient intervention had an effect that was additional to any placebo effect, which is 
consistent with previous research investigating the same broad-spectrum micronutrient formula 
showing greater improvement in psychological functioning in adults compared to placebo 
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control (Rucklidge et al., 2014b) as well as against single/lower dose nutrients (Rucklidge et al., 
2012). Additionally, the visual analyses of the multiple-baseline times series data show 
consistency whereby the positive effects of the micronutrients were replicated across a variety of 
measures, intervention phases and participants. This confirms that the changes were due to the 
micronutrient intervention, and that it is improbable that the results are due to natural 
improvements over time or regression to the mean. This replication of Lothian and colleagues 
(Lothian et al., 2016) research provides further evidence that broad-spectrum micronutrients are 
useful for the reduction of insomnia symptoms, and contributes to the idea that a range of 
micronutrients may be more beneficial and reliable for treating chronic insomnia than single 
nutrients alone. Thus, this challenges the typical experimental method of only providing single 
nutrients to evoke insomnia and other psychological symptom change (Rucklidge & Kaplan, 
2013). The findings of the present research are also consistent with numerous other studies 
demonstrating the benefits broad-spectrum micronutrient formulas have on mental health 
(Kaplan, Rucklidge, Romijn, & McLeod, 2015; Rucklidge & Kaplan, 2013).  
The effect of the intervention can also be demonstrated in a qualitative way through 
comments by participants. Six participants commented that they were “not waking up as much 
during the night”; and seven commented they “get back to sleep quickly” if they did awake; and 
eight commented “I have more energy” and “feel more refreshed”. Additionally, three 
participants noted that they “feel more clam”, especially given the busyness of the end of the 
school year.  
Cognitive and physiological hyperarousal are often associated with insomnia. A stressful 
emotional climate (e.g., a classroom with many children with behaviour problems) is likely to 
enhance the risk of hyperarousal through worry, anxiety and rumination, which can thus 
contribute to disruption of neurobiologic systems that modulate stress-response and sleep-wake 
regulation (Palagini et al., 2014). Therefore, it is reasonable to assume that cortical and 
physiological hyperarousal (i.e., disrupted sleep physiology) may be reduced and emotional 
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processing abilities enhanced due to a constant supply of an abundance of micronutrients, which 
help to support all the biochemical processes necessary for optimal brain function (Kaplan et al., 
2015b). Consistent with this, and as will be discussed below, in the current study, out of the 
MBI-ES measures, the micronutrients had the greatest effect on reported emotional exhaustion 
levels. 
Sleep diary data provided by the current sample was often variable, which is in contrast 
to the findings of Lothian and colleagues (Lothian et al., 2016). Some variability observed was 
associated with factors related to the teaching profession (e.g., staying up late writing reports). 
For example, whilst all teachers would have been report writing during the micronutrient phase, 
staying up late was noted in sleep diaries by participant P2 in weeks six and seven; by participant 
P5 in week seven; by participant P6 in weeks three four and five; and in person by participant 
P4. Additionally, participant P6 noted that they spent a considerable amount of time organising a 
school hangi during week 2; and participant P5 spent time organising a class presentation for an 
assembly in week one. Such a pattern is consistent with the idea that teaching is a stressful 
occupation with a high workload (Kyriacous, 2001). Other factors contributing to disrupted sleep 
included personal and family sickness throughout the intervention period, and social events over 
the Christmas holiday period at the end of the micronutrient phase. For example, participants P1, 
P2, P3, P5, P9, P10, P14 and P16 noted over varying days and weeks of the micronutrient phase 
that they were experiencing personal sickness; participants P3, P13, and P16 noted in weeks 3 
and 5 respectively that sleep was disrupted due to family sickness; and participants P2, P5, P6, 
P7, P11, P13, and P17 noted that they attended social events during the final week that disrupted 
their normal routine. However, although sleep patterns varied from night to night, the 
micronutrient intervention often reduced variability, which in itself may be beneficial.  
The times-series graphs show that for some participants sleep was disrupted during the 
last week of the intervention (i.e., decreases seen in sleep efficiency and total sleep time, and 
increases in number of night wakings). Additionally, the treatment effect for all groups 
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combined is slightly less at treatment end (dav = -1.37) compared to week 4 of treatment (dav = -
1.44), albeit these effect sizes are still large and statistically reliable. Therefore, one 
consideration when interpreting the findings is that although teachers were not teaching in the 
classroom at then end of treatment, the micronutrient phase of the intervention was completed 
the week of Christmas, and the external factors around Christmas, a known stressful, busy and 
active social time, may have impacted results.  
 Depression, anxiety and stress symptoms.  In terms of wellbeing measures, the 
hypothesis that the micronutrient intervention would be associated with improvements in stress, 
anxiety and mood symptoms if relevant, relative to placebo was not supported. In terms of 
anxiety, end of treatment relative to initial baseline scores indicates that reduction in anxiety was 
statistically reliable (i.e., the mean change in scores were statistically significantly different from 
zero) with a medium-large effect size  (dav = -0.73, CLES = 82%). However, decrease in anxiety 
from initial baseline to mean placebo was statistically reliable with a small effect size (dav = -
0.36, CLES = 68%); and although a small reduction in anxiety from mean placebo to end of 
treatment was observed (dav = -0.34, CLES = 67%), the mean change cannot be interpreted as 
reliable (i.e., the mean change in scores were not statistically significantly different from zero). 
Additionally, any clinically or statistically significant reduction in anxiety is unlikely because 
anxiety levels were not generally clinically elevated in baseline and therefore there is a floor 
effect. Consequently, not only is any further effect of the micronutrients compared to placebo 
hard to detect, it is also hard to detect anything other than deterioration because of the floor 
effect. 
 In terms of depression and stress, the results for changes in depression and stress levels 
were not statistically reliable at end of treatment relative to initial baseline, despite the mean 
reductions being in the desired clinical direction. Additionally, mean reductions in stress at both 
week four and end of treatment relative to mean placebo were not statistically reliable, as well as 
mean reduction in depression at week four. The end of treatment relative to mean placebo saw a 
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slight increase in depression scores at end of treatment, albeit this increase was not statistically 
significant. The scores of two participants increased to the clinical cut-off line, perhaps due to 
the time of the year at end of treatment assessment (as discussed above). Note that one 
participant was experiencing difficult family circumstances at the time of the end of treatment 
assessment. Lack of clinically and statistically significant reduction in depression and stress 
scores is again unlikely as few participants were in the clinical range for stress and depression at 
initial baseline, thus reflecting a floor effect. This general floor effect again makes anything 
other than deterioration and any additional effect of the micronutrients compared to placebo hard 
to detect. Thus, micronutrient consumption was not associated with a significant reduction in 
stress and depression levels, and the hypothesis that the micronutrient intervention would have 
an effect additional to any placebo on wellbeing measures was not supported, but this conclusion 
has to be qualified by noting that levels were not generally clinically raised to begin with. 
 The finding that anxiety levels were not significantly reduced relative to placebo after 
micronutrient consumption is in contrast with previous research investigating the effect of broad-
spectrum micronutrients on anxiety in adults after stressful life events (Kaplan, Rucklidge, 
Romijn, & Dolph, 2015; Rucklidge et al., 2012; Rucklidge et al., 2014; Rucklidge & Blampied, 
2011); however, it is important to note that these studies did not use placebo control. 
Furthermore, reduction in stress in the current study was not reliable. Although sixteen out of 
seventeen participants’ stress scores were below the clinical cut-off level, the lack of significant 
reduction in stress levels at end of treatment appears contrary to the findings of Lothian and 
colleagues (Lothian et al., 2016) and several other previous studies investigating the effect of 
broad-spectrum micronutrients on stress and anxiety (Rucklidge et al., 2012; Rucklidge et al., 
2014; Rucklidge & Blampied, 2011). But again, this reflects a floor effect as few participants 
scored above the clinical cut-off at initial baseline. Additionally, the finding that the current 
study did not yield a significant reduction in depression levels is contrary to previous research 
using clinical samples of individuals with depression (Gately & Kaplan, 2009; Rucklidge & 
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Harrison, 2010; Simmons, 2003), but is however, consistent with previous research using non-
clinical samples for depression (Kaplan, Rucklidge, Romijn, & Dolph, 2015; Long & Benton, 
2013).  
The finding that the micronutrient intervention did not have an effect additional to any 
placebo on wellbeing measures is in contrast with the previous research mentioned above using 
placebo control (Rucklidge et al., 2014b), and single/lower dose nutrient comparisons 
(Rucklidge et al., 2012). This finding too, is also in contrast with previous research investigating 
multi-ingredient micronutrient formulas, which are not EMP+, against placebo (Carroll et al., 
2000; Stough et al., 2011); however, comparisons are difficult due to the varying formulas and 
doses used. 
There are several possible reasons for the lack of significant effect of micronutrients on 
stress, anxiety and depression levels in the current study. First, participants were selected for the 
study if they met criteria for insomnia, not for high anxiety, depression and stress scores. The 
current sample were a non-clinical sample with respect to depression, anxiety and stress, thus 
scores were low at initial baseline meaning there was not much room for any further reduction. It 
is noteworthy, however that depression scores, as well as stress and anxiety scores, did not 
significantly deteriorate over the course of the intervention.  
The finding that reduction in stress scores was not reliable was unforeseen as this sample 
was selected due to their high-stress working environment. However, only two participants’ 
scores were above the clinical cut-off at initial baseline. One explanation for low baseline scores 
is that baseline measures were taken in the second week of the school holidays in order that the 
intervention could begin in term 4 of the school year. Thus, teachers had not been in the stressful 
classroom environment for over a week preceding initial baseline assessment, potentially 
providing teachers with enough time to de-stress without other significant factors (e.g., 
Christmas), before the intervention began. However, as previously mentioned, stress is not the 
sole cause of insomnia. It is possible that worry, rumination and physiological hyperarousal 
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played a larger role in maintaining insomnia at the time baseline measures were assessed than 
stress. Another plausible explanation is the possibility that there was some inadequacy in the 
DASS-21 measure, which may not have been sensitive to stress in the current sample. A scale 
specifically measuring teacher occupational stress, such as the Teacher Stress Inventory (Fimian, 
1984), may have been more sensitive and thus detect any change in stress. 
Burnout. Burnout was measured in this study because it has been widely investigated as 
a deleterious state experienced by teachers (and other employees) who have worked under 
stressful conditions for periods of time. The hypothesis that the micronutrient intervention would 
be associated with improvements in the burnout dimensions of emotional exhaustion (EE) and 
depersonalization (DP) was partially supported in that the group mean ratings for the EE 
subscale of the MBI-ES dropped from 31.59 at baseline to 22.18 at treatment end with a 
statistically reliable and large effect size (Cohen’s dav = -1.08, CLES = 93%). A clinically 
significant reduction was observed in 11 out of 17 participants in the EE subscale. No clinically 
or statistically significant reduction was observed in the DP subscale because DP levels were not 
generally clinically elevated in baseline and therefore there is a floor effect; consequently, it is 
hard to detect anything other than deterioration. 
Although previous micronutrient research has not specifically focused on EE, the finding 
that micronutrient consumption is associated with improvements in EE is consistent with 
previous research in the sense that broad-spectrum micronutrients have been associated with 
improvements in sleep, anxiety and stress (Lothian et al., 2016; Rucklidge et al., 2012). This is 
because, as EE refers to a depletion of emotional resources and shortage of energy (Maslach, 
Schaufeli, & Leiter, 2001), it is not surprising that improvements in sleep are likely to positively 
impact EE. Micronutrient supplementation may have also provided participants with a renewed 
capacity to process emotional states effectively as a result of renewed energy from sleeping 
efficiently. 
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Furthermore, as EE is likely to place individuals under cognitive strain, the findings of 
the current study are consistent with previous research finding improvements in cognitive 
functioning and mental fatigue after micronutrient consumption (Haskell et al., 2010). The 
finding that Christchurch teachers reported significant improvement in EE is both positive and 
encouraging as being able to function optimally is vital to not only their teaching role, but also to 
cope effectively with the extra stressors children in their classrooms bring (e.g., behaviour 
problems, difficulty concentrating). Such findings also confirm the idea that better sleep leads to 
improvements in daytime functioning and vice versa.  
An explanation for the lack of significant decrease in DP in the current study is that 
scores were not high at initial baseline. First, this may be due to the fact that participants were 
not teaching in the classroom at this time. Second, EE is a probable precursor to DP (Maslach et 
al., 2001), thus, the micronutrients may have protected against the onset of DP occurring due to 
its successful reduction of EE. Third, and perhaps the more likely scenario, low scores observed 
may reflect the characteristics of the particular study sample used. Thus, although participants 
were fatigued, they did not exhibit negative or indifferent attitudes toward their students or 
psychological detachment from their work (Maslach et al., 1996). It is also noteworthy that 
scores did not worsen over the course of the intervention indicating that micronutrient 
supplementation may have supported maintenance of low scores.  
 Follow-up. The hypothesis that improvements would be maintained over the follow-up 
period if participants remained on the micronutrient formula; and that improvements would be 
maintained at a lower level for participants who discontinued was partially supported. All 17 
participants provided follow-up data. In the overall group, no further reduction in severity of 
insomnia was seen from the end of the intervention to the 3-month follow-up, and the majority 
of participants displayed some moderate return back toward initial baseline. Statistically 
significant improvements in insomnia symptoms over the follow-up period relative to initial 
baseline were maintained, thus indicating an enduring effect of the micronutrients even in those 
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that discontinued use after the intervention; however, although mean reduction in insomnia 
severity observed at follow-up relative to mean placebo was in the desired clinical direction, this 
difference was not statistically reliable. Thus, although 10 participants demonstrate clinically 
significant reduction in insomnia levels at follow up relative to placebo (i.e., they were below the 
clinical cut-off), there was no statistically significant additional enduring effect of the 
micronutrients relative to the placebo effect. As such, although improvements in insomnia 
severity were maintained at follow up relative to initial baseline, reduction in insomnia severity 
was not statistically significantly reduced at follow up in comparison to the placebo effect 
observed.  
Of the four participants who continued taking EMP+ after the intervention,  
treatment benefits were maintained and large and medium-large effects were shown at follow-up 
relative to initial baseline (dav = -0.90, CLES = 88%) and mean placebo (dav = -0.64, CLES = 
69%) respectively. However, a slight increase in insomnia severity is seen at follow-up relative 
to end of treatment, as mean insomnia severity rating scores increased from 18.5 at treatment end 
to 19.75 at follow-up (dav = 0.07, CLES = 54%). Although this is contrary to the hypothesis, it is 
noteworthy that one of these 4 participants experienced a death in the family, which is likely to 
have significantly impacted this finding, as such an event is upsetting and stressful, thus 
negatively impacting sleep. When this participant is taken out of the analysis, treatment 
continued to confer benefit as mean insomnia severity scores dropped from 13.67 at treatment 
end to 10 at follow-up, with a small effect size (dav = -0.35, CLES = 63%), and dropped from 
30.17 at mean placebo to 10 at follow-up, with a very large effect size (dav = -6.14, CLES = 
100%), indicating both continued reduction in severity of insomnia for these three participants 
and an additional enduring effect of the micronutrients relative to the placebo effect. However, 
these findings should be interpreted with caution as the 95% CI on d was not computable 
(because the data violated the requirements for iterative computation built into the software), 
therefore it cannot be determined whether this change was statistically reliable. 
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 Considering depression, anxiety and stress scores, no further improvement was seen at the 
3-month follow-up, with the majority of participants displaying some return back toward initial 
baseline. Of the four participants that continued, no further improvement was seen in total 
DASS-21 scores at follow-up compared to initial baseline, as mean total DASS-21 scores 
increased from 10 at treatment end to 12.25 at follow-up, with a small effect size (dav = 0.22, 
CLES = 54%). Again, this is largely due to participant P6 experiencing very difficult family 
circumstances. When this participant is taken out of the analysis, treatment continues to confer 
benefit as mean total DASS-21 scores dropped from 8.67 at treatment end to 6 at follow-up, with 
a medium effect size (dav = -0.50, CLES = 71%), indicating continued reduction in total DASS-
21 scores. Mean scores of these three participants decreased from 16 at initial baseline to 8.89 at 
mean placebo, with a large effect size (dav = -1.01, CLES = 82%), thus indicating a placebo 
effect. Furthermore, no further reduction in DASS-21 scores was seen in these participants at end 
of treatment relative to mean placebo, as mean scores decreased only from 8.89 at mean placebo 
to 8.67 at treatment end (dav = -0.04, CLES = 52%); which is consistent with the floor effect 
observed in the overall sample. Despite this, a reduction in total DASS-21 scores continued to be 
observed relative to placebo as mean total DASS-21 scores dropped from 8.89 at mean placebo 
to 6 at follow-up, with a large effect size (dav = -0.90, CLES = 88%), thus indicating that there 
may have been an additional enduring effect of the micronutrients in those that continued at 
follow-up relative to the placebo effect. However, again, these findings should be interpreted 
with caution as the 95% CI on d was not computable it cannot be determined whether this 
change was statistically reliable.  
 The finding that those who continued taking EMP+ reported greater maintained 
improvements in insomnia and daily functioning at follow-up compared to those who chose to 
discontinue is consistent with previous research into other psychiatric diagnoses such as anxiety 
and ADHD (Rucklidge et al., 2014; Rucklidge et al., 2014b). Together these findings indicate 
that the benefits of micronutrients produce greater positive treatment effect in those that 
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continue, and diminish in those that do not. One participant in the current study (P10) who 
responded remarkably to the micronutrients during the intervention reported switching back to 
medication (zopiclone) and the end of the trial due to the cost of the micronutrients. At follow-
up, this participant reported an increase in severity of insomnia from a PIRS-20 score of 3 at the 
end of the intervention to 37 at follow-up. Total DASS-21 scores also increased from 3 and 
treatment end to 17 at follow-up. Thus, insomnia severity increased and overall wellbeing 
decreased upon discontinuation of the micronutrients for this participant despite their resumption 
of medication. This is in line with Rucklidge and colleagues (Rucklidge et al., 2014; Rucklidge 
et al., 2014b), who found in their follow-up studies that participants who switched to 
medications from micronutrients experienced a worsening in symptoms. This is also consistent 
with research demonstrating the negative outcomes of long-term medication use in both 
insomnia (Krakow, Ulibarri, & Romero, 2010) and other psychiatric diagnoses such as 
depression, anxiety and ADHD (Advokat, 2010; Offidani, Fava, Tomba, & Baldessarini, 2013). 
Thus, the findings that consumption of micronutrients led to continued improvement in 
symptoms over time suggest that micronutrient supplementation for chronic insomnia and other 
psychiatric difficulties is a viable treatment option in the long term.  
Reasons given by participants for continuing the micronutrients included improved sleep, 
mental health and improved physical health conditions including irritable bowel syndrome 
(Nicholson et al., 2012) and reduction in menopause symptoms (e.g., night-sweats and hot 
flushes). For example, one participant commented that “I feel better and I sleep better”, another 
“my sleep has improved and irritable bowel is gone!” and another “the micronutrients helped me 
get back to sleep and my night sweats and hot flushes are way better”. As discussed in the 
introduction, there is a strong relationship between gut dysbiosis, inflammation and many 
chronic disorders. Both psychological and physiological stress (e.g., disturbed sleep physiology) 
negatively alter the balance of good and bad gut bacteria, and reduction in beneficial bacteria can 
evoke inflammatory responses and can thus be an underlying cause of inflammatory diseases 
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such as IBS (Berk et al., 2013). Reported reduction in IBS in the current study is consistent with 
the idea that insomnia and other psychiatric diagnoses are associated with gut dysbiosis and 
elevated levels of proinflammatory cytokines, which can in turn be corrected through 
micronutrient supplementation (Kaplan, Rucklidge, Romijn, & McLeod, 2015). Additionally, 
microbiome and hormonal changes occur as individual’s age and can be negatively altered 
during menopause for women (Zapata & Quagliarello, 2015). Reported reduction in menopause 
symptoms in the current study may thus indicate that micronutrients could correct these 
imbalances, which in turn may keep menopausal symptoms at bay. Though, it is important to 
remember these theories cannot be confirmed in the present research as proinflammatory 
biomarkers were not measured. However, the link between micronutrient supplementation and 
premenstrual syndrome is currently being investigated (Retallick-Brown, Rucklidge, & 
Blampied, 2016), which may provide further information on the association between hormonal 
changes and micronutrient supplementation.   
Reasons given by participants for not continuing to take the micronutrients included cost, 
procrastination, life stress, that no difference in sleep or positive effect was noticed during the 
intervention and simply that they did not suit. For example, one participant commented, “I did 
not find they made much difference”; another “I didn't feel certain that they were improving the 
quality of my sleep. Interestingly, having completed this survey, I realise the quality of my sleep 
may be where it was pre-intervention so the nutrients probably made some difference”; and 
another “wanted to try without them and see if there was a difference or not”. Importantly, side 
effects or feasibility of taking the pills were not identified as a reason to discontinue the 
micronutrients.  
 Side effects. The final hypothesis that the micronutrient intervention would not be 
associated with significant side effects, and if present, these would be minor and transitory, was 
supported. Side effects were reported by a total of 11 participants: 10 participants during the 
micronutrient phase. Of these, four participants also reported side effects during the placebo 
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phase. One participant reported headaches and gastrointestinal disturbances during the placebo 
phase only. Six participants never reported any side effects. The majority of adverse side effects 
experienced by participants were mild (e.g., headaches, gastrointestinal disturbance), with one 
participant experiencing side effects at a moderate level (e.g., headaches). Side effects 
experienced were transitory and able to be remedied through increased water and food intake. 
No participant withdrew because of adverse side effects. Furthermore, side effects reported 
during placebo phases (e.g., headaches and gastrointestinal disturbance) by five participants may 
have been due to the expectation that side effects will occur, thus meaning these individuals may 
have been more likely to attribute ambiguous or pre-existing sensations to pill taking. This may 
also have been true for some participants during the micronutrient phase, as participants 
commonly reported that they were not sure if the side effects they were currently experiencing 
were due the micronutrients or not; however, this theory cannot be confirmed. Additionally, four 
out of the five participants reporting side effects during placebo reported that they were not used 
to taking any sort of pills, thus it may have been that reported side effects were due to the body 
adapting to pill taking with the placebo formula.  
 The finding that the current study was not associated with any significant adverse side-
effects or safety concerns is consistent with previous research (Lothian et al., 2016; Rucklidge et 
al., 2012; Rucklidge et al., 2014a; J. S. A. Simpson et al., 2011). The current study thus adds to 
the existing literature demonstrating the positive safety and tolerability findings of EMP+.   
4.2 Research Strengths 
One strength of this study was the strengthening of the multiple-baseline design with 
placebo control. Use of a placebo meant that the first two weeks of the intervention was double-
blinded and from thereafter single-blinded. This allowed for detection of the portion of the 
overall treatment effect that was attributable to the micronutrients. It also allowed for any 
expectancy effects to be controlled for, and multiple replications of treatment benefit could be 
seen across participants throughout the micronutrient phase. This design also allowed for 
 115 
baseline stability of symptoms to be evaluated and for symptoms to repeatedly be assessed. 
Taken together, this demonstrates that positive treatment effects found in the current study are 
beyond that of regression to the mean effects or people improving naturally over time. The 
design also allowed for all participants to receive the active intervention, and for between and 
within-group comparisons of the intervention to be made. This has ethical advantages over 
conventional designs, which consign some participants to control conditions and denying them 
access to benefits of the active treatment.  
 Retention rate in the current study was high with no dropouts, compliance was very good, 
and four participants chose to continue taking the micronutrients, indicating that micronutrient 
supplementation is a feasible and viable treatment option. One factor that this may be due to is 
that throughout the intervention, the researcher often met with participants at a place of their 
convenience, and not at the University. This meant participants did not have to leave their place 
of work or home and travel a fair distance to the university, thus keeping disruption to their lives 
to a minimum and making it convenient for them to remain in the study. Additionally, there was 
a low level of missing data. It is likely that use of online surveys helped with this, and use of a 
paper and pen sleep diary made it simple to fill out and easily accessible to participants. 
A further strength is that because this study was occupationally focused and only 
recruited teachers, this controlled for any differences that might have been introduced due to 
individuals being in different jobs or having different sources of daily stressors. Another strength 
is that this trial was prospectively registered on the Australia New Zealand Clinical Trials 
Registry, which ensured that key methodological aspects of the study such as the primary 
outcome measures were not changed after the study was registered, ensuring reporting of 
outcomes was transparent (Bradley, Rucklidge, & Mulder, 2016).   
4.3 Limitations 
There were several limitations of the present study that must be acknowledged. First, one 
major limitation is that the DASS-21 measure used at screening and over the course of the 
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intervention may not have been the appropriate measure to use to detect teacher stress, anxiety 
and depression. Alternate measures of anxiety and depression, and a scale specifically designed 
to measure teacher occupational stress, such as the Teacher Stress Inventory (Fimian, 1984), may 
have been more sensitive. Second, another major limitation is the timing that measures were 
assessed. All baseline measures were assessed in the second week of the school holidays. This is 
likely to have impacted the findings as participants were not in their normal daily routines and 
were not currently teaching in the classroom. Thus, it is possible that participants were less 
stressed and more relaxed at the time of baseline assessment. Furthermore, end of treatment 
measures were assessed during the week of Christmas. This is again likely to affect the current 
findings due to Christmas being a stressful and busy time of year, with many participants 
attending numerous social events and being out of their normal daily routine, which in turn 
affects sleeping patterns.   
Influences contributing to the positive findings may include improved sleep patterns and 
sleep hygiene through use of completing a daily sleep diary. Some participants commented that 
they learnt that they did not have healthy sleeping habits and patterns, and it is thus plausible that 
some participants may have tried to rectify this. However, previous research shows that there is 
an inadequate amount of empirical evidence to suggest sleep hygiene education is an effective 
treatment on its own (Stepanski & Wyatt, 2003), with one study showing that it is ineffective as 
a stand-alone treatment (Schoicket, Bertelson, & Lacks, 1988). Additionally, daily routines may 
have improved through the need to eat regularly and drink plenty of water with the pills. 
However, as sleep habits, sleep hygiene, and nutritional intake were not assessed, the degree to 
which these factors influenced the findings cannot be verified.   
Another limitation of the present research is that as nutritional intake and pro-
inflammatory and oxidative stress biomarkers were not assessed, possible mechanisms of action 
for insomnia could not be identified. However, it is important to note that collection of this data 
was beyond the practical scope of this study.  
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 Researcher contact and therapeutic input are often involved in research trials such as 
these, and may have contributed to the improvements seen in the current study. However, 
therapeutic input and contact is unlikely to explain the magnitude of positive change observed in 
participants throughout the intervention as the study was designed to keep researcher contact to a 
minimum, meetings were kept short (generally less than 30 minutes), sleep diaries were 
completed at home, and the remaining assessments completed online. Meetings were arranged to 
discuss how participation was going and to check for any side effects and compliance. 
Participants were not provided with psychological strategies to cope with their insomnia.  
 Spontaneous remission of symptoms should also be considered; however, because a 
positive effect was experienced by the majority of participants experiencing chronic insomnia, 
spontaneous remission being responsible for the treatment effect observed is improbable. 
Additionally, the pattern of change seen i.e., stability of baselines and greatest improvements 
observed in the micronutrient phase, makes treatment effects observed due to spontaneous 
remission unlikely.  
 Although a placebo was used to help control for any expectancy effects, experimenter 
bias should be considered as a possible contributing factor to improvements seen. While the first 
two weeks of pill taking were double-blind, meaning neither the participant nor researcher knew 
if they were in active intervention, after two-weeks the researcher knew that all participants were 
receiving the micronutrients. This meant that the study then became single-blinded and 
experimenter bias may have occurred during later meetings with the participants. However, 
again this is unlikely as meetings were kept to a minimum, a multiple-baseline design was used 
and measures completed at home or online. Furthermore, treatment benefits were small initially 
and increased the longer participants had been taking the micronutrients.  
  Further limitations include the small sample size. However, the fact that significant 
improvement in insomnia was found in both the current study and that of Lothian and colleagues 
(Lothian et al., 2016) who had a small sample size of 14 participants, suggests that the effect of 
 118 
micronutrients on insomnia could be a considerable one. Second, generalizability (i.e., the 
external validity) of the results are limited as the current study was occupationally focused and 
consisted of teachers in Christchurch working in a city affected by earthquakes and in turn 
experiencing multiple stressors. Thus, generalizing to teachers working in a city not affected by 
earthquakes and to other occupations who experience different sources of stress is difficult. 
Despite this, it is important to remember that the current findings of the effect of micronutrient 
supplementation on insomnia replicate the findings of Lothian and colleagues (Lothian et al., 
2016) whose sample was a general adult population. However, in both the current study and that 
of Lothian and colleagues (Lothian et al., 2016) the majority of the samples consisted of women, 
therefore, generalizability to men is difficult to determine. It is important to remember however, 
that insomnia affects more women than men (Morin & Jarrin, 2013) and could explain why both 
study samples were predominantly female. Additionally, teachers also tend to be predominantly 
female, which is therefore a further explanation as to why the current study sample contained 
fewer men.  
4.4 Implications 
 The current research has a number of implications for future research and practice. First, 
the present research contributes to the limited research on the effect of broad-spectrum 
micronutrients and chronic insomnia. The current body of research provides mixed results across 
various individual vitamin and mineral treatments for insomnia, as well as lower dose multi-
nutrient treatments. The findings of the present research indicate that there needs to be a focus on 
providing individuals with a broad range of micronutrients at higher doses in order to see a 
significant improvement in chronic insomnia. This is consistent with the idea that physiological 
functioning is enhanced when vitamins and minerals are given in combination as they affect both 
the absorption and effectiveness of one another. Thus, the present study offers further evidence 
that use of broad-spectrum micronutrients for the treatment of chronic insomnia has potential as 
a viable treatment option and is worthy of further exploration; and that it is important for 
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clinicians to be open to and recommend alternative treatment options for chronic insomnia, such 
as EMP+. This would ensure teachers and individuals with chronic insomnia are provided with 
an additional treatment option, and can make an informed decision about which treatment may 
suit them best.  
 Second, the potential metabolic mechanisms specifically associated with insomnia are 
unable to be identified in the current study, as the aim was to determine any intervention effect 
of micronutrient supplementation. However, present findings suggest metabolic mechanisms 
discussed in the introduction section are important to take into consideration with the effects of 
EMP+ on chronic insomnia. This theory undoubtedly deserves further exploration. Thus, the 
present research provides a foundation for further investigation into the application of broad-
spectrum micronutrient supplementation for chronic insomnia in clinical populations. 
4.5 Future Research 
As mental health needs continue to rise in Christchurch post-disaster (McLennan, 2016), 
many people seek alternative treatment for insomnia as well as other psychiatric disorders due to 
the limited availability of public services, cost of therapeutic intervention, and lack of efficacy, 
long-term risks and side effects associated with pharmacological treatment (Rucklidge & 
Kaplan, 2013). Thus, alternative treatments for these difficulties need to be explored. The 
objective of the current study was to determine whether micronutrients would be one such 
alternative for insomnia and work-related stress. Because possible mechanisms of action of 
micronutrients associated with insomnia were not measured in the present research, nutritional 
intake and metabolic levels of vitamins and minerals were not assessed. Future research 
however, should endeavour to incorporate such measures, which could inform whether the 
dietary intake of individuals with insomnia working in a stressful environment is inadequate or 
whether nutritional needs increase in response to the increased physiological and external stress, 
or both. 
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Furthermore, as the findings suggest there may be a likely link between the gut, oxidative 
stress, inflammation and mitochondrial dysfunction and insomnia, especially as one participant 
who experienced reduction in insomnia also experienced reported reduction of IBS; and given 
the association between elevated pro-inflammatory biomarkers, gut health and insomnia 
(Motivala, 2011; Vgontzas et al., 2003), future research should endeavour to collect information 
on levels of pro-inflammatory biomarkers (e.g., TNF-alpha, IL-6, IL-1, CRP) and oxidative 
stress biomarkers (e.g., SOD). This would allow determination of the effect of micronutrients on 
the inflammatory nature of chronic insomnia. Faecal sampling would be beneficial in future 
research as a way to further assess micronutrient outcome on insomnia and to determine whether 
micronutrients can increase the diversity of bacteria in the gut, which in turn increases gut 
health, thus enhancing micronutrient absorption (Kaplan, Rucklidge, Romijn, & McLeod, 2015). 
Research clarifying the specific mechanisms of action of micronutrients on insomnia would also 
be beneficial, because as previously mentioned in the Introduction, currently the mechanisms of 
action specifically related to insomnia have not been identified (Berk et al., 2013). Such 
methodology would add to the growing body of literature on the role of micronutrients in mental 
health, and would add to the knowledge of the etiology, maintenance and treatment of chronic 
insomnia.   
The present research could be extended by employing a randomised controlled trial 
design incorporating a placebo. Such research would add to evidence of the micronutrients’ 
effectiveness (or otherwise), and would further minimise any bias and unknown confounding 
variables through random allocation to active and placebo control conditions. Additionally, 
numerous treatment variants (e.g., length of trial, dose, formula) and participant (e.g., gender, 
age) aspects should be systematically replicated in future research to determine generality of the 
treatment effect over diverse cases and treatment settings. This can most efficiently be done by 
use of systematic replications within single-case research  (Blampied, 2013). In the current 
study, some participants noted at the end of the intervention (after about 8 weeks receiving 
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micronutrients) that they started to notice an improvement in sleep (i.e., a reduction in insomnia 
symptoms). This suggests that longer trials may produce greater reduction in insomnia in 
participants. Also, it is reasonable to assume that optimal doses for therapeutic benefits vary 
between individuals; it may be that a higher dose than that used in the present study would be of 
greater benefit to some individuals while some may be able to retain benefits at a lower dose. 
Therefore, it is of great importance that varying doses and longer intervention phases are 
explored. Furthermore, given that the samples in both the current study and that of Lothian and 
colleagues (Lothian et al., 2016) were predominantly female, future research should endeavour 
to obtain gender balance or specifically investigate males in subsequent trials in order to increase 
generality of findings. Also, future research should employ appropriate occupationally focused 
measures, as well as anxiety and depression measures, to detect for any change in stress, anxiety 
and depression. Additionally, it is desirable for future research to conduct comparisons with 
psychological treatments for insomnia such as CBT-I (Morin, 2004; Siebern, Suh & 
Nowakowski, 2012), as it may be found that symptom reduction and the effectiveness of 
psychological treatment is enhanced when micronutrients are used in conjunction.  
Given the positive findings of the current study and that of Lothian and colleagues 
(Lothian et al., 2016), it is plausible that micronutrient supplementation may also be useful for 
the prevention of insomnia. In the present research, teachers were teaching in the classroom for 
the majority of the intervention. Thus, for most of the teachers insomnia symptoms reduced 
whilst teaching in a stressful working environment. These findings suggest that micronutrients 
may protect against the development of insomnia. Because of the earthquakes, Christchurch 
teachers are facing different challenges than those around the rest of New Zealand, therefore, 
supplementing with micronutrients before mental health problems arise, or in anticipation of or 
early in exposure to stressful events, may prove invaluable, and is something that future research 
should explore.  
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 Long-term efficacy and safety of micronutrient use over several years has not yet been 
ascertained (Rucklidge & Kaplan, 2013), therefore, further research should establish long-term 
outcomes, for the most part on brain development. However, preliminary reports of continued 
use without adverse effects (J. S. A. Simpson et al., 2011) provide positive support for long-term 
use. Additionally, it would be beneficial for future research to systematically determine, once 
reduction of symptoms has been attained, whether the dose can be decreased to a maintenance 
level.  
4.6 Conclusion 
 The aim of the current study was to investigate the effect of a broad-spectrum 
micronutrient formula taken over an over an 8-10 week period when compared with placebo for 
the treatment of chronic insomnia in teachers in Christchurch. The findings show that broad-
spectrum micronutrient supplementation is beneficial for the treatment of chronic insomnia in 
teachers working in a stressful environment, as well as for the reduction of emotional exhaustion 
in Christchurch teachers. It is possible that the lack of effect of micronutrients on stress, anxiety 
and depression is due to scores not being generally clinically raised in the sample to begin with; 
as well as potential inaccuracy in the measure. The positive effect of micronutrients on insomnia 
confirm the findings of Lothian and colleagues (Lothian et al., 2016), and provide further 
support to the current body of research demonstrating that improvements in a range of 
psychiatric symptoms and overall functioning occur after supplementation with a broad-
spectrum of micronutrients. These findings indicate that broad-spectrum micronutrients are a 
viable treatment option for Christchurch teachers experiencing chronic insomnia. In turn, 
teachers who are functioning optimally will be able to provide the best education and care that 
they can for their students, including those that continue to display problem behaviours as a 
result of the earthquakes. While future research is needed to both replicate and strengthen the 
findings and determine the specific biological mechanisms associated with insomnia and the 
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effect micronutrients have on them, the present research establishes a solid foundation upon 
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Appendix A: Ingredient List of EMPowerplus 
EMPowerPlus Advanced Supplement Facts   
Amount Per Serving (2 capsules)*                           % Daily Value   
 
Vitamin A (as retinyl 
palmitate)  
 




Vitamin C (as ascorbic acid)  
 




Vitamin D (as cholecalciferol)  
 




Vitamin E (as d-alpha  
tocopheryl succinate)  
 




Thiamin (as thiamin 
mononitrate)  
 










Niacin (as niacinamide)  
 




Vitamin B6 (as pyridoxine 
hydrochloride)  
 




Folic acid   
 




Vitamin B12 (as 
methylcobalamin)  
 










Pantothenic acid (as calcium 
pantothenate)  
 




Calcium (as chelate)  
 




Iron (as chelate)  
 




Phosphorus (as chelate)  
 




Iodine (from Pacific kelp)  
 




Magnesium (as chelate)  
 




Zinc (as chelate)  
 




Selenium (as chelate)  
 




Copper (as chelate)  
 




Manganese (as chelate)  
 




Chromium (as chelate)  
 




Molybdenum (as chelate)  
 




Potassium (as chelate)  
 





Propriety blend: Choline bitartrate, DL-phenylalanine, citrus Bioflavonoids, Inositol, L-Glutamine, 
L-Methionine, Grape seed extract, Gingko biloba leaf extract, ermanium sesquioxide, Boron (as 
chelate), Vanadium (as chelate), Nickel (as chelate).  
 
 Other ingredients: capsule shell (gelatin, titanium dioxide) microcrystalline cellulose, glycine, citric 
acid, magnesium stearate, silicon dioxide, mineral wax 
 
*Amount per serving on this list is for 2 capsules. Participants need to be aware that they 
are taking 4x this amount (8 capsules per day).  
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Appendix B: Information sheet and FAQ sheet 
Telephone: +64 0273754496 
Email: alison.carley@pg.canterbury.ac.nz 
Date: 10/05/16 
Investigating the Effect of Micronutrients on Insomnia  in Teachers: A 
Multiple-Baseline Design 
Information Sheet for Teachers Experiencing Insomnia 
Principal Investigator: Alison Carley (Alison.carley@pg.canterbury.ac.nz) 
 
Other Investigators: Professor Neville Blampied 
(Neville.blampied@canterbury.ac.nz), Professor Julia Rucklidge 
(Julia.rucklidge@canterbury.ac.nz), Associate Professor Kathleen Liberty 
(Kathleen.liberty@canterbury.ac.nz)  
 
What is the purpose of the study? 
This study is investigating the effects of a micronutrient formula (vitamins and 
minerals) on insomnia in teachers. The supplement we are studying is called 
EMPowerplus (EMP+) and the aim of the study is to determine whether this 
micronutrient formula can impact on symptoms of insomnia in teachers working in 
earthquake affected schools.   
 
What would I have to do? 
 If you volunteer to participate in the study, before it begins you will be screened 
for eligibility first through an online questionnaire (approximately 30 minutes) and 
secondly through an interview with the researcher either at the University of 
Canterbury or a place of convenience for you, where written informed consent will 
be obtained and inclusion criteria will be reviewed (approximately 1 hour).  
 
 
This study has two phases, and if you agree to take part, you will be asked   to do 
the following: 
• Phase one: You will complete the online baseline questionnaire on sleep 
quality and associated psychological measures. These will take 5-10 minutes 
each to fill out. After the first initial meeting, you will be asked to complete 
a daily sleep diary to be filled out every morning for 7 days, that asks 
questions about the previous night’s sleep, in order to obtain baseline 
measures of sleep. This will take 5 – 10 minutes each day.  
• Phase two: After the 7 days of baseline you will complete the questionnaires 
online again. Phase two is where the placebo and micronutrient phase 
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begins, where you will have up to 11 weeks of taking capsules (non-active 
placebo and active micronutrient). You will take 8 capsules daily, as two 
doses of four capsules twice a day. During this phase, you will continue to 
monitor your sleep daily using the sleep diary. You will be asked to meet 
with the researcher once a month or as necessary to assist with compliance 
and or resolve any side effects. You will be asked to complete online 
questionnaires at weeks 2, 3, 4, and 8. These will take 5 – 10 minutes to 
complete. At the end of the phase you will be asked to fill out again the 
questionnaires on sleep and associated psychological measures.  
• Approximately three months after the trial is over you will be asked to fill 
out two online questionnaires for a final time on your insomnia symptoms 
and associated psychological measures.   
 
What are the risks? 
This type of supplement has been used for many years by many people without any 
unpleasant results reported. More recently, investigators in Canada have published 
a research paper outlining the safety of the micronutrients being studied. Data were 
assembled from all the known published and unpublished studies for the formula 
with the largest amount of published research in mental health. Biological safety 
data from 144 adults and children were available from six sources: there were no 
occurrences of clinically meaningful negative outcomes/effects or abnormal blood 
tests that could be attributed to toxicity (Simpson et al., 2011). In our trials 
conducted here at Canterbury, we have assessed hundreds of participants taking 
micronutrients for up to 4 months to date, and there were no abnormal results that 
concluded these micronutrients were having an adverse effect on liver or kidney 
function. Further, any side effects reported have been temporary and mild.  
The most common ‘side effects’ are; relief from previously-experienced 
constipation and sleep improvement, i.e., positive side effects rather than adverse 
events. Other side effects that are reported by people taking micronutrients are 
headaches and stomach aches although they are typically mild and transitory. 
These difficulties can be avoided by taking capsules on a full stomach, so we 
suggest you always take your capsules with food and plenty of water. We will 
review side effects fortnightly and make a referral to a medical practitioner if 
necessary. We are happy to provide you with copies of the studies that have been 
done to date on EMPowerplus.  
Micronutrients have the potential to interact with other medicines or drugs so you 
should avoid taking other medicines while taking the nutrients. For this reason, we 
are only including individuals in the study who are not being concurrently treated 
for their illness using prescribed medications. With respect to whether to take 
other medications, such as over the counter medications to treat colds, flu, stomach 
upset and sleep problems, because they may interact with the micronutrients, you 
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should first discuss with us or your pharmacist before use. For safety reasons if 
you are, or become pregnant, you will have to withdraw from the study. 
Pregnancy should be avoided while taking the micronutrients. Further, we advise 
women that during the trial, if relevant, they use some form of contraception 
because the safety of micronutrients during pregnancy has not been established 
(although there is no reason to think they are dangerous in such circumstances.  
Will I benefit if I take part? 
Everyone who takes part in this study will receive the micronutrients at some point 
during the trial. Previous research has shown that micronutrient formulas have a 
positive effect on insomnia, so you may benefit by taking part in this study. There 
is always a possibility that the micronutrients may not be effective for you; 
generally you must take the micronutrient formula for at least six weeks before an 
observable change occurs, therefore it is important that you keep on taking your 
assigned pills.    
Do I have to participate? 
Absolutely not. Participation is voluntary and you have the right to withdraw from 
the project at any time without penalty. This decision will not influence your 
ongoing health care in any way. Similarly, the study’s investigators may choose to 
end your participation in the study at any time for any reason. If new information 
becomes available that might affect your willingness to participate in the study, 
you will be informed as soon as possible. If you choose to withdraw, I will use my 
best endeavors to remove any of the information relating to you from the project, 
including any final publication, provided that this remains practically achievable.  
Will I be paid for participating, or do I have to pay for anything? 
Arrangements will be made with each individual participant to ensure that your 
transportation costs to the university (to meet with the investigator) and parking are 
covered. The capsules you will be taking during the study will be provided at no 
cost. A koha of a grocery voucher will be given to participants upon completion of 
the study.  
Will my records be kept private? 
The results of the project may be published, but you are assured of the complete 
confidentiality of data gathered in this investigation: your identity will not be made 
public without your prior consent and is only shared within the context of the 
Mental Health and Nutrition Research Team. Complete anonymity of identity 
cannot be guaranteed as with regards to this study, the researchers’ will know 
the identities of the participants as there will be face to face meetings both at 
recruitment, and during the study in order to check for compliance to 
treatment and to check for side effects. We will take particular care to ensure the 
confidentiality of all data gathered for this study. We will also take care to ensure 
anonymity in publications of the findings. Data will be stored in password 
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protected computer files on the University of Canterbury (UC) system and paper 
records held in locked storage in the Psychology Department. All hard-copy 
questionnaire data will be stored in a locked private research office, in a locked 
cabinet file in site at University of Canterbury. Neville Blampied, Julia Rucklidge, 
and Kathleen Liberty will have access to the data obtained during the study. After 
seven years have passed, paper records will be destroyed. My thesis will be a 
public document and will be available through the UC Library but it will contain 
no information that identifies any participant.     
What happens after the study? 
If you feel you have benefited at the end of the trial, and want to continue taking 
the micronutrients, it is commercially available. If you choose to purchase EMP+, 
we will provide the necessary information on how to purchase it in New Zealand.  
The results of this research will be reported in a thesis held digitally in the UC 
library, reported on at professional and scientific conferences, submitted for 
publication in peer reviewed scientific articles, and may be publicized in the 
media. You may request the reports from this study. Please indicate to the 
researcher on the consent form if you would like a copy of the summary of results 
of the project.  
Who can I contact during the study if I have a question? 
The project is being carried out as a requirement for the degree of Master of 
Science in Psychology by Alison Carley (details above), under the supervision of 
Neville Blampied (Neville.blampied@canterbury.ac.nz), Julia Rucklidge 
(Julia.rucklidge@canterbury.ac.nz), and Kathleen Liberty 
(Kathleen.liberty@canterbury.ac.nz). We will be pleased to discuss any concerns 
you may have about participation in the project as well as any questions you may 
have throughout the study. This project has been reviewed and approved by the 
University of Canterbury Educational Research Human Ethics Committee, and 
participants should address any complaints to The Chair, Educational Research 
Human Ethics Committee, University of Canterbury, Private Bag 4800, 












EMPowerPlus Advanced Supplement Facts   
Amount Per Serving (2 capsules)*                           % Daily Value   
 
Vitamin A (as retinyl 
palmitate)  
 




Vitamin C (as ascorbic acid)  
 




Vitamin D (as cholecalciferol)  
 




Vitamin E (as d-alpha  
tocopheryl succinate)  
 




Thiamin (as thiamin 
mononitrate)  
 










Niacin (as niacinamide)  
 




Vitamin B6 (as pyridoxine 
hydrochloride)  
 




Folic acid   
 




Vitamin B12 (as 
methylcobalamin)  
 










Pantothenic acid (as calcium 
pantothenate)  
 




Calcium (as chelate)  
 




Iron (as chelate)  
 




Phosphorus (as chelate)  
 




Iodine (from Pacific kelp)  
 




Magnesium (as chelate)  
 




Zinc (as chelate)  
 




Selenium (as chelate)  
 




Copper (as chelate)  
 




Manganese (as chelate)  
 




Chromium (as chelate)  
 




Molybdenum (as chelate)  
 




Potassium (as chelate)  
 




Propriety blend: Choline bitartrate, DL-phenylalanine, citrus Bioflavonoids, Inositol, L-Glutamine, 
L-Methionine, Grape seed extract, Gingko biloba leaf extract, ermanium sesquioxide, Boron (as 




Other ingredients: capsule shell (gelatin, titanium dioxide) microcrystalline cellulose, glycine, citric 
acid, magnesium stearate, silicon dioxide, mineral wax 
 
*Amount per serving on this list is for 2 capsules. Participants need to be aware that they 











































Appendix C: Screening Questionnaire 
Insomnia Screening Survey 
 
Q1 The following questions are being asked in order to assess your eligibility to take part in this 
study, and to gain some background information on the types of people who will take part in this 
study. This research is aimed at exploring the effect of a micronutrient supplement on insomnia. 
The choice of a micronutrient supplement is based on previous research which indicates that 
micronutrients can lower levels of stress, anxiety, and intrusive thoughts which are all thought to 
negatively impact sleep.   You are now invited to answer a series of questions. The questions 
will take approximately 30 minutes to complete. The information gained from this survey will be 
kept confidential. Your specific contact details are being requested in order for us to contact you 
if you are eligible, they will not be used for any other purposes.    
 
Q2 I understand that the information that I provide will be used for the purposes of assessing my 
eligibility to take part in this study and that all personal information gained about me will be kept 
strictly confidential. I agree to answer the following questions about myself. 
m I AGREE with the above conditions (1) 
m I DISAGREE with the above conditions (2) 
If I DISAGREE with the above c... Is Selected, Then Skip To End of Block 
 
Q3 Please complete the following contact details so that we can contact you about the study 
First name (8) 
Last name (9) 
Email address (10) 
Cell phone (15) 
Home phone (16) 
Home Address (17) 
 
Q4 I am aged 18 years or older. 
m Yes (1) 
m No (2) 
If No Is Selected, Then Skip To End of Block 
 
Q5 Are you a registered teacher with at least 2 years experience working full time?  
m Yes (1) 
m No (2) 
If No Is Selected, Then Skip To End of Block 
 
Q6 Do you have access to a computer and home internet connection? 
m Yes (1) 
m No (2) 
If No Is Selected, Then Skip To End of Block 
 
Q7 Do you have Sleep Apnoea? 
m Yes (1) 
m No (2) 
If Yes Is Selected, Then Skip To End of Block 
 
Q8 Are you pregnant or breastfeeding or intend to have children in the near future? 
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m Yes (1) 
m No (2) 
If Yes Is Selected, Then Skip To End of Block 
 
Q9 Do you currently have a child that is 2 years or under? 
m Yes (1) 
m No (2) 
If Yes Is Selected, Then Skip To End of Block 
 
Q10 Are you currently taking any psychoactive medications on a regular basis? These 
include antidepressants, anxiety medications, Ritalin, sleep medications etc. 
m Yes (1) 
m No (2) 
 
Display This Question: 
If Are you currently taking any psychoactive medication... Yes Is Selected 
Q11 Please indicate which psychoactive or sleep medications you are currently taking, and how 
long you have been taking them 
m 1. (1) ____________________ 
m 2. (2) ____________________ 
m 3. (3) ____________________ 
m 4. (4) ____________________ 
m 5 (5) ____________________ 
 
Q12 Are you currently taking any other types of medications? 
m Yes (1) 
m No (2) 
 
Display This Question: 
If Are you currently taking any medications? Yes Is Selected 
Q13 Which medications are you currently taking? 
 
Q14 Are you currently taking any herbal or nutritional supplements or formulas? (e.g vitamins, 
omega 3s, melatonin, St John's Wort) 
m Yes (1) 
m No (2) 
 
Display This Question: 
If Are you currently taking any other herbal or nutritional ... Yes Is Selected 
Q15 Please indicate which nutritional supplements you are currently taking and how long you 







Q16 Have you ever been described as having any of the following? Please indicate if this was in 
the past or currently. 
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	 You	suffered	in	the	past	 You	are	currently	suffering	
	 Yes (1) No (2) Yes (1) No (2) 
Anxiety disorder 
(1) m  m  m  m  
Major Depressive 
disorder (2) m  m  m  m  




m  m  m  m  
Psychotic disorder 








m  m  m  m  
Learning problems 





m  m  m  m  
 
If Neurological disorder (e.g.... Is Selected, Then Skip To End of Block 
 





Q18  What is your gender? 
m Male (1) 
m Female (2) 
 
Q19 Please indicate which of the following ethnic groups you belong to (you may select more 
than one).    
m NZ European/Pakeha (1) 
m NZ Maori (2) 
m Samoan (3) 
m Tongan (4) 
m Niuean (5) 
m Chinese (6) 
m Indian (7) 
m Other (8) ____________________ 
 
 
Q20 Please indicate your highest educational qualification using the list below: 
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m University Bursary or Scholarship (4) 
m Overseas qualification (5) 
m Post-secondary (e.g., diploma, trade certificate) (6) 
m University degree (7) 
m Other qualification (8) ____________________ 
 
Q22 Please indicate which of the following best describes your total household income before 
tax (include income from all sources): 
m less than $20,000 (1) 
m from $20,000 to $40,000 (2) 
m from $40,000 to $60,000 (3) 
m from $60,000 to $80,000 (4) 
m more than $80,000 (5) 
 
Q23 Do you have a serious medical condition for which major medical interventions are 
happening over the next month?                                               
m Yes (1) 
m No (2) 
 
Display This Question: 
If Do you have a serious medical condition for which major m... Yes Is Selected 
Q24 What is the serious medical condition?    
 
Q25 Have you recently taken an oral antibiotic? 
m No (1) 
m Yes in the past 2 weeks (2) 
m Yes in the past 4 weeks (3) 
m Yes in the past 6 weeks (4) 
m Yes, more than 6 weeks ago (5) 
 
Q26 Are you currently taking an oral antibiotic? 
m Yes (1) 
m No (2) 
 
Display This Question: 
If Are you currently taking an oral antibiotic? Yes Is Selected 
Q27 How long have you been taking the antibiotic? 
 
Display This Question: 
If Are you currently taking an oral antibiotic? Yes Is Selected 
Q28 For what symptoms or health condition have you been taking the oral antibiotic? 
 
Q29 Please indicate if you suffer from any kind of illness indicated below  (you can select more 
than one option). 
q Renal (1) 
q Hepatic (2) 
q Cardiovascular (3) 
q Respiratory (4) 
q None (5) 
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Display This Question: 
If Please indicate if you suffer from any kind of disease in... Renal Is Selected 
Or Please indicate if you suffer from any kind of disease in... Hepatic Is Selected 
Or Please indicate if you suffer from any kind of disease in... Cardiovascular Is Selected 
Or Please indicate if you suffer from any kind of disease in... Respiratory Is Selected 
Q30 Please, specify which kind of disease you suffer from: 
 
Q31 Do you have thyroid problems? 
m Yes (1) 
m No (2) 
 
Display This Question: 
If Do you have thyroid problems Yes Is Selected 
Q32 If you have thyroid problems choose the best answer from the drop down box that best 
describes your CURRENT thyroid functioning. 
m Under control/stabilised (1) 
m Unstable (2) 
m Hyperthyroid (3) 
m Hypothyroid (4) 
 
Q33 Do you have digestive problems or bowel-related problems (e.g., Chrohn’s disease, 
ulcerative colitis, haemorrhoids, other)?  
m Yes (1) 
m No (2) 
 
Display This Question: 
If Do you have  digestive problems or bowel-related problems ... Yes Is Selected 
Q34 Please, specify which kind of digestive or bowel-related problem you have. 
Click to write Choice 1 (1) 
Click to write Choice 2 (2) 
Click to write Choice 3 (3) 
Click to write Form field 4 (4) 
 
Q35 Thank you for your participation. Unfortunately you are not eligible for this study. For any 
further information on counseling and sleep disorder services in Christchurch, please visit our 
website http://bit.ly/UCnutritionresearch 
 
Q36 Instructions: Below is a list of common sleep complaints. During the past month, how many 





















m  m  m  m  m  m  
 
 
Q37 Has this symptom lasted for longer than 4 weeks? 
m Yes (1) 
m No (2) 
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m  m  m  m  m  m  
 
Q39 Has this symptom lasted for longer than 4 weeks? 
m Yes (1) 
m No (2) 
 





















from  sleep. 
(1) 
m  m  m  m  m  m  
 





















sleep is not 
sound. (1) 
m  m  m  m  m  m  
 
























m  m  m  m  m  m  
 
Q43 Has this symptom lasted for longer than 4 weeks? 
m Yes (1) 
m No (2) 
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Q44 Instructions: If you have experienced any sleep symptoms during the past month please 
choose the appropriate level to let us know how your sleep is affecting your daily life. 
	 Not	at	all	(1)	 A	little	bit	(2)	 Moderately	
(3)	
Quite	a	bit	(4)	 Extremely	(5)	
6. How much 
do your sleep 
problems 
bother you? (1) 
m  m  m  m  m  





m  m  m  m  m  




social life? (3) 
m  m  m  m  m  





of your life? 
(4) 
m  m  m  m  m  
10. Have your 
sleep 
difficulties 
made you feel 
irritable? (5) 
m  m  m  m  m  
11. Have your 
sleep problems 




m  m  m  m  m  
12. Have your 
sleep 
difficulties 
made you feel 
fatigued? (7) 
m  m  m  m  m  
13. How 
sleepy do you 
feel during the 
day? (8) 





Q46 The following questions ask about your sleep in the past 7 days and nights. Please choose 
the one best answer for each question. 
 









1. One or more 
awakenings after 
getting to sleep (1) 
m  m  m  m  
2. Not getting 
enough sleep (2) m  m  m  m  
3. Sleep that 
doesn't fully 
refresh you (3) 
m  m  m  m  
 









4. Poor alertness 
during the daytime 
(1) 





m  m  m  m  
6. Others noticing 
you appeared tired 
or fatigued (3) 
m  m  m  m  
 









7. Too many 
difficulties to 
overcome (2) 
m  m  m  m  
8. Bad mood(s) 
because you had 
poor sleep (3) 
m  m  m  m  
9. Lack of energy 
because of poor 
sleep (4) 
m  m  m  m  
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m  m  m  m  
11. Being unable 
to sleep (2) m  m  m  m  
12. Being able to 
do only enough to 
get by (3) 
m  m  m  m  
 
Q51   Please choose the best answer for each question about the past week:      
13. From the time you tried to go to sleep, how long did it take to fall asleep on the most nights? 
m Less than 1/2 an hour (1) 
m Between 1/2 to 1 hour (2) 
m Between 1 to 3 hours (3) 
m More than 3 hours or I didn't sleep (4) 
 
Q52 14. If you woke up during the night, how long did it take to fall back to sleep on most 
nights? 
m Less than 1/2 an hour (1) 
m Between 1/2 to 1 hour (2) 
m Between 1 to 3 hours (3) 
m More than 3 hours or I didn't sleep (4) 
 
Q53 15. Not counting times when you were awake in bed, how many hours of actual sleep did 
you get during the worst night?    
m More than 7 hours (1) 
m Between 4 to 7 hours (2) 
m Between 2 to 4 hours (3) 
m Less than 2 hours or I didn't sleep (4) 
 
Q54 16. On how many days did you have trouble coping because of poor sleep? 
m None or 1 day (1) 
m On 2 or 3 days (2) 
m On 4 or 5 days (3) 
m On 6 or all days (4) 
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Q55 Over the past week, how would you rate: 
	 Excellent	(1)	 Good	(2)	 Fair	(3)	 Poor	(4)	
17.  Your sleep 
quality, compared 
to most people (1) 
m  m  m  m  
18. Your 
satisfaction with 
your sleep (2) 
m  m  m  m  
19. The regularity 
of your sleep (5) m  m  m  m  
20. The soundness 
of your sleep (6) m  m  m  m  
 
Q56 21. Please feel free to tell us about any aspects of your sleep or wakefulness we may have 
missed: 
 
Q57   Please read each statement and select one of the choices which indicates how much the 
statement applied to you over the PAST WEEK. There are no right or wrong answers. Do not 
spend too much time on any statement. Please answer all questions in one sitting. Once you have 
completed these last questions, we will be in contact with you. 
 
Q58 I found it hard to wind down (over the past week) 
m Did not apply to me at all (1) 
m Applied to me to some degree, or some of the time (2) 
m Applied to me to a considerable degree, or a good part of time (3) 
m Applied to me very much, or most of the time (4) 
 
Q59 I was aware of dryness of my mouth (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q60 I couldn't seem to experience any positive feeling at all (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q61 I experienced breathing difficulty (e.g., excessively rapid breathing,breathlessness in the 
absence of physical exertion) (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
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Q62 I found it difficult to work up the initiative to do things (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q63     I tended to over-react to situations (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q64 I experienced trembling (e.g., in the hands) (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q65 I felt that I was using a lot of nervous energy (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q66 I was worried about situations in which I might panic and make a fool of myself (over the 
past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q67 I felt that I had nothing to look forward to (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q68 I found myself getting agitated (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q69 I found it difficult to relax (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
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Q70 I felt down-hearted and blue (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q71 I was intolerant of anything that kept me from getting on with what I was doing (over the 
past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q72 I felt I was close to panic (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q73 I was unable to become enthusiastic about anything (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q74     I felt I wasn't worth much as a person (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q75 I felt that I was rather touchy (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q76 I was aware of the action of my heart in the absence of physical exertion (e.g., sense of 
heart rate increase, heart missing a beat) (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
 
Q77     I felt scared without any good reason (over the past week) 
m Did not apply to me at all  (0) 
m Applied to me to some degree, or some of the time  (1) 
m Applied to me to a considerable degree, or a good part of time  (2) 
m Applied to me very much, or most of the time (3) 
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Q78 I felt that life was meaningless (over the past week) 
m Did not apply to me at all (1) 
m Applied to me to some degree, or some of the time (2) 
m Applied to me to a considerable degree, or a good part of time (3) 
m Applied to me very much or most of the time (4) 
 
Q79 If you are eligible to take part in this study, we will be inviting you to meet with the 
researcher and have the opportunity to share information about your participation in the study. 
Please indicate which times you would be available to attend this initial appointment. You can 
select more than one time option (the following question will ask you to indicate preferred days). 
q Mornings 9-12 noon (1) 
q Afternoons 12-3pm (2) 
q Evenings 3-6 pm (3) 
 
Q80 Please indicate your preferred days to meet with us. 
q Monday (1) 
q Tuesday (2) 
q Wednesday (3) 
q Thursday (4) 
q Friday (5) 
 
Q81 This study will last approximately 3 months. Are you willing to participate in the study for 
this amount of time? 
m Yes (1) 
m No (2) 
 
Q82 Thank you very much for your time, your participation has been very important to us.  We 
will contact you if you are eligible for this study.  In the meantime, please visit our 
website http://bit.ly/UCnutritionresearch for information on counseling and sleep disorder 




Appendix D: Consent Form 
 
Telephone: +64 0273754496 
Email: alison.carley@pg.canterbury.ac.nz 
Date: 10/05/16 
Investigating the Effect of Micronutrients on Insomnia in Teachers: A Multiple-Baseline 
Design 
Consent Form for Teachers Experiencing Insomnia 
Principle Investigator: Alison Carley 
Other Investigators: Professors Neville Blampied, Julia Rucklidge, and Associate Professor 
Kathleen Liberty 
I have read and I understand the information sheet for volunteers taking part in the study 
designed to assess the impact of a micronutrient formula on insomnia in teachers. I have had the 
opportunity to ask questions and discuss this study, and I am satisfied with the answers that have 
been given. I understand that my participation in this study is voluntary (my choice) and that I 
may withdraw from the study at any time without penalty and this will in no way affect my 
continuing health care. I also understand that I may withdraw any information already provided.  
I understand that my participation in this study is confidential and that no material which could 
identify me will be used in any reports of this study. I understand that the micronutrients will be 
stopped if they should appear harmful to me. I understand the compensation provisions for this 
study. I have had time to consider whether to take part. I know who to contact if I have any side 
effects to the study, or if anything occurs which I would consider a reason to withdraw from the 
study. I know who to contact if I have any questions about the study.  
I wish to receive a copy of the results                                                                                      
YES/NO 
Participants should be advised that a significant delay may occur between data collection and 
publication of the results.  
I consent to being contacted 3 months after completion of the study regardless of whether I chose 
to       continue to take the micronutrient formula and at that point I can choose whether to 
complete questionnaires.                                                                                                                         
YES/NO   
I consent to my name being placed in a separate database so that I can be contacted in the future 
should there be other studies for me to participate in with the understanding that I can choose 
whether to participate in such studies or not.                                                                           
YES/NO 
I consent to the use of my data for future related studies, which have been given ethical approval 





I hereby consent to participate. 
 
  
          
Signed:  Date:  
  
Printed name:  
  
Signature of person 
who gained consent: 
 
  
Address for results:  
 
 
The person who may be contacted about the research is: 
 
Principle Investigator: Alison Carley alison.carley@pg.canterbury.ac.nz  
 
Or: Professors Neville Blampied & Julia Rucklidge, or Associate Professor Kathleen 
Liberty  
 





 Appendix E: Side Effect Questionnaire 
Q25 Please answer yes or no if you have experienced any of the following symptoms in the 
PAST TWO WEEKS.   
 
 Yes (1) No (2) 
Dry mouth (1)  m  m  
Urinary retention (2)  m  m  
Blurred vision (3)  m  m  
Constipation (4)  m  m  
Sedation/lethargy (5)  m  m  
Sleep disruption (6)  m  m  
Nightmares (7)  m  m  
Change in appetite (8)  m  m  
Skin rash (9)  m  m  
Weight gain (10)  m  m  
Headache (11)  m  m  
Nausea (12)  m  m  
Gastrointestinal 
disturbance/diarrhoea (13)  
m  m  
Abdominal pain (14)  m  m  
Inability to achieve an erection 
(15)  
m  m  
Inability to achieve an orgasm 
(16)  
m  m  
Loss of libido (17)  m  m  
Agitation (18)  m  m  
Anxiety (19)  m  m  
 
Q26 Any other symptoms 
 
Q27 If you have experienced ANY of the symptoms what have you done to remedy them?  
